<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000509.pub5" GROUP_ID="NEONATAL" ID="398699073011214263" MERGED_FROM="" MODIFIED="2016-12-23 16:45:02 +0000" MODIFIED_BY="Colleen Ovelman" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Short title (no longer in use): Inhaled nitric oxide in preterm infants&lt;/p&gt;&lt;p&gt;CL 1/06 (update)&lt;br&gt;CL 3/07 (substantive update)&lt;/p&gt;&lt;p&gt;sent to Loni for NICHD formatting June 8&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2016-12-23 11:44:13 -0500" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="008" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.0">
<COVER_SHEET MODIFIED="2016-12-23 11:40:41 -0500" MODIFIED_BY="Colleen Ovelman">
<TITLE>Inhaled nitric oxide for respiratory failure in preterm infants</TITLE>
<CONTACT>
<PERSON ID="15171" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Keith</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Barrington</LAST_NAME>
<SUFFIX/>
<POSITION>Chief, Division of Neonatology</POSITION>
<EMAIL_1>keith.barrington@umontreal.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Pediatrics</DEPARTMENT>
<ORGANISATION>CHU Ste-Justine</ORGANISATION>
<ADDRESS_1>3175 Cote Ste Catherine</ADDRESS_1>
<ADDRESS_2/>
<CITY>Montreal</CITY>
<ZIP>H3T 1C5</ZIP>
<REGION>QC</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>514 345 4931 ext. 5929</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-12-23 11:40:41 -0500" MODIFIED_BY="Colleen Ovelman">
<PERSON ID="15171" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Keith</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Barrington</LAST_NAME>
<SUFFIX/>
<POSITION>Chief, Division of Neonatology</POSITION>
<EMAIL_1>keith.barrington@umontreal.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Pediatrics</DEPARTMENT>
<ORGANISATION>CHU Ste-Justine</ORGANISATION>
<ADDRESS_1>3175 Cote Ste Catherine</ADDRESS_1>
<ADDRESS_2/>
<CITY>Montreal</CITY>
<ZIP>H3T 1C5</ZIP>
<REGION>QC</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>514 345 4931 ext. 5929</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7015" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Neil</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Finer</LAST_NAME>
<SUFFIX/>
<POSITION>Director of Neonatology</POSITION>
<EMAIL_1>nfiner@ucsd.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Pediatrics</DEPARTMENT>
<ORGANISATION>University of California San Diego</ORGANISATION>
<ADDRESS_1>200 W Arbor Dr</ADDRESS_1>
<ADDRESS_2/>
<CITY>San Diego</CITY>
<ZIP>92103-8774</ZIP>
<REGION>California</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>1 619 543 3759</PHONE_1>
<PHONE_2/>
<FAX_1>1 619 543 3812</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1505261444013977529812598646318" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Thomas</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pennaforte</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>thomas.pennaforte@umontreal.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Université de Montréal</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Montreal</CITY>
<ZIP/>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-08-23 11:08:49 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;New studies found and included or excluded: 01/10/06&lt;/p&gt;&lt;p&gt;Conclusions changed: 01/12/06&lt;/p&gt;" NOTES_MODIFIED="2016-08-23 11:08:49 -0400" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="15" MONTH="1" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="1" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="8" MONTH="9" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-12-18 21:53:28 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;This review is an update of the existing review &amp;quot;Inhaled nitric oxide for respiratory failure in preterm infants&amp;quot; (Barrington 2006).&lt;br&gt;&lt;br&gt;This update includes additional information regarding completed trials by Ballard, Kinsella and Srisuparp. &lt;br&gt;&lt;br&gt;Overall analyses have been deleted as study characteristics differed too much for this to be useful. Subgroup analyses are presented instead.&lt;/p&gt;" NOTES_MODIFIED="2016-12-18 21:53:28 -0500" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-12-18 21:53:28 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="12" YEAR="2016"/>
<DESCRIPTION>
<P>This updates the review, "Inhaled nitric oxide for respiratory failure in preterm infants", which was published in the <I>Cochrane Database of Systematic Reviews.</I>
</P>
<P>Three new trials have been added. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-12-12 07:15:57 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="1" YEAR="2016"/>
<DESCRIPTION>
<P>This updates again the review, "Inhaled nitric oxide for respiratory failure in preterm infants", which was published in the <I>Cochrane Database of Systematic Reviews</I> (<LINK REF="REF-Barrington-2006" TYPE="REFERENCE">Barrington 2006</LINK>).</P>
<P>The search was updated in January 2016. One new trial has been added (<LINK REF="STD-Wei-2014" TYPE="STUDY">Wei 2014</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-12-12 07:15:47 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="1" YEAR="2016"/>
<DESCRIPTION>
<P>Conclusions remain unchanged.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-12-12 07:17:07 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2016-12-12 07:16:33 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="10" YEAR="2010"/>
<DESCRIPTION>
<P>This review suggests that no clear indications are known for iNO in preterm infants. Previous versions of this review suggested that early routine treatment might be beneficial, but with addition of the EUNO 2009 results, reduction in death or BPD and reduction in brain injury, which appeared possible previously, are no longer significant.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-12-12 07:16:42 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="10" YEAR="2010"/>
<DESCRIPTION>
<P>This updates the review, "Inhaled nitric oxide for respiratory failure in preterm infants", which was published in the <I>Cochrane Database of Systematic Reviews</I> (<LINK REF="REF-Barrington-2006" TYPE="REFERENCE">Barrington 2006</LINK>).</P>
<P>The search was updated in June 2010. Three new trials have been added, along with follow-up data from other studies.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-12-09 06:11:04 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>This review has been converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-12-09 06:09:22 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="3" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendments have been made.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-12-12 07:17:07 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="3" YEAR="2007"/>
<DESCRIPTION>
<P>This review is an update of the existing review, "Inhaled nitric oxide for respiratory failure in preterm infants" (Barrington 2006).<BR/>
<BR/>This update includes additional information regarding completed trials by Ballard, Kinsella and Srisuparp.<BR/>
<BR/>Overall analyses have been deleted, as study characteristics differ too much for these to be useful. Subgroup analyses are presented instead.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-12-11 16:33:33 -0500" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2016-12-11 16:33:33 -0500" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2016-12-11 16:33:33 -0500" MODIFIED_BY="[Empty name]">
<NAME>Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Editorial support of the Cochrane Neonatal Review Group has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN275201600005C</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-12-23 11:43:42 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-12-12 07:22:58 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-28 10:35:56 -0400" MODIFIED_BY="[Empty name]">Inhaled nitric oxide for respiratory failure in preterm infants</TITLE>
<SUMMARY_BODY MODIFIED="2016-12-12 07:22:58 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Review question: </B>Does giving inhaled nitric oxide gas to preterm infants with pulmonary disease improve survival without long-term brain or lung injury?</P>
<P>
<B>Background:</B> Breathing failure in preterm newborn babies may be complicated by raised pressure within the vessels that carry blood to the lungs (pulmonary hypertension). Mechanically assisted ventilation is used to support such infants, and sedative medications may be given. Inhaled nitric oxide gas (iNO) helps regulate muscle tone in the arteries of the lungs and decreases pulmonary hypertension; therefore, it may reduce the need for assisted ventilation, leading to less lung injury. However, iNO has effects on platelet function and is believed to potentially increase bleeding (haemorrhage), in particular bleeding into the brain.</P>
<P>
<B>Study characteristics:</B> Review authors found 17 randomised controlled trials of iNO in the preterm newborn through searches updated until January 2016. These trials studied preterm babies with very different baseline characteristics; therefore, we decided to divide them into three groups: (1) trials of babies treated in the first few days of life with severe lung disease, (2) studies providing treatment after the first few days of life to babies who were at increased risk of chronic lung disease and (3) trials providing routine early treatment for babies who experienced respiratory distress.</P>
<P>
<B>Key results:</B> In none of the three groups of trials did iNO improve survival, and no consistent evidence suggests that iNO decreases lung injury. Studies in group 1 (early rescue treatment) reported a 20% increase in severe bleeding into the brain. This finding was close to statistically significant. The quality of the evidence was moderate to high.</P>
<P>This review of studies found that inhaled nitric oxide therapy does not appear to improve the chances of improved outcomes for preterm infants with pulmonary disease. When given to babies who were very ill, iNO did not seem to help and may have contributed to increased risk of intracranial haemorrhage.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-12-23 11:42:29 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-02-29 11:37:24 -0500" MODIFIED_BY="[Empty name]">
<P>Inhaled nitric oxide (iNO) is effective in term infants with hypoxic respiratory failure. The pathophysiology of respiratory failure and the potential risks of iNO differ substantially in preterm infants, necessitating specific study in this population.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-12-10 15:48:09 -0500" MODIFIED_BY="[Empty name]">
<P>To determine effects of treatment with inhaled nitric oxide (iNO) on death, bronchopulmonary dysplasia (BPD), intraventricular haemorrhage (IVH) or other serious brain injury and on adverse long-term neurodevelopmental outcomes in preterm newborn infants with hypoxic respiratory failure.</P>
<P>Owing to substantial variation in study eligibility criteria, which decreases the utility of an overall analysis, we divided participants post hoc into three groups: (1) infants treated over the first three days of life because of defects in oxygenation, (2) preterm infants with evidence of pulmonary disease treated routinely with iNO and (3) infants treated later (after three days of age) because of elevated risk of BPD.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-12-10 13:13:27 -0500" MODIFIED_BY="[Empty name]">
<P>We used standard methods of the Cochrane Neonatal Review Group. We searched MEDLINE, Embase, Healthstar and the Cochrane Central Register of Controlled Trials in the Cochrane Library through January 2016. We also searched the abstracts of the Pediatric Academic Societies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-12-10 13:14:18 -0500" MODIFIED_BY="[Empty name]">
<P>Eligible for inclusion were randomised and quasi-randomised studies in preterm infants with respiratory disease that compared effects of iNO gas versus control, with or without placebo.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-12-10 13:14:41 -0500" MODIFIED_BY="[Empty name]">
<P>We used standard methods of the Cochrane Neonatal Review Group and applied the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the quality of evidence.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-12-12 07:19:24 -0500" MODIFIED_BY="[Empty name]">
<P>We found 17 randomised controlled trials of iNO therapy in preterm infants. We grouped these trials post hoc into three categories on the basis of entry criteria: treatment during the first three days of life for impaired oxygenation, routine use in preterm babies along with respiratory support and later treatment for infants at increased risk for bronchopulmonary dysplasia (BPD). We performed no overall analyses.</P>
<P>Eight trials providing early rescue treatment for infants on the basis of oxygenation criteria demonstrated no significant effect of iNO on mortality or BPD (typical risk ratio (RR) 0.94, 95% confidence interval (CI) 0.87 to 1.01; 958 infants). Four studies examining routine use of iNO in infants with pulmonary disease reported no significant reduction in death or BPD (typical RR 0.94, 95% CI 0.87 to 1.02; 1924 infants), although this small effect approached significance. Later treatment with iNO based on risk of BPD (three trials) revealed no significant benefit for this outcome in analyses of summary data (typical RR 0.92, 95% CI 0.85 to 1.01; 1075 infants).</P>
<P>Investigators found no clear effect of iNO on the frequency of all grades of IVH nor severe IVH. Early rescue treatment was associated with a non-significant 20% increase in severe IVH.</P>
<P>We found no effect on the incidence of neurodevelopmental impairment.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-12-23 11:42:29 -0500" MODIFIED_BY="[Empty name]">
<P>iNO does not appear to be effective as rescue therapy for the very ill preterm infant. Early routine use of iNO in preterm infants with respiratory disease does not prevent serious brain injury or improve survival without BPD. Later use of iNO to prevent BPD could be effective, but current 95% confidence intervals include no effect; the effect size is likely small (RR 0.92) and requires further study.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-12-23 11:43:42 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-12-23 11:42:43 -0500" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2016-12-12 07:24:44 -0500" MODIFIED_BY="[Empty name]">
<P>Respiratory failure in the preterm newborn may be complicated by pulmonary hypertension (<LINK REF="REF-Walther-1992" TYPE="REFERENCE">Walther 1992</LINK>). Conventional therapy for pulmonary hypertension involves respiratory support, which includes assisted ventilation and continuous distending pressure, administration of surfactant and sedation and muscle relaxation if necessary. The systemic circulation is often supported with inotropic agents in the sickest infants. Since the time surfactant was introduced, mortality from respiratory failure in preterm infants has fallen significantly (<LINK REF="REF-Soll-2001" TYPE="REFERENCE">Soll 2001</LINK>). However, some infants do not show adequate improvement in oxygenation after receiving surfactant treatment. Preterm infants receiving mechanical respiratory support are at increased risk of bronchopulmonary dysplasia (BPD) as the result of lung injury, which may have a significant long-term impact.</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-12-12 07:30:27 -0500" MODIFIED_BY="[Empty name]">
<P>Regulation of vascular muscle tone at the cellular level occurs via nitric oxide (NO) (<LINK REF="REF-Abman-1990" TYPE="REFERENCE">Abman 1990</LINK>). Nitric oxide is generated enzymatically from L-arginine by one of three NO synthases. NO activates guanylyl cyclase by binding to its heme component, leading to the production of cyclic guanosine monophosphate (cGMP), which causes vasodilation (<LINK REF="REF-Finer-1998" TYPE="REFERENCE">Finer 1998</LINK>). NO gas can be mixed with inspired gases and delivered directly to the peripheral airways, where it may cause local vasodilation.</P>
</INTERVENTION>
<THEORY MODIFIED="2016-12-12 07:30:14 -0500" MODIFIED_BY="[Empty name]">
<P>Pulmonary vascular resistance of foetal animals is regulated by endogenous (<LINK REF="REF-Cornfield-1992" TYPE="REFERENCE">Cornfield 1992</LINK>) or exogenous NO (<LINK REF="REF-Kinsella-1992" TYPE="REFERENCE">Kinsella 1992</LINK>). In several newborn animal models, pulmonary hypertension was reversed by inhaled exogenous nitric oxide (<LINK REF="REF-Frostell-1991" TYPE="REFERENCE">Frostell 1991</LINK>; <LINK REF="REF-Roberts-1993" TYPE="REFERENCE">Roberts 1993</LINK>). In general, researchers have noted little or no effect of inhaled nitric oxide (iNO) on the systemic circulation (<LINK REF="REF-Finer-1998" TYPE="REFERENCE">Finer 1998</LINK>). Studies in adults and in full-term human infants have confirmed that iNO causes selective pulmonary vasodilation, reducing pulmonary arterial pressure and improving ventilation/perfusion mismatch. In adult respiratory distress syndrome (ARDS), reduced pulmonary arterial pressure and decreased intrapulmonary shunting occur within 40 minutes of iNO treatment (<LINK REF="REF-Rossaint-1993" TYPE="REFERENCE">Rossaint 1993</LINK>). In these patients, the major benefit was likely due to improvement in ventilation/perfusion matching because iNO causes vasodilation only in ventilated lung units.</P>
<P>Preterm animals with hyaline membrane disease have elevated pulmonary vascular resistance, and pulmonary artery pressure and oxygenation may be improved by iNO (<LINK REF="REF-Kinsella-1994" TYPE="REFERENCE">Kinsella 1994</LINK>; <LINK REF="REF-Skimming-1995" TYPE="REFERENCE">Skimming 1995</LINK>). These animal models are very similar to preterm human neonates with respiratory failure. In the term neonate with hypoxic respiratory failure, iNO decreases the requirement for extracorporeal membrane oxygenation (ECMO) but does not decrease overall mortality (<LINK REF="REF-Finer-2000" TYPE="REFERENCE">Finer 2000</LINK>).</P>
<P>Owing to differences in pathophysiology, different entry criteria and different outcomes, treatment results in term infants cannot be extrapolated to preterm infants. Entry criteria used for studies of iNO in the term neonate have different implications for the preterm neonate because, at the same levels of the oxygenation index (OI), mortality is much higher among preterm than term infants.</P>
<P>Although pulmonary artery pressure is increased in preterm infants with respiratory failure, this elevation in pulmonary artery pressure is rarely sufficient to cause reversal of the ductal shunt. Therefore, the haemodynamic profile differs somewhat from that of the term neonate. ECMO is not used for preterm infants owing to concerns regarding haemorrhagic complications; therefore, the requirement for ECMO cannot be used as an outcome criterion.</P>
<P>Animal models of BPD suggest that prolonged treatment with iNO may modify lung injury (<LINK REF="REF-Bland-2005" TYPE="REFERENCE">Bland 2005</LINK>). Inhaled nitric oxide has effects that may reduce pulmonary inflammation and improve vascular remodeling in the preterm lung with acute injury.</P>
<P>Preterm infants are at risk of long-term pulmonary disability associated with BPD. The importance of preventing or ameliorating BPD is related to the association between BPD and subsequent development of neurodevelopmental impairment (<LINK REF="REF-Vohr-2005" TYPE="REFERENCE">Vohr 2005</LINK>; <LINK REF="REF-Wood-2005" TYPE="REFERENCE">Wood 2005</LINK>), chronic medical illness and rehospitalisation. If iNO therapy leads to a decrease in the need for ventilator support, reduction in lung injury may lead to prevention or amelioration of BPD. Nitric oxide participates in both production of and protection from oxidative injury (<LINK REF="REF-McAndrew-1997" TYPE="REFERENCE">McAndrew 1997</LINK>). Therefore, effects of iNO therapy on the developing lung deserve careful evaluation before iNO is introduced into clinical practice.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-12-23 11:42:43 -0500" MODIFIED_BY="[Empty name]">
<P>Of particular concern in the preterm infant is the effect of iNO on coagulation. Inhaled nitric oxide has been shown to increase bleeding time in adult volunteers (<LINK REF="REF-Hogman-1993" TYPE="REFERENCE">Hogman 1993</LINK>) as well as in adults with ARDS (<LINK REF="REF-Samama-1995" TYPE="REFERENCE">Samama 1995</LINK>). This appears to occur via cGMP-dependent mechanisms; presumably, intraplatelet cGMP is increased during the passage of platelets through the lung. Preterm infants are at high risk of developing intraventricular haemorrhage (IVH), which has substantial effects on long-term developmental outcome. Therefore, it is important for investigators to evaluate iNO in terms of its effect on IVH rates among preterm infants.</P>
<P>The few case reports and case series published before randomised controlled trials (RCTs) were conducted demonstrate that preterm infants with severe respiratory failure who have not responded to conventional management, including surfactant and high-frequency ventilation, may have improved oxygenation with iNO (<LINK REF="REF-Abman-1993" TYPE="REFERENCE">Abman 1993</LINK>; <LINK REF="REF-Peliowski-1995" TYPE="REFERENCE">Peliowski 1995</LINK>; <LINK REF="REF-Van-Meurs-1997" TYPE="REFERENCE">Van Meurs 1997</LINK>). These reports describe mortality and IVH.</P>
<P>In <LINK REF="STD-Skimming-1997" TYPE="STUDY">Skimming 1997</LINK>, researchers randomised 23 surfactant-treated preterm infants requiring conventional mechanical ventilation with at least 50% oxygen to 5 ppm or 20 ppm of iNO for 15 minutes (non-blinded). Twelve infants received 20 ppm and 11 received 5 ppm. Mean gestational age was 28 ± 0.6 weeks, and mean postnatal age was 49.8 ± 8.1 hours. Results show significant increases in partial pressure of oxygen in arterial blood (PaO<SUB>2</SUB>) and peripheral capillary oxygen saturation (SpO<SUB>2</SUB>), a significant fall in the spontaneous respiratory rate (all P &lt; 0.01) and no differences in response between the two doses of iNO, suggesting that if iNO is to be used in preterm infants, a dose of 5 ppm would be adequate.</P>
<P>More recent animal studies showing direct effects of iNO in protecting the preterm lung from adverse effects of hyperoxia (<LINK REF="REF-Bland-2005" TYPE="REFERENCE">Bland 2005</LINK>) and supporting microvascular development (<LINK REF="REF-McCurnin-2005" TYPE="REFERENCE">McCurnin 2005</LINK>) suggest possible direct benefits for reduction of BPD. Other published systematic reviews of iNO in the preterm are inconclusive (<LINK REF="REF-Hoehn-2006" TYPE="REFERENCE">Hoehn 2006</LINK>; <LINK REF="REF-Wirbelauer-2010" TYPE="REFERENCE">Wirbelauer 2010</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-12-10 15:47:43 -0500" MODIFIED_BY="[Empty name]">
<P>To determine effects of treatment with inhaled nitric oxide (iNO) on death, bronchopulmonary dysplasia (BPD), intraventricular haemorrhage (IVH) or other serious brain injury and on adverse long-term neurodevelopmental outcomes in preterm newborn infants with hypoxic respiratory failure.</P>
<P>Owing to substantial variation in study eligibility criteria, which decreases the utility of an overall analysis, we divided participants post hoc into three groups: (1) infants treated over the first three days of life because of defects in oxygenation, (2) preterm infants with evidence of pulmonary disease treated routinely with iNO and (3) infants treated later (after three days of age) because of elevated risk of BPD.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-12-16 16:54:23 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-12-10 15:53:08 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-12-10 15:49:50 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised and quasi-randomised clinical trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-12-10 15:49:54 -0500" MODIFIED_BY="[Empty name]">
<P>Preterm infants (less than 35 weeks' gestation) with respiratory failure after adequate treatment with surfactant.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-12-10 15:50:00 -0500" MODIFIED_BY="[Empty name]">
<P>Inhaled nitric oxide compared with placebo or control in addition to conventional treatment for respiratory failure.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-12-10 15:53:08 -0500" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-12-10 15:50:41 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>Death before hospital discharge</LI>
<LI>Bronchopulmonary dysplasia (oxygen dependence at 36 weeks' postmenstrual age)</LI>
<LI>Death or bronchopulmonary dysplasia (at 36 weeks' postmenstrual age)</LI>
<LI>Intraventricular haemorrhage (any grade and more severe, grades 3 and 4)</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-12-10 15:53:08 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>Periventricular leukomalacia</LI>
<LI>Neurodevelopmental disability (proportion of survivors with neurological abnormality sufficient to affect quality of life or developmental index more than two standard deviations below the mean based on a validated scale at greater than 12 months of age; or mean developmental index among survivors greater than 12 months of age)</LI>
<LI>Retinopathy of prematurity (any stage and &#8805;stage 3)</LI>
</OL>
<P>Post hoc outcomes (reported in trials but not prespecified) include the following.</P>
<OL>
<LI>Oxygenation within two hours of therapy.</LI>
<LI>Pulmonary artery pressure.</LI>
<LI>Duration of assisted ventilation.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-12-16 16:54:23 -0500" MODIFIED_BY="[Empty name]">
<P>We used criteria and standard methods of Cochrane and the Cochrane Neonatal Review Group (see <A HREF="http://neonatal.cochrane.org/resources-review-authors">the Cochrane Neonatal search strategy for specialized register</A>).</P>
<P>We used paper indices from 1995 to 2006 to search for abstracts of annual Pediatric Academic Societies meetings, and subsequently searched on-line abstracts.</P>
<P>We updated this search in January 2016.</P>
<ELECTRONIC_SEARCHES MODIFIED="2016-12-16 16:54:23 -0500" MODIFIED_BY="[Empty name]">
<P>For the 2016 update, we conducted a comprehensive search including: Cochrane Central Register of Controlled Trials (CENTRAL 2016, Issue 1) in The Cochrane Library; MEDLINE via PubMed (1966 to 15 January 2016); EMBASE (1980 to 15 January 2016); and CINAHL (1982 to 15 January 2016) using the following search terms: (nitric oxide), plus database-specific limiters for RCTs and neonates (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for the full search strategies for each database). We did not apply language restrictions.<BR/>
<BR/>We searched clinical trials registries for ongoing or recently completed trials (<A HREF="http://clinicaltrials.gov">clinicaltrials.gov</A>; the World Health Organization&#8217;s International Trials Registry and Platform <A HREF="http://www.whoint/ictrp/search/en/">www.whoint/ictrp/search/en/</A>, and the ISRCTN Registry <A HREF="http://www.isrctn.com/">http://www.isrctn.com/</A>).<BR/>
</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-12-12 07:50:03 -0500" MODIFIED_BY="[Empty name]">
<P>We used Cochrane standard methods. Review authors independently assessed trials for inclusion and methodological quality and resolved differences by discussion. We planned to contact study authors to request additional information, if needed.</P>
<STUDY_SELECTION MODIFIED="2016-12-10 16:07:37 -0500" MODIFIED_BY="[Empty name]">
<P>All three review authors screened titles and abstracts of all studies identified by the above search strategy. We assessed the full text of potentially eligible reports and excluded studies that did not meet all of the inclusion criteria. We discussed disagreements until we achieved consensus.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-12-10 16:08:31 -0500" MODIFIED_BY="[Empty name]">
<P>All three review authors extracted data separately and discussed disagreements until achieving consensus. We contacted trial authors to request further information if trial reports provided insufficient data.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-12-12 07:45:19 -0500" MODIFIED_BY="[Empty name]">
<P>We used criteria and standard methods of the <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/NEONATAL/sect0-meta.html">Cochrane Neonatal Group</A>. We assessed the methodological quality of studies by using the following key criteria: allocation concealment (blinding of randomisation), blinding of intervention, completeness of follow-up and blinding of outcome measurement/assessment. We assessed each criterion as 'yes', 'no' or 'cannot determine'. We requested additional information from trial authors to clarify methods and results as necessary. We included this information in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<P>Review authors independently assessed risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We assessed the methodological quality of studies by using the following criteria.</P>
<OL>
<LI>Sequence generation (evaluating possible selection bias). For each included study, we described the method used to generate the allocation sequence as adequate (any truly random process, e.g. random number table; computer random number generator), inadequate (any non-random process, e.g. odd or even date of birth; hospital or clinic record number) or unclear.</LI>
<LI>Allocation concealment (evaluating possible selection bias). For each included study, we described the method used to conceal the allocation sequence as adequate (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes), inadequate (open random allocation; unsealed or non-opaque envelopes; alternation; date of birth) or unclear.</LI>
<LI>Blinding (evaluating possible performance bias). For each included study, we described the methods used to blind study participants and personnel from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes. We assessed these methods as adequate, inadequate or unclear for participants; adequate, inadequate or unclear for study personnel; and adequate, inadequate or unclear for outcome assessors.</LI>
<LI>Incomplete outcome data (evaluating possible attrition bias through withdrawals, drop-outs, protocol deviations). For each included study and for each outcome, we described the completeness of data including attrition and exclusions from analysis. We stated whether attrition and exclusions were reported, numbers included in the analysis at each stage (compared with the total number of randomised participants), reasons for attrition or exclusion when reported and whether missing data were balanced across groups or were related to outcomes. We assessed methods as adequate (&lt; 20% missing data), inadequate (&#8805; 20% missing data) or unclear.</LI>
<LI>Selective reporting bias. For each included study for which the protocol was available (through trials registers), we described how we investigated the possibility of selective outcome reporting bias and what we found. We assessed these methods as adequate (when it was clear that all of the study's prespecified outcomes and all expected outcomes of interest for the review had been reported), inadequate (when not all of the study's prespecified outcomes had been reported; one or more reported primary outcomes were not prespecified; outcomes of interest were reported incompletely and so could not be used; the study failed to include results of a key outcome that would have been expected to have been reported) or unclear.</LI>
<LI>Other sources of bias. We noted other possible sources of bias (e.g. whether a potential source of bias was related to the specific study design, whether the trial was stopped early owing to some data-dependent process). We assessed whether each study was free of other problems that could put it at risk of bias as yes, no or unclear.</LI>
<LI>Funding sources. When reported, we divided funding sources into funding from local funds (hospital, research centre or university), charitable foundations, government agencies or industry. If funding was obtained from industry, and industry had substantial input into study design, conduct and/or analysis, we determined that the study was at high risk of bias. We considered funding from sources that would derive no potential financial benefit from the results to introduce low risk of bias. We considered unclear or partial funding to involve unclear risk of bias.</LI>
</OL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-12-12 07:46:43 -0500" MODIFIED_BY="[Empty name]">
<P>We calculated risk ratio (RR) and risk difference (RD) for dichotomous data, and mean difference (MD) for continuous data, with respective 95% confidence intervals (CIs). When it was deemed appropriate to combine two or more study arms, we obtained treatment effects from data combined according to methods described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We determined the number needed to treat for an additional beneficial outcome (NNTB) or the number needed to treat for an additional harmful outcome (NNTH) when we noted a statistically significant difference in RD.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-12-10 16:23:37 -0500" MODIFIED_BY="[Empty name]">
<P>We examined treatment effects of individual trials and heterogeneity between trial results by inspecting forest plots. We calculated the I² statistic for each analysis to quantify inconsistency across studies and to describe the percentage of variability in effect estimates that may be due to heterogeneity rather than to sampling error. If we detected substantial heterogeneity (I² statistic &gt; 50%), we explored possible causes (e.g. differences in study design, participants, interventions or completeness of outcome assessments) by performing sensitivity analyses.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-12-10 16:24:00 -0500" MODIFIED_BY="[Empty name]">
<P>We planned to investigate publication bias by using funnel plots if we included at least 10 clinical trials in the systematic review (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-12-12 07:48:53 -0500" MODIFIED_BY="[Empty name]">
<P>We used the standard methods of the Cochrane Neonatal Review Group. For categorical outcomes, we calculated typical estimates for risk ratio (RR) and risk difference (RD), along with their 95% confidence intervals. For significant results, we planned on reporting the number needed to treat for an additional beneficial outcome or the number needed to treat for an additional harmful outcome (NNTB/NNTH), assuming a fixed-effect model. We analysed continuous outcomes using weighted mean difference, also assuming a fixed-effect model.</P>
<SUBSECTION>
<HEADING LEVEL="3">Quality of evidence</HEADING>
<P>We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, as outlined in the <I>GRADE Handbook</I> (<LINK REF="REF-Sch_x00fc_nemann-2013" TYPE="REFERENCE">Schünemann 2013</LINK>), to assess the quality of evidence for the following (clinically relevant) outcomes: death before discharge (studies with entry before three days based on oxygenation), death before discharge (studies with entry after three days based on BPD risk), death before discharge (studies of routine use in preterm infants on respiratory support), death or bronchopulmonary dysplasia at 36 weeks (studies with entry before three days based on oxygenation), death or bronchopulmonary dysplasia at 36 weeks (studies of routine use in preterm infants on respiratory support), intraventricular haemorrhage (grade 3 or 4; studies with entry before three days based on oxygenation), intraventricular haemorrhage (grade 3 or 4; studies of routine use in preterm infants on respiratory support), neurodevelopmental disability (studies with entry before three days based on oxygenation), neurodevelopmental disability (studies with entry after three days based on BPD risk) and neurodevelopmental disability (studies of routine use in preterm infants on respiratory support).</P>
<P>Two review authors independently assessed the quality of evidence for each of the outcomes listed above. We considered evidence from RCTs as high quality but downgraded the evidence one level for serious (or two levels for very serious) limitations on the basis of the following: design (risk of bias), consistency across studies, directness of evidence, precision of estimates and presence of publication bias. We used the <LINK REF="REF-GRADEpro" TYPE="REFERENCE">GRADEpro</LINK> Guideline Development Tool to create a &#8216;Summary of findings&#8217; table to report the quality of evidence.</P>
<P>Use of the GRADE approach results in assessment of the quality of a body of evidence and assignment to one of four grades.</P>
<OL>
<LI>High: We are very confident that the true effect lies close to the estimate of effect.</LI>
<LI>Moderate: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different.</LI>
<LI>Low: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect.</LI>
<LI>Very low: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.</LI>
</OL>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-12-12 07:50:03 -0500" MODIFIED_BY="[Empty name]">
<P>In view of variable eligibility criteria for these trials, we divided them post hoc into three groups of trials.</P>
<OL>
<LI>In one group of trials, enrolment occurred early, over the first few days of life, for infants who were eligible because they had significantly impaired oxygenation. Investigators considered these studies to explore early 'rescue' therapy and designed them to determine effects on survival and early complications of prematurity.</LI>
<LI>Another group of trials enrolled infants after three days on the basis of clinical characteristics that predicted increased risk of BPD.</LI>
<LI>The third group of trials enrolled infants shortly after birth to provide routine 'prophylactic' use of iNO.</LI>
</OL>
<P>Review authors analysed these studies in three separate groups because study findings had very different implications for clinical practice. Within each subgroup, we examined heterogeneity by using the I<SUP>2</SUP> statistic, as outlined above.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-12-23 11:43:42 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-12-12 09:16:44 -0500" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2016-12-10 16:38:57 -0500" MODIFIED_BY="[Empty name]">
<P>The previous version of this review included 14 trials. The latest updated search in January 2016 revealed 463 titles after removal of duplicates. Screening of these articles led to inclusion of three new trials (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-12-12 09:16:44 -0500" MODIFIED_BY="[Empty name]">
<P>We identified 17 published RCTs that compared inhaled nitric oxide (iNO) versus control in preterm infants (<LINK REF="STD-Ballard-2006" TYPE="STUDY">Ballard 2006</LINK>; <LINK REF="STD-Dani-2006" TYPE="STUDY">Dani 2006</LINK>; <LINK REF="STD-EUNO-2009" TYPE="STUDY">EUNO 2009;</LINK> <LINK REF="STD-Hascoet-2005" TYPE="STUDY">Hascoet 2005</LINK>; <LINK REF="STD-INNOVO-2005" TYPE="STUDY">INNOVO 2005</LINK>; <LINK REF="STD-Kinsella-1999" TYPE="STUDY">Kinsella 1999</LINK>; <LINK REF="STD-Kinsella-2006" TYPE="STUDY">Kinsella 2006</LINK>; <LINK REF="STD-Kinsella-2014" TYPE="STUDY">Kinsella 2014;</LINK> <LINK REF="STD-Mercier-1999" TYPE="STUDY">Mercier 1999</LINK>; <LINK REF="STD-Schreiber-2003" TYPE="STUDY">Schreiber 2003</LINK>; <LINK REF="STD-Srisuparp-2002" TYPE="STUDY">Srisuparp 2002</LINK>; <LINK REF="STD-Su-2007" TYPE="STUDY">Su 2007</LINK>; <LINK REF="STD-Subhedar-1997" TYPE="STUDY">Subhedar 1997</LINK>; <LINK REF="STD-Van-Meurs-2005" TYPE="STUDY">Van Meurs 2005</LINK>; <LINK REF="STD-Van-Meurs-2007" TYPE="STUDY">Van Meurs 2007</LINK>; <LINK REF="STD-Wei-2014" TYPE="STUDY">Wei 2014</LINK>; <LINK REF="STD-Yoder-2013" TYPE="STUDY">Yoder 2013</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Trials of iNO in preterm infants eligible within the first three days because they met oxygenation criteria (early rescue therapy)</HEADING>
<P>Studies were eligible to be considered in this first group if they included acutely ill ventilated preterm infants, most of whom were enrolled within the first three days of life, if infants satisfied a severity of illness criterion. We included in this group 10 trials of iNO in preterm infants (<LINK REF="STD-Dani-2006" TYPE="STUDY">Dani 2006</LINK>; <LINK REF="STD-Hascoet-2005" TYPE="STUDY">Hascoet 2005</LINK>; <LINK REF="STD-INNOVO-2005" TYPE="STUDY">INNOVO 2005</LINK>; <LINK REF="STD-Kinsella-1999" TYPE="STUDY">Kinsella 1999</LINK>; <LINK REF="STD-Mercier-1999" TYPE="STUDY">Mercier 1999</LINK>; <LINK REF="STD-Srisuparp-2002" TYPE="STUDY">Srisuparp 2002</LINK>; <LINK REF="STD-Su-2007" TYPE="STUDY">Su 2007;</LINK> <LINK REF="STD-Van-Meurs-2005" TYPE="STUDY">Van Meurs 2005</LINK>; <LINK REF="STD-Van-Meurs-2007" TYPE="STUDY">Van Meurs 2007</LINK>; <LINK REF="STD-Wei-2014" TYPE="STUDY">Wei 2014</LINK>). Mean oxygenation indices of infants enrolled in these "rescue" studies ranged from 12 to 32 (32 for <LINK REF="STD-INNOVO-2005" TYPE="STUDY">INNOVO 2005</LINK>, 23 for <LINK REF="STD-Van-Meurs-2005" TYPE="STUDY">Van Meurs 2005</LINK>, approximately 25 for <LINK REF="STD-Van-Meurs-2007" TYPE="STUDY">Van Meurs 2007</LINK>,18 to 20 in <LINK REF="STD-Mercier-1999" TYPE="STUDY">Mercier 1999</LINK>, 12 to 15 for <LINK REF="STD-Hascoet-2005" TYPE="STUDY">Hascoet 2005</LINK>, 30 for <LINK REF="STD-Su-2007" TYPE="STUDY">Su 2007</LINK> and 24 for <LINK REF="STD-Wei-2014" TYPE="STUDY">Wei 2014</LINK>).</P>
<P>
<LINK REF="STD-Kinsella-1999" TYPE="STUDY">Kinsella 1999</LINK>
</P>
<P>Kinsella and colleagues randomised 80 preterm infants to blinded administration of 5 ppm iNO or no additional gas (79 had received surfactant). Infants underwent baseline cranial ultrasonography before administration of the study gas, results of which were noted but did not constitute an exclusion criterion. Investigators randomised infants if the ratio of arterial to alveolar partial pressure of oxygen (PO<SUB>2</SUB>) was less than 0.1 on two successive blood gases in the first seven days of life. They chose this criterion to enrol infants with expected mortality of 50%. The study was powered to detect a 30% reduction in mortality with iNO, which led to a planned sample size of 210 infants. Researchers planned to perform an interim analysis after 2.5 years and found no detectable difference in the main outcome (survival to discharge). They excluded seven participants from the analysis of acute oxygenation response because of early protocol violations but included them in all other outcome data. Forty-eight infants received iNO, and 32 infants served as controls. Baseline characteristics of the groups were similar, except that a greater number of infants treated with iNO had no intracranial haemorrhage at the start of the study (73% vs 59%). The ratio of partial pressure of oxygen in arterial blood (PaO<SUB>2</SUB>) to fraction of inspired oxygen (FiO<SUB>2</SUB>) was 42 (standard deviation (SD) 18) in the iNO group and 42 (SD 16) in the control group. Researchers continued treatment for seven days, after which they made attempts to wean iNO. They then restarted study gas for an increase in oxygenation index of 15% or more. The maximum duration of treatment was 14 days.</P>
<P>
<LINK REF="STD-Mercier-1999" TYPE="STUDY">Mercier 1999</LINK>
<BR/>The Franco-Belgium Collaborative NO trial group randomised near-term and preterm infants to separate strata and reported most results for the two strata separately. The cutoff between strata for this study occurred at 33 weeks' gestation. Admission criteria included postnatal age less than seven days and oxygenation index between 12.5 and 30. All except one of the 85 preterm infants received surfactant, and most (75%) received high-frequency ventilation. A majority of the infants were enrolled on the first or second day of life. Researchers randomised infants to iNO at 10 ppm or to control. If the oxygenation index (OI, mean airway pressure × FiO<SUB>2</SUB> × 100)/PaO<SUB>2</SUB>) exceeded 30 during the two-hour study period, then iNO at 20 ppm was used. The median baseline OI was 18 in the control group and 20.2 in the iNO group. The primary outcome variable was OI two hours after the start of therapy; after two hours, if a response was noted, iNO was reduced to 5 ppm, then was weaned 'slowly', but the maximum duration of therapy is not clear.</P>
<P>
<LINK REF="STD-Srisuparp-2002" TYPE="STUDY">Srisuparp 2002</LINK>
<BR/>Srisuparp and colleagues in a single-institution study randomised intubated preterm infants weighing less than 2000 grams who had received surfactant, had clinical respiratory distress syndrome (RDS) and were less than 72 hours of age. OI entry criteria varied with birth weight: OI had to be &gt; 4 for infants &lt; 1000 grams, &gt; 6 for infants 1001 to 1250 grams, &gt; 8 for infants 1251 to 1500 grams, &gt; 10 for infants 1501 to 1750 grams and &gt; 12 for infants 1751 to 2000 grams. Infants had central arterial catheters in place and were without major malformations. Treatment consisted of open-label iNO at 20 ppm or control. iNO was weaned by protocol and was limited to seven days. This was a pilot study for <LINK REF="STD-Schreiber-2003" TYPE="STUDY">Schreiber 2003</LINK>. Although no hypothesis was clearly stated, study authors indicated that they were assessing effects on oxygenation and potential adverse effects of iNO.</P>
<P>
<LINK REF="STD-Van-Meurs-2005" TYPE="STUDY">Van Meurs 2005</LINK>
<BR/>The study of Van Meurs and colleagues was a multi-centre US study. Initial entry criteria restricted enrolment to infants less than 34 weeks' gestation with birth weight between 401 and 1500 grams (with three birth weight strata: 401 to 750 grams, 751 to 1000 grams and 1001 to 1500 grams). Eligible infants were receiving assisted ventilation at least four hours after surfactant therapy and were considered at high risk because they had an OI of at least 10 on two consecutive blood gases. Investigators revised this criterion (after initial interim analysis showed an unexpectedly high mortality rate) to an OI of at least five followed by an OI of at least 7.5 after at least 30 minutes. The primary outcome was the combined outcome of BPD (oxygen dependence at 36 weeks) or death. The actual oxygenation indices of enrolled participants were 23 (SD 17) in the intervention group and 22 (SD 17) in the control group. Investigators in the study of Hintz 2007 reported neurological and developmental outcomes (Bayley Scales of Infant Development) at 18 to 22 months' corrected age.</P>
<P>
<LINK REF="STD-Hascoet-2005" TYPE="STUDY">Hascoet 2005</LINK>
<BR/>Hascoet and colleagues conducted a multi-centre study at 10 European centres. They enrolled and randomised intubated preterm infants but revealed randomisation only if infants developed hypoxic respiratory failure, defined as an arterial-alveolar oxygen ratio (a/AO<SUB>2</SUB> ratio = PaO<SUB>2</SUB>/713 × FiO<SUB>2</SUB> - partial pressure of carbon dioxide in arterial blood (PaCO<SUB>2</SUB>)) less than 0.22 at between six and 48 hours of age. Unfortunately, a large quantity of reported data pertain to the overall group of 860 infants, many of whom were not eligible to receive the assigned intervention. A total of 61 iNO infants and 84 control infants were actually exposed to the study intervention. Infants who developed refractory hypoxaemia at any time (defined as PO<SUB>2</SUB> &lt; 50 and PCO<SUB>2</SUB> &lt; 50 mmHg for FiO<SUB>2</SUB> = 1.0) were defined as "failures" with regard to the primary outcome measure, and iNO was given according to French Drug Agency recommendations. All consented infants started to receive the study intervention when they met hypoxic respiratory failure criteria, defined as the need for mechanical ventilation, FiO<SUB>2</SUB> &gt; 40% and a/AO<SUB>2</SUB> ratio &lt; 0.22. The first hour of iNO treatment consisted of a dose of 5 ppm iNO. Researchers determined subsequent dosages according to the a/AO<SUB>2</SUB> response. As soon as the response was positive (defined as an a/AO<SUB>2</SUB> increase &gt; 0.22), investigators decreased iNO to 2 ppm for two hours, then weaned participants according to the results of blood gas evaluations. The primary outcome variable was survival without respiratory support, oxygen supplementation or IVH &gt; grade 1 to 28 days of age.</P>
<P>
<LINK REF="STD-INNOVO-2005" TYPE="STUDY">INNOVO 2005</LINK>
<BR/>Investigators in this European multi-centre study planned to enrol 200 infants at less than 34 weeks' gestation and less than 28 days old. Eligibility was limited to "severe respiratory failure requiring assisted ventilation if the responsible physician was uncertain about whether an infant might benefit from iNO". The protocol suggested that iNO should be started at 5 ppm and could be doubled up to a maximum of 40 ppm. Study authors listed two primary outcome criteria in the main publication, but they calculated the sample size on the basis of a reduction in frequency of the combined outcome of death or severe disability at one year corrected postnatal age. Researchers had enrolled 108 infants when the study was terminated. The primary publication of the trial included data on neurological and developmental outcomes to one year of corrected age (obtained from a questionnaire completed by the local paediatrician); investigators in Huddy 2008 reported further follow-up to four to five years' corrected age (British Ability Scales).</P>
<P>
<LINK REF="STD-Dani-2006" TYPE="STUDY">Dani 2006</LINK>
<BR/>Dani and colleagues planned to enrol 52 infants at less than 30 weeks' gestation and less than one week of age in a single-centre study. Infants ventilated with severe respiratory distress were eligible if they had FiO<SUB>2</SUB> &gt; 0.5 and an a/AO<SUB>2</SUB> ratio &lt; 0.15 despite surfactant treatment. Forty infants had been enrolled at termination of the study. Mean age at the start of the intervention was 43 hours in the iNO group. Infant treatment began at 10 ppm of iNO, which was decreased to 6 ppm after four hours; treatment then continued until extubation or until weaning criteria were reached.</P>
<P>
<LINK REF="STD-Van-Meurs-2007" TYPE="STUDY">Van Meurs 2007</LINK>
</P>
<P>At the same time that they enrolled preterm infants with birth weight less than 1500 grams into the <LINK REF="STD-Van-Meurs-2005" TYPE="STUDY">Van Meurs 2005</LINK> study, the same group of investigators enrolled larger preterm infants at less than 34 weeks' gestation and weighing more than 1500 grams into a pilot RCT. They applied the same eligibility criteria of severe hypoxic respiratory failure, which was defined as an OI of 15 or more on two consecutive measurements of arterial blood gases (ABGs) between 30 minutes and 12 hours apart. Study authors expected the sample size to be small, and indeed they were able to randomise only 29 infants. They started infant treatment with iNO or placebo gas at a dose of 5 ppm, with an option to increase to 10 ppm depending on response. Maximum treatment duration was 14 days.</P>
<P>
<LINK REF="STD-Su-2007" TYPE="STUDY">Su 2007</LINK>
</P>
<P>This single-centre trial performed in Taiwan included a short-term primary outcome variable of oxygenation response 24 hours after enrolment. Investigators randomised 65 babies at less than 31 weeks' gestation and weighing less than 1500 grams with OI of at least 25. They commenced iNO at 5 ppm and could vary dosage according to oxygenation response, up to a maximum of 20 ppm. The maximum duration of therapy was not described. The actual OI before treatment averaged just over 30 in each group.</P>
<P>
<LINK REF="STD-Wei-2014" TYPE="STUDY">Wei 2014</LINK>
</P>
<P>This single-centre trial in China enrolled 60 infants at &#8804; 34 weeks' gestation. Admission criteria included postnatal age less than seven days and OI of at least 11, which persisted after two hours of surfactant therapy. Treatment for infants in the NO group started at 5 ppm and could be varied according to oxygenation response. Researchers continued iNO inhalation for at least seven days or until ventilation withdrawal. Study authors did not report time of enrolment but stated that the short-term primary outcome variable was OI before treatment and at one, 12, 24, 48 and 72 hours post treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trials of iNO in preterm infants eligible after three days of age because of elevated risk of BPD</HEADING>
<P>Review authors included studies in the second group if they enrolled preterm infants who were more than three days old after using a risk score or other method to determine that infants were at increased risk for BPD. This group consisted of three trials of iNO in preterm infants (<LINK REF="STD-Ballard-2006" TYPE="STUDY">Ballard 2006</LINK>; <LINK REF="STD-Subhedar-1997" TYPE="STUDY">Subhedar 1997</LINK>; <LINK REF="STD-Yoder-2013" TYPE="STUDY">Yoder 2013</LINK>). <LINK REF="STD-Ballard-2006" TYPE="STUDY">Ballard 2006</LINK> enrolled infants after seven days of age if they remained ventilated or, for the smallest infants, were receiving continuous positive airway pressure (CPAP). <LINK REF="STD-Subhedar-1997" TYPE="STUDY">Subhedar 1997</LINK> enrolled infants at 96 hours of age who met the main eligibility criterion of a score predicting high risk of BPD. <LINK REF="STD-Yoder-2013" TYPE="STUDY">Yoder 2013</LINK> included infants who were five to 14 days of age and still required respiratory support. Thus, infants in the three studies (<LINK REF="STD-Ballard-2006" TYPE="STUDY">Ballard 2006</LINK>; <LINK REF="STD-Subhedar-1997" TYPE="STUDY">Subhedar 1997</LINK>; <LINK REF="STD-Yoder-2013" TYPE="STUDY">Yoder 2013</LINK>) were enrolled after the major risk period for development of IVH. <LINK REF="STD-Ballard-2006" TYPE="STUDY">Ballard 2006</LINK> reported a respiratory severity score (which cannot be directly converted to the OI, as it does not take into account the PaO<SUB>2</SUB> - few eligible infants would have had arterial lines) calculated as FiO<SUB>2</SUB> multiplied by mean airway pressure in cmH<SUB>2</SUB>O. The median score was 3.5 in each group (mean 4.1), which suggests mild illness. In <LINK REF="STD-Yoder-2013" TYPE="STUDY">Yoder 2013</LINK>, the mean score on the same scale was 2.9.</P>
<P>
<LINK REF="STD-Subhedar-1997" TYPE="STUDY">Subhedar 1997</LINK>
<BR/>Subhedar and colleagues performed an open randomised trial of iNO in preterm infants at less than 32 weeks' gestation who were enrolled at 96 hours of age if still intubated. Entry criteria included "high" risk for developing BPD, as determined by a previously published risk score (<LINK REF="REF-Ryan-1996" TYPE="REFERENCE">Ryan 1996</LINK>). The actual score required for eligibility was not given. Investigators randomised nfants in a 2 × 2 factorial design to receive iNO only (n = 10), iNO plus dexamethasone (n = 10), dexamethasone only (n = 11) or neither (n = 11). Treatment consisted of 20 ppm of iNO, reduced to 5 ppm according to treatment response. The dexamethasone dose was 1 mg/kg/d for three days, then 0.5 mg/kg/d for three additional days. The study included 42 infants with a mean birth weight of 882 grams (range 416 to 1354 grams) and a mean gestational age of 27 weeks (range 24 to 30 weeks) for the 20 iNO infants compared with a mean birth weight of 762 grams (range 520 to 1320 grams) and a mean gestational age of 27 weeks (range 22 to 31 weeks) for the 22 non-iNO infants. Study authors did not present results separately for each of the four groups randomised in this study. They presented almost all data as iNO versus no iNO, regardless of whether dexamethasone was given. Therefore, it is not possible to assess possible interactions or to compare the effects of iNO solely among infants who did not receive steroids. Investigators performed developmental assessments (Bayley Scales of Infant Development) and neurological examinations at 30 months' corrected age and reported results in Bennett 2001.<BR/>
<B>
<BR/>
</B>
<LINK REF="STD-Ballard-2006" TYPE="STUDY">Ballard 2006</LINK>
<BR/>Ballard and colleagues studied 582 infants at &#8804; 32 weeks' gestation with birth weight of 500 to 1250 grams who were receiving mechanical ventilation for lung disease (not apnoea) between seven and 21 days of age. Infants with birth weight of 500 to 799 grams who were being treated with nasal CPAP were also eligible. Investigators initially treated infants with 20 ppm of study gas (iNO or nitrogen placebo) for 48 to 96 hours, and subsequently decreased doses to 10, 5 and 2 ppm at weekly intervals. Minimum treatment duration was 24 days. The median respiratory severity score (calculated as FiO<SUB>2</SUB> multiplied by mean airway pressure in cmH<SUB>2</SUB>O) was 3.5 in each group, which suggests, on average, relatively mild respiratory disease. Study authors calculated that a severity score of 3.5 is equivalent to an OI between 5 and 9. Twelve percent of participants in the iNO group had a score &gt; 10, as did 13% in the control group. Walsh 2010 reported neurological and developmental outcomes (Bayley Scales of Infant Development) at 24 months' corrected age.</P>
<P>
<LINK REF="STD-Yoder-2013" TYPE="STUDY">Yoder 2013</LINK>
</P>
<P>This multi-centre trial (funded by Ikaria) enrolled 451 infants at less than 30 weeks' gestation with birth weight less than 1250 grams if they still required assisted ventilation at five to 14 days of age. Infants weighing less than 800 grams could be enrolled if on CPAP; larger infants - 800 to 1249 grams - were eligible only if intubated on positive-pressure ventilation. The dosing regimen was 20 ppm given for 72 to 96 hours, then reduced to 10 ppm for 10 days, then to 5 ppm to complete 24 total days of therapy. The mean respiratory severity score was 2.9, compared with 4.1 in <LINK REF="STD-Ballard-2006" TYPE="STUDY">Ballard 2006</LINK>. The primary outcome variable was survival without BPD; data presented to this point include respiratory outcomes out to one year of corrected age. Data on neurological and developmental outcomes to 18 months of age are awaited.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trials of routine prophylactic use of iNO in preterm infants</HEADING>
<P>Studies were eligible to be included in this third group if they enrolled infants early in life (at less than three days of age) and required no minimum severity of illness criteria other than the need for respiratory support. We included four trials in this category (<LINK REF="STD-EUNO-2009" TYPE="STUDY">EUNO 2009</LINK>; <LINK REF="STD-Kinsella-2006" TYPE="STUDY">Kinsella 2006</LINK>; <LINK REF="STD-Kinsella-2014" TYPE="STUDY">Kinsella 2014</LINK>; <LINK REF="STD-Schreiber-2003" TYPE="STUDY">Schreiber 2003</LINK>).</P>
<P>
<LINK REF="STD-Schreiber-2003" TYPE="STUDY">Schreiber 2003</LINK>
<BR/>This single-centre study enrolled intubated preterm infants at less than 34 weeks' gestation with birth weight less than 2 kg at less than 72 hours of age. Study authors stated no specific oxygenation criteria. The study used a 2 × 2 factorial design and examined seven days of iNO or oxygen placebo with high-frequency oscillatory ventilation provided by the SensorMedics device (SensorMedics Corporation, Yorba Linda, California, USA) or conventional ventilation. Treatment began as iNO given at 10 ppm the first day, followed by 5 ppm for six days. The iNO intervention was blinded. Entry criteria did not require a prespecified disease severity. The median OI was 7.3 for the iNO group and 6.8 for the control group. The primary outcome was survival without chronic lung disease (oxygen requirement at 36 weeks' postmenstrual age). Mestan 2003 reported neurological outcomes and developmental progress (Bayley Scales of Infant Devleopment) of infants at two years' corrected age.</P>
<P>
<LINK REF="STD-Kinsella-2006" TYPE="STUDY">Kinsella 2006</LINK>
<BR/>Kinsella and colleagues conducted one of the largest multi-centre trials completed to date. They achieved the planned sample size of 792 infants and enrolled infants at &lt; 34 weeks' gestation who were ventilated for respiratory failure in the first 48 hours and were expected to remain intubated for longer than 48 hours. They included no further requirement for severity of illness. Investigators administered 5 ppm of iNO or nitrogen placebo to infants until extubation or for up to 21 days. The primary outcome variable was survival without BPD; the main secondary outcomes were severe IVH, periventricular leukomalacia and cerebral ventricular dilation. The OI at baseline was 5.4 (SD 5.2) in the treatment group and 5.8 (SD 6.7) in the placebo group. At one year of corrected age, researchers performed neurological examination and developmental evaluation (Bayley Scales of Infant Development); Watson 2009 reported these results.</P>
<P>
<LINK REF="STD-EUNO-2009" TYPE="STUDY">EUNO 2009</LINK>
</P>
<P>Mercier and colleagues completed EUNO (European trial of iNO) in 2009. This multi-centre trial randomised 800 infants within the first 26 hours of life to 5 ppm of iNO for a minimum of seven days (up to 21 days if still on respiratory support) or to placebo. Infants were eligible if they were between 24 weeks' gestation and 28 weeks and six days. Investigators applied two entry criteria. Infants were eligible if they were intubated and received surfactant before 24 hours of age, or if they required &#8805; 30% oxygen and were supported by CPAP. Researchers excluded infants in either group if they required more than 50% oxygen to maintain arterial saturation greater than 85%. The primary outcome variable was survival without BPD, defined according to Walsh's physiological criteria at 36 weeks' postmenstrual age. Secondary outcome criteria were survival without serious brain injury defined according to findings of head ultrasonography. Durrmeyer 2013 reported follow-up neurological and developmental evaluations. Follow-up of this study was based on the third version of the Bayley Scales of Infant Development, and results are not directly comparable with scores reported by the other two trials. The absolute proportion of children with developmental delay was much lower when the third version of the Bayley Scales of Infant Development was used; as developmental delay is the largest component of the outcome of neurodevelopmental Impairment, fewer infants had this outcome in the EUNO follow-up trial. iNO Therapeutics funded this trial.</P>
<P>
<LINK REF="STD-Kinsella-2014" TYPE="STUDY">Kinsella 2014</LINK>
</P>
<P>This multi-centre trial enrolled infants with birth weight between 50 and 1250 grams only if they were receiving non-invasive respiratory support along with some additional oxygen within the first 72 hours of life. Investigators added iNO at 10 ppm to the inspired gases, to achieve an effective concentration of at least 5 ppm. The study was masked, and controls received placebo nitrogen gas. The primary outcome was the combined outcome of death or BPD. Researchers continued to provide study gas until 30 weeks' postmenstrual age, for a minimum of two weeks.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-12-11 07:25:27 -0500" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Skimming-1997" TYPE="STUDY">Skimming 1997</LINK>
<BR/>Skimming and colleagues conducted a randomised comparison of response to 5 ppm and 20 ppm of iNO. All infants received iNO.</P>
<P>
<LINK REF="STD-Lindwall-2005" TYPE="STUDY">Lindwall 2005</LINK>
<BR/>This short-term (30-minute) cross-over study of preterm infants receiving CPAP for RDS examined effects on gas exchange. All infants received iNO as the first or second gas administered.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-12-12 08:38:08 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Trials of iNO in preterm infants eligible within the first three days because they met oxygenation criteria (early rescue therapy)</HEADING>
<P>
<LINK REF="STD-Kinsella-1999" TYPE="STUDY">Kinsella 1999</LINK>
<BR/>This multi-centre study reported masked allocation and masked intervention. Investigators stratified randomisation by centre and gestational age (&#8804; 28 weeks and &gt; 28 weeks) and performed intention-to-treat (ITT) analysis. The study was terminated after 80 of the planned 210 infants were enrolled, when an interim analysis suggested that significant benefit was not likely to be detected "within a reasonable time frame". Researchers planned the interim analysis at the start of the study but did not state whether slow enrolment was a predesignated stopping criterion.</P>
<P>
<LINK REF="STD-Mercier-1999" TYPE="STUDY">Mercier 1999</LINK>
<BR/>This multi-centre international trial provided the unmasked intervention and adequately concealed randomisation at the co-ordinating centre by using sealed envelopes. Investigators designed the study to assess the primary outcome after two hours. They permitted later treatment with iNO if the infant's oxygenation worsened such that the OI exceeded 30. Five of the control infants eventually received iNO. The availability of back-up iNO treatment for control infants limited the ability of the study to address long-term outcomes. Researchers planned to enrol a total of 360 infants across both gestational age strata, but the study was terminated because of slowing enrolment after two years. It was not stated whether early analysis or cessation criteria were predesignated. Researchers performed ITT analysis. All baseline characteristics were similar between groups.</P>
<P>
<LINK REF="STD-Srisuparp-2002" TYPE="STUDY">Srisuparp 2002</LINK>
<BR/>This single-centre trial included ventilated preterm infants with birth weight less than 2000 grams. Enrolled infants had received surfactant, were less than 72 hours old and had an arterial line in place. Oxygenation criteria allowed randomisation of the smallest babies (&#8804; 1000 grams) with only mild disease (OI &#8805; 4) and required increased OI for enrolment of infants with increasing birth weight (&#8805; 12 with birth weight 1751 to 2000 grams). The adequacy of masking is uncertain, as allocation was completed according to a "card-picking scheme". Researchers did not mask the intervention. The primary outcome variable was severe IVH. Investigators weaned iNO at 20 ppm within six to 12 hours; a subsequent weaning protocol planned weaning within 72 hours unless deterioration was evident. The maximum duration of treatment was seven days.</P>
<P>
<LINK REF="STD-Van-Meurs-2005" TYPE="STUDY">Van Meurs 2005</LINK>
<BR/>This multi-centre study used a telephone system to mask randomisation. Investigators masked the intervention by using simulated flow of gas as a placebo, performed ITT analysis and masked the outcome assessment. Researchers assessed all infants for the primary outcome. They initially planned to recruit 440 infants; the study was terminated after two-thirds of the infants had been assessed for the primary outcome because an increase in severe IVH was apparent with no benefit in terms of the primary outcome. By the time the analysis was completed, researchers had enrolled 420 infants, and the study was terminated.</P>
<P>
<LINK REF="STD-Van-Meurs-2007" TYPE="STUDY">Van Meurs 2007</LINK>
</P>
<P>This study followed the same design as the primary <LINK REF="STD-Van-Meurs-2005" TYPE="STUDY">Van Meurs 2005</LINK> trial. Investigators determined sample size by progression of the primary trial; masked randomisation, intervention and outcome assessment; and performed ITT analysis.</P>
<P>
<LINK REF="STD-Hascoet-2005" TYPE="STUDY">Hascoet 2005</LINK>
<BR/>This multi-centre trial conducted at 10 tertiary perinatal centres in France and Belgium achieved masked randomisation with a call-in telephone system and did not mask the intervention. Refractory hypoxaemia before six hours of age occurred in 20 infants, who therefore were not entered into the study. An additional 20 iNO infants and 28 control infants received open-label iNO for refractory hypoxaemia, further complicating analyses of results through significant contamination of control infants. Researchers achieved the initially planned sample size and the approximately expected incidence of hypoxic respiratory failure.</P>
<P>
<LINK REF="STD-INNOVO-2005" TYPE="STUDY">INNOVO 2005</LINK>
<BR/>This multi-centre trial attained masked allocation with a telephone system. Investigators assigned treatment by minimisation ("with a probabilistic element") rather than by strict randomisation and did not mask the intervention. Researchers performed ITT analysis and reported that follow-up was complete for all except one infant. Follow-up was not formally blinded. Investigators enrolled 55 iNO infants and 53 controls. The study was stopped at the end of the calendar year 2001; apparently, this had been planned, although it was not mentioned in the on-line version of the trial protocol nor in the register of controlled trials.</P>
<P>
<LINK REF="STD-Dani-2006" TYPE="STUDY">Dani 2006</LINK>
<BR/>This study randomised infants by using sealed opaque envelopes and, therefore, was presumably masked. The intervention was not masked. The study was terminated after 40 of the initially planned 52 infants had been enrolled, after a previously unplanned interim analysis confirmed the investigators' impression that BPD was reduced. This early termination provided insufficient protection from type 1 errors.</P>
<P>
<LINK REF="STD-Su-2007" TYPE="STUDY">Su 2007</LINK>
</P>
<P>Researchers did not describe the randomisation process used in this study; therefore, masking is uncertain. The intervention was not masked, nor was the evaluation of outcomes. Investigators pre-planned and achieved the planned sample size and performed ITT analysis.</P>
<P>
<LINK REF="STD-Wei-2014" TYPE="STUDY">Wei 2014</LINK>
</P>
<P>Study authors did not describe the randomisation process; therefore, masking of allocation is uncertain. They reported no masking of the intervention and provided no information about sample size determination.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trials of iNO in preterm infants eligible after three days of age because of elevated risk of BPD</HEADING>
<P>
<LINK REF="STD-Subhedar-1997" TYPE="STUDY">Subhedar 1997</LINK>
<BR/>This study provided unmasked intervention but adequately concealed randomisation with the use of sealed envelopes. Researchers initially planned a sample size of 88 participants. However, the study was terminated at a sample size of 42 because at a predesignated 12-month review, the incidence of the primary outcome of death or BPD was much higher than planned, "which would have enabled the planned outcome to be detected with a much smaller group." It was not stated whether this was a predesignated stopping criterion. Investigators performed ITT analysis. Despite randomisation, oxygenation was not well matched between groups at baseline. The median OI in control infants was 3.9 (range 1.2 to 11.5) and in iNO infants 7.9 (range 1.6 to 46.7). The iNO group included a greater proportion of males (12/20 vs 5/22); other baseline characteristics were similar.</P>
<P>
<LINK REF="STD-Ballard-2006" TYPE="STUDY">Ballard 2006</LINK>
<BR/>This multi-centre trial reported masked allocation. Investigators masked study gas (iNO or nitrogen) to all except the study respiratory therapist. Follow-up to assessment of the primary outcome was complete, and investigators remained masked. Investigators performed ITT analysis. A data safety monitoring committee oversaw the study, and researchers performed interim analyses according to preplanned rules. The study was allowed to proceed to the initially planned sample size.</P>
<P>
<LINK REF="STD-Yoder-2013" TYPE="STUDY">Yoder 2013</LINK>
</P>
<P>This study reported masked allocation and masked intervention. Follow-up to assessment of the primary outcome was complete, and researchers performed ITT analysis. They achieved the initially planned sample size.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Trials of routine use of iNO in preterm infants on respiratory support</HEADING>
<P>
<LINK REF="STD-Schreiber-2003" TYPE="STUDY">Schreiber 2003</LINK>
<BR/>This single-centre study reported masked randomisation. Investigators masked the iNO intervention by using an oxygen placebo and performed ITT analysis. Follow-up of enrolled infants was complete. Researchers assessed the primary outcome in a masked fashion and did not state whether long-term neurodevelopmental follow-up was also masked. They achieved the planned sample size.</P>
<P>
<LINK REF="STD-Kinsella-2006" TYPE="STUDY">Kinsella 2006</LINK>
<BR/>This multi-centre trial described masked allocation. Investigators masked study gas (iNO or nitrogen). Follow-up was complete with respect to assessment of the primary outcome, which researchers assessed in a masked fashion. They performed ITT analysis. A data safety monitoring committee oversaw the study, and study authors performed interim analyses according to preplanned rules. The study was allowed to proceed to the initially planned sample size.</P>
<P>
<LINK REF="STD-EUNO-2009" TYPE="STUDY">EUNO 2009</LINK>
</P>
<P>This multi-centre trial reported masked allocation and intervention. Investigators administered placebo study gas to controls. Follow-up was complete with respect to assessment of the primary outcome, which researchers assessed in a masked fashion. They performed ITT analysis. A data safety monitoring committee oversaw the study, and investigators conducted interim analyses according to preplanned rules. The study was allowed to proceed to the initially planned sample size.</P>
<P>
<LINK REF="STD-Kinsella-2014" TYPE="STUDY">Kinsella 2014</LINK>
</P>
<P>This multi-centre trial reported masked allocation and intervention. Follow-up was complete to hospital discharge or death, and investigators performed ITT analysis. They planned sample size for a reduction in the primary outcome variable and achieved this size.</P>
<P>We have provided summaries of risk of bias evaluations in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-12-23 11:43:42 -0500" MODIFIED_BY="[Empty name]">
<P>Review authors considered the usefulness of analyses that included all trials of iNO in preterm infants to be limited because of differing entry criteria for these studies. Severity of illness criteria and age at entry varied so greatly that pooling of results was not considered appropriate. Control group mortality also varied substantially (6% to 64%), further emphasising differences among eligible patients; we have reported only subgroup analyses.</P>
<P>As noted above, we grouped trials post hoc into three categories that created groups of studies, each of which was fairly homogeneous in terms of age of entry and severity of illness criteria (and control group mortality).</P>
<OL>
<LI>Entry in the first three days of life based on oxygenation criteria.</LI>
<LI>Routine use in preterm babies receiving respiratory support.</LI>
<LI>Later enrolment based on BPD risk.</LI>
</OL>
<P>The post hoc group of studies that randomised ventilated preterm infants with an oxygenation defect in the first few days of life were fairly similar. All studies randomised infants to low-dose iNO. <LINK REF="STD-INNOVO-2005" TYPE="STUDY">INNOVO 2005</LINK> did not provide precise criteria for entry but stated that the criterion was "if the responsible physician was uncertain about whether an infant might benefit from iNO". Despite this difference, mortality and BPD frequencies are not very dissimilar from those reported by the other studies in this group. Methods used for calculation of the oxygenation defect in remaining studies were different and were not all directly comparable. Several studies reported the OI. In this group of studies, most participants were entered before three days of age, although some studies allowed enrolment up to seven days of age. <LINK REF="STD-Srisuparp-2002" TYPE="STUDY">Srisuparp 2002</LINK> was a pilot study of 34 infants that was designed primarily to evaluate changes in oxygenation. <LINK REF="STD-Srisuparp-2002" TYPE="STUDY">Srisuparp 2002</LINK> did not report on BPD. Of note, both <LINK REF="STD-Hascoet-2005" TYPE="STUDY">Hascoet 2005</LINK> and <LINK REF="STD-Mercier-1999" TYPE="STUDY">Mercier 1999</LINK> allowed back-up treatment of controls with iNO if their condition worsened to a prespecified degree. This may have led to underestimation of both benefit and risk. Most of the studies in this group reported comparable mortality in control groups, at between 30% and 44%; the single exception was INNOVO, which reported mortality of 64% among controls. <LINK REF="STD-Van-Meurs-2007" TYPE="STUDY">Van Meurs 2007</LINK>, which enrolled somewhat larger babies, reported slightly lower mortality among controls, at four of 15. <LINK REF="STD-Wei-2014" TYPE="STUDY">Wei 2014</LINK> reported a lower mortality rate in the NO group than in the control group (3% vs 13%, P &lt; 0.05).</P>
<P>Three studies evaluated infants at more than three days of age on the basis of elevated risk of BPD. <LINK REF="STD-Subhedar-1997" TYPE="STUDY">Subhedar 1997</LINK> was quite different from the other trials; investigators examined both iNO and dexamethasone therapy using a factorial design. They selected infants at 96 hours of age on the basis of high risk of BPD. Indeed, investigators found an almost universal incidence of BPD at 36 weeks. <LINK REF="STD-Ballard-2006" TYPE="STUDY">Ballard 2006</LINK> enrolled infants who were still ventilator dependent at seven to 21 days of age (or, in the case of the smallest infants, at birth weight 500 to 799 grams and requiring CPAP) with no other criteria for increased BPD risk; enrolled infants received 24 days of iNO starting at 20 ppm. <LINK REF="STD-Yoder-2013" TYPE="STUDY">Yoder 2013</LINK>, which shared many features with <LINK REF="STD-Ballard-2006" TYPE="STUDY">Ballard 2006</LINK>, enrolled infants between five and 14 days of age if they were still requiring mechanical respiratory support, without requiring other criteria for increased risk of BPD; and using prolonged treatment with iNO starting at 20 ppm. These trials were not similar to <LINK REF="STD-Subhedar-1997" TYPE="STUDY">Subhedar 1997</LINK>, which applied a unique entry criterion and a factorial design. For this reason, we performed a sensitivity analysis with and without <LINK REF="STD-Subhedar-1997" TYPE="STUDY">Subhedar 1997</LINK>. As the Subhedar trial enrolled very small numbers of infants, results of analyses with and without this study are identical. The mortality of control groups in <LINK REF="STD-Ballard-2006" TYPE="STUDY">Ballard 2006</LINK> and <LINK REF="STD-Yoder-2013" TYPE="STUDY">Yoder 2013</LINK> was only 6% and 7%, respectively, reflecting older age at entry compared with the other two groups of studies, as well as lesser severity of illness than in early rescue studies.</P>
<P>Four studies enrolled infants without specific minimum criteria for disease severity. <LINK REF="STD-Schreiber-2003" TYPE="STUDY">Schreiber 2003</LINK> randomised preterm infants who were ventilator dependent after receiving surfactant, without requiring a specific disease severity. Similarly, <LINK REF="STD-Kinsella-2006" TYPE="STUDY">Kinsella 2006</LINK> enrolled infants at less than 34 weeks who were ventilated and were expected to be ventilated for longer than 48 hours. They applied no other severity of illness criteria. Eighty percent had received surfactant. <LINK REF="STD-EUNO-2009" TYPE="STUDY">EUNO 2009</LINK> enrolled infants who were intubated for surfactant or were on CPAP with a modest oxygen requirement. This study excluded infants who required more than 50% oxygen. Infants in this group of trials were substantially less sick as demonstrated by lower OIs than were reported for infants in the first group of studies. Control group mortalities were comparable in the first two studies, at 23% and 25%, and were lower, at 11%, in the most recent study (<LINK REF="STD-EUNO-2009" TYPE="STUDY">EUNO 2009</LINK>. <LINK REF="STD-Kinsella-2014" TYPE="STUDY">Kinsella 2014</LINK> enrolled children who were receiving non-invasive support with some supplemental oxygen within the first 72 hours of age; infants were less sick again than in the other trials, with three deaths among 124 infants, and with 40% developing BPD.</P>
<P>We have provided below the results for each subgroup.</P>
<SUBSECTION>
<HEADING LEVEL="3">Death before hospital discharge (Outcome 1.1)</HEADING>
<P>All trials assessed survival to discharge. None of the individual trials noted a significant effect, except <LINK REF="STD-Wei-2014" TYPE="STUDY">Wei 2014</LINK>. The three subgroups showed no effect on hospital mortality (Early studies with entry before three days based on oxygenation criteria: typical risk ratio (RR) 1.02, 95% confidence interval (CI) 0.89 to 1.18; 10 studies, 1066 infants; typical RD 0.01, 95% CI 0.05 to 0.07; Entry after three days of age based on BPD risk: typical RR 1.18, 95% CI 0.81 to 1.71; three studies, 1075 infants; typical RD 0.01, 95% CI -0.02 to 0.05; Studies of early routine use: typical RR 0.90, 95% CI 0.74 to 1.10; four studies, 1924 infants; typical RD -0.02, 95% CI -0.05 to 0.02).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Death before 36 weeks' postmenstrual age (Outcome 1.2)</HEADING>
<P>Nine studies reported this outcome, five of which included 458 infants and were grouped under early entry on the basis of oxygenation criteria. For infants entered early (before three days) on the basis of oxygenation criteria, investigators reported no significant effect of iNO on this outcome (typical RR 0.89, 95% CI 0.72 to 1.11; typical RD -0.05, 95% CI -0.13 to 0.04). <LINK REF="STD-Subhedar-1997" TYPE="STUDY">Subhedar 1997</LINK>, with entry after three days of age based on BPD risk, also reported this result and did not show a significant effect. <LINK REF="STD-EUNO-2009" TYPE="STUDY">EUNO 2009</LINK> showed no significant effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Bronchopulmonary dysplasia (oxygen dependence among survivors at 36 weeks' postmenstrual age) (Outcome 1.3)</HEADING>
<P>All published studies except <LINK REF="STD-Hascoet-2005" TYPE="STUDY">Hascoet 2005</LINK> and <LINK REF="STD-Srisuparp-2002" TYPE="STUDY">Srisuparp 2002</LINK> reported BPD rates at 36 weeks; the principal investigator supplied data from Hascoet to review authors (for four of the iNO infants and for 10 controls, data on oxygen dependency at 36 weeks were missing, although these infants were known to have survived). None of the individual trials reported a significant effect. Heterogeneity for each of the subgroups was substantial, and no subgroups noted a statistically significant difference in BPD. Results included the following.</P>
<OL>
<LI>Studies with entry before three days of age based on oxygenation criteria: typical RR 0.89, 95% CI 0.76 to 1.04; eight studies, 681 infants; I<SUP>2</SUP> = 29%; typical RD -0.05, 95% CI -0.12 to 0.01.</LI>
<LI>Studies with entry after three days of age based on BPD risk: typical RR 0.91, 95% CI 0.83 to 1.01; three studies, 990 infants; I<SUP>2</SUP> = 11%; typical RD -0.06, 95% CI -0.12 to 0.00.</LI>
<LI>Studies of routine use in intubated preterm infants: typical RR 0.95, 95% CI 0.85 to 1.05; four studies, 1782 infants; I<SUP>2</SUP> = 10%; typical RD -0.02, 95% CI -0.07 to 0.02.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Death or bronchopulmonary dysplasia (Outcome 1.4)</HEADING>
<P>The combined outcome of death or bronchopulmonary dysplasia (or its converse, survival without bronchopulmonary dysplasia) was available for all studies.</P>
<P>None of the individual trials with entry based on an oxygenation deficit found a significant effect, and this subgroup of studies showed no effect (typical RR 0.94, 95% CI 0.87 to 1.01; eight studies, 958 infants; typical RD -0.05, 95% CI -0.10 to 0.01). Similarly, studies with entry after three days of age based on BPD risk did not individually show a significant effect, and group results were not significant (typical RR 0.92, 95% CI 0.85 to 1.01; three studies, 1075 infants; typical RD -0.05, 95% CI -0.11 to 0.01). The group of studies of routine early use also showed no significant effect (typical RR 0.94, 95% CI 0.87 to 1.01; four studies, 1924 infants; typical RD -0.03, 95% CI -0.08 to 0.01).</P>
<P>Of note, the published report of <LINK REF="STD-Ballard-2006" TYPE="STUDY">Ballard 2006</LINK> showed a modest but statistically significant improvement in survival without BPD, from 36.8% to 43.9% (P = 0.042). This finding is different from that of the analysis performed for this review because study authors used a statistical method that cannot be replicated from published summary data - the multiple outputation technique (see below).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Any intraventricular haemorrhage (Outcome 1.5)</HEADING>
<P>Four studies with entry in the first three days of life based on oxygenation criteria reported this outcome. No evidence suggested an effect of iNO on overall IVH frequency (typical RR 0.94, 95% CI 0.69 to 1.28; 314 infants; typical RD -0.02, 95% CI -.012 to 0.08). Among routine early treatment studies, <LINK REF="STD-Kinsella-2006" TYPE="STUDY">Kinsella 2006</LINK> reported a small reduction and <LINK REF="STD-EUNO-2009" TYPE="STUDY">EUNO 2009</LINK> reported a barely significant increase. Overall researchers noted no effect (typical RR 1.04, 95% CI 0.88 to 1.23; two studies, 1573 infants; typical RD 0.01, 95% CI -0.03 to 0.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Severe intraventricular haemorrhage (grade 3 or 4) (Outcome 1.6)</HEADING>
<P>Six of the studies reporting entry in the first three days of life based on oxygenation criteria reported on severe IVH. Meta-analysis of these studies showed an almost significant increase in the incidence of severe IVH (typical RR 1.20, 95% CI 0.98 to 1.47; 773 infants; typical RD 0.05, 95% CI -0.00 to 0.10).</P>
<P>Most cases of IVH occur in the first three days of life; therefore, studies with later entry would not be expected to report an effect on IVH. Evolution of preexisting abnormalities, development of hydrocephalus and occurrence of periventricular leukomalacia were reported as a single variable by <LINK REF="STD-Ballard-2006" TYPE="STUDY">Ballard 2006</LINK> and were not different between groups.</P>
<P>Studies of routine use of iNO in intubated preterm infants reported a small and non-significant reduction in severe haemorrhage (typical RR 0.89, 95% CI 0.73 to 1.09; four studies, 1913 infants; typical RD -0.01, 95% CI -0.04 to 0.01). Heterogeneity for this result is evident (I<SUP>2</SUP> = 52%): <LINK REF="STD-EUNO-2009" TYPE="STUDY">EUNO 2009</LINK> reported an increase, and <LINK REF="STD-Schreiber-2003" TYPE="STUDY">Schreiber 2003</LINK> and <LINK REF="STD-Kinsella-2006" TYPE="STUDY">Kinsella 2006</LINK> described a decrease.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Severe intraventricular haemorrhage or periventricular leukomalacia (Outcome 1.7)</HEADING>
<P>Studies with entry in the first three days of age based on oxygenation criteria showed no significant effect but noted a small non-significant increase in this adverse outcome (typical RR 1.08, 95% CI 0.88 to 1.33; eight studies, 901 infants; typical RD 0.02, 95% CI -0.04 to 0.08).</P>
<P>Studies of routine use of iNO in intubated preterm infants showed a small and non-significant reduction in this outcome (typical RR 0.90, 95% CI 0.73 to 1.12; three studies, 1747 infants; typical RD -0.02, 95% CI -0.05 to 0.02). This result shows major heterogeneity (I<SUP>2</SUP> = 80%): <LINK REF="STD-EUNO-2009" TYPE="STUDY">EUNO 2009</LINK> showed a small increase, whereas the other two trials (<LINK REF="STD-Kinsella-2006" TYPE="STUDY">Kinsella 2006</LINK>; <LINK REF="STD-Schreiber-2003" TYPE="STUDY">Schreiber 2003</LINK>) described a decrease in this outcome.</P>
<SUBSECTION>
<HEADING LEVEL="4">Periventricular leukomalacia</HEADING>
<P>This outcome was not reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Neurodevelopmental outcome (Outcomes 1.8, Neurodevelopmental disability; and 1.9, Bayley Mental Development Index or Physical Development Index &lt; -2 SD)</HEADING>
<P>All results are expressed among the number of survivors evaluated.</P>
<P>To date, studies reporting neurodevelopmental outcomes include <LINK REF="STD-Subhedar-1997" TYPE="STUDY">Subhedar 1997</LINK>; <LINK REF="STD-Schreiber-2003" TYPE="STUDY">Schreiber 2003</LINK>; <LINK REF="STD-INNOVO-2005" TYPE="STUDY">INNOVO 2005</LINK>; <LINK REF="STD-Van-Meurs-2005" TYPE="STUDY">Van Meurs 2005</LINK>; <LINK REF="STD-Kinsella-2006" TYPE="STUDY">Kinsella 2006</LINK>; <LINK REF="STD-Van-Meurs-2007" TYPE="STUDY">Van Meurs 2007</LINK>; and <LINK REF="STD-Ballard-2006" TYPE="STUDY">Ballard 2006</LINK>.</P>
<P>
<LINK REF="STD-Subhedar-1997" TYPE="STUDY">Subhedar 1997</LINK> (Bennett 2001): Twenty-two children were still alive at 30 months of age, and 21 were formally examined (seven iNO infants and 14 control infants). Findings revealed no significant differences in outcomes. The definition of "severe neurodisability" in the outcome manuscript was very similar to our definition of neurodevelopmental disability. All five infants with severe neurodisability (mental development index (MDI) or physical development index (PDI) &lt; 71, cerebral palsy or sensorineural impairment) were control infants.</P>
<P>
<LINK REF="STD-Schreiber-2003" TYPE="STUDY">Schreiber 2003</LINK> (Mestan 2005): At two years' corrected age, the original study included 168 survivors, 139 of whom (82%) were evaluated. This study showed a significant reduction in the frequency of a composite outcome of neurodevelopmental disability (cerebral palsy, bilateral blindness, bilateral hearing loss or a score on the Bayley Scales of Infant Development &gt; 2 SD below the mean). This improvement was largely the result of a decrease in the incidence of a Bayley score greater than two SDs below the mean. The occurrence of cerebral palsy was similar between groups.</P>
<P>
<LINK REF="STD-INNOVO-2005" TYPE="STUDY">INNOVO 2005</LINK> reported the incidence of major disability at one year of age among 43 of 44 survivors. Severe disability was not different between iNO and control groups. Investigators defined severe disability as no/minimal head control or inability to sit unsupported or no/minimal response to visual stimuli (equivalent to developmental quotient &lt; 50). Results showed no differences between groups (7/55 vs 3/53), but lack of formal testing and earlier age at assessment made comparison with Schreiber difficult. Differences in definition did now allow these results to be combined in a meta-analysis. Infants were also evaluated more formally at four to five years of age (Huddy 2008). Investigators performed a neurological examination and used the British Ability Scales to evaluate 38 of 43 survivors, noting no differences between groups.</P>
<P>
<LINK REF="STD-Van-Meurs-2005" TYPE="STUDY">Van Meurs 2005</LINK> (Hintz 2007) performed standardised testing (Bayley II) at 18 to 22 months of age among 193 of 213 surviving infants (90%), and reported neurodevelopmental impairment defined identically in this review. Researchers reported no differences between groups in neurodevelopmental impairment but more frequent moderate to severe cerebral palsy in the group that had received iNO (18/90 vs 11/102, adjusted RR 2.01, 95% CI 1.01 to 3.98) (adjusted data from Hintz 2007).</P>
<P>
<LINK REF="STD-Kinsella-2006" TYPE="STUDY">Kinsella 2006</LINK> (Watson 2009) reported results of neurological examination and Bayley testing at one year corrected age in 455 of 615 survivors (74%). Results showed no differences between groups in terms of neurodevelopmental impairment occurring as cerebral palsy, blindness or severe hearing loss (Bayley MDI &lt; 70 or PDI &lt; 70).</P>
<P>
<LINK REF="STD-Van-Meurs-2007" TYPE="STUDY">Van Meurs 2007</LINK> applied the same testing protocol for larger infants in this study as was applied for <LINK REF="STD-Van-Meurs-2005" TYPE="STUDY">Van Meurs 2005</LINK>. Of 20 survivors, 17 were seen, and results presented in the main publication showed no differences between groups.</P>
<P>
<LINK REF="STD-Ballard-2006" TYPE="STUDY">Ballard 2006</LINK> (Walsh 2010) performed follow-up examinations including a Bayley II evaluation at two years' corrected age. Researchers evaluated 477 of 535 survivors in this way (89%) and diagnosed neurodevelopmental impairment by using criteria identical to those of this review. Results showed no differences between groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cerebral palsy (Outcome 1.10)</HEADING>
<P>Of note in the meta-analysis of effects of iNO on cerebral palsy, <LINK REF="STD-Schreiber-2003" TYPE="STUDY">Schreiber 2003</LINK> and <LINK REF="STD-Subhedar-1997" TYPE="STUDY">Subhedar 1997</LINK> presented data on all severities of CP, whereas the other trials (<LINK REF="STD-Ballard-2006" TYPE="STUDY">Ballard 2006</LINK>; <LINK REF="STD-Kinsella-2006" TYPE="STUDY">Kinsella 2006</LINK>; <LINK REF="STD-Van-Meurs-2005" TYPE="STUDY">Van Meurs 2005</LINK>; <LINK REF="STD-Van-Meurs-2007" TYPE="STUDY">Van Meurs 2007</LINK>) provided results showing moderate/severe or disabling cerebral palsy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Severe retinopathy of prematurity (Outcome 1.11)</HEADING>
<P>Investigators expressed results among the number of survivors evaluated. Evidence did not suggest an effect on severe retinopathy of prematurity (as reported by <LINK REF="STD-Schreiber-2003" TYPE="STUDY">Schreiber 2003</LINK> and by <LINK REF="STD-Van-Meurs-2005" TYPE="STUDY">Van Meurs 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Retinopathy requiring surgery (Outcome 1.12)</HEADING>
<P>No evidence suggests an effect on this outcome. Results were as follows.</P>
<OL>
<LI>Studies with entry before three days of age based on oxygenation criteria: typical RR 0.87, 95% CI 0.59 to 1.29; four studies, 673 infants; typical RD -0.02, 95% CI -0.07 to 0.03.</LI>
<LI>Studies with entry after three days of age based on BPD risk: typical RR 1.04, 95% CI 0.78 to 1.38; one study, 582 infants; typical RD 0.01, 95% CI -0.06 to 0.08.</LI>
<LI>Studies of routine use in intubated preterm infants: typical RR 1.08, 95% CI 0.79 to 1.47; two studies, 917 infants; typical RD 0.01, 95% CI -0.03 to 0.06.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other reported results</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Oxygenation within two hours of therapy</HEADING>
<P>
<LINK REF="STD-Kinsella-1999" TYPE="STUDY">Kinsella 1999</LINK> reported improvement in PaO<SUB>2</SUB> after 60 minutes of about 40 mmHg compared with about 10 mmHg among controls.</P>
<P>
<LINK REF="STD-Subhedar-1997" TYPE="STUDY">Subhedar 1997</LINK> reported that treated infants had a sustained fall of OI on iNO; a 25% reduction in oxygenation index or a 0.10 reduction in FiO<SUB>2</SUB> was more likely during the first two hours among treated infants (13/20) compared with control infants (4/22). This was reflected by the greater percentage decrease in OI in the treated group (16.9%) compared with the control group (no change); however, OI was higher at baseline among treated infants.</P>
<P>
<LINK REF="STD-Mercier-1999" TYPE="STUDY">Mercier 1999</LINK> demonstrated effects of iNO on oxygenation at two hours, with a median 5.4 fall in OI for nitric oxide infants, and a median 3.6 fall in OI for control infants. Study authors presented oxygenation results in ways that were too variable to allow meta-analysis. Overall, it appeared that improvements in oxygenation were probably more frequent when infants received iNO compared with no therapy.</P>
<P>
<LINK REF="STD-Srisuparp-2002" TYPE="STUDY">Srisuparp 2002</LINK> reported significant increases in PaO<SUB>2</SUB> and SpO<SUB>2</SUB> from baseline for the iNO group.</P>
<P>
<LINK REF="STD-Wei-2014" TYPE="STUDY">Wei 2014</LINK> reported no significant changes in blood gas markers (PaO<SUB>2</SUB>, SpO<SUB>2</SUB>, OI) after 60 minutes between the NO group and the control group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Pulmonary artery pressure</HEADING>
<P>
<LINK REF="STD-Subhedar-1997" TYPE="STUDY">Subhedar 1997</LINK> reported a reduction in pulmonary artery pressure as assessed by echocardiography within 30 minutes of treatment compared with no change in control infants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of assisted ventilation</HEADING>
<P>
<LINK REF="STD-Kinsella-1999" TYPE="STUDY">Kinsella 1999</LINK> found a significant reduction in ventilator days among iNO survivors (median 26, range three to 69 days among iNO infants; median 37, range eight to 395 days among control infants). However, <LINK REF="STD-Mercier-1999" TYPE="STUDY">Mercier 1999</LINK> reported no significant difference in the duration of assisted ventilation among survivors (iNO, median 12 days; control, median 16 days). As only median results were given with a different descriptor of variance (interquartile range), projecting a typical estimate was not possible. <LINK REF="STD-Hascoet-2005" TYPE="STUDY">Hascoet 2005</LINK> supplied data regarding ventilator days among iNO-treated survivors compared with controls (iNO 14.5 days, SD 11.4 (median 9 days); control 17.1 days, SD 16.4 (median 10 days)). <LINK REF="STD-Wei-2014" TYPE="STUDY">Wei 2014</LINK> reported no significant differences in time spent when mechanical ventilation or nasal CPAP supplementary ventilation was used among survivors (iNO, median 98 days; control, median 112 days).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-12-12 09:23:49 -0500" MODIFIED_BY="[Empty name]">
<P>This review suggests that no clear indications are known for inhaled nitric oxide (iNO) in preterm infants. Previous versions of this review suggested that early routine treatment might be beneficial, but with the addition of <LINK REF="STD-EUNO-2009" TYPE="STUDY">EUNO 2009</LINK> results, reduction in death or bronchopulmonary dysplasia (BPD) and reduction in brain injury, which appeared possible previously, are no longer significant. Heterogeneity for these results remains unexplained, and further investigation of the reasons behind this heterogeneity may be helpful.</P>
<P>Early rescue treatment does not appear successful and may lead to a non-significant increase in brain injury. However, preterm infants with clear evidence of pulmonary hypertension have not been separately identified in these studies and may constitute a subgroup with a different response.</P>
<SUBSECTION>
<HEADING LEVEL="2">Mortality</HEADING>
<P>None of the individual trials showed a reduction in mortality, except <LINK REF="STD-Wei-2014" TYPE="STUDY">Wei 2014</LINK>. Meta-analysis of the first two trials that evaluated routine use of iNO in intubated infants suggested a potential difference, but addition of the similar <LINK REF="STD-EUNO-2009" TYPE="STUDY">EUNO 2009</LINK> trial revealed no apparent effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Survival without bronchopulmonary dysplasia</HEADING>
<P>Studies investigating iNO as routine treatment in preterm infants showed no effect on the combined outcome of death or bronchopulmonary dysplasia. Studies with entry before three days of age based on oxygenation criteria revealed no apparent benefit from iNO.</P>
<P>
<LINK REF="STD-Ballard-2006" TYPE="STUDY">Ballard 2006</LINK> reported a reduction in the combined outcome of death or BPD in a large multi-centre trial upon analysis of data, as planned, with the multiple outputation technique. A preplanned subgroup analysis in the subgroup of infants who were seven to 14 days of age at enrolment, and in the subgroup of infants who were less unwell (respiratory severity score &lt; 3.5), showed greatest benefit. <LINK REF="STD-Yoder-2013" TYPE="STUDY">Yoder 2013 </LINK>conducted a further trial specifically enrolling such children and showed, in contrast, no benefit of iNO. The summary overall effect noted in trials of later treatment to prevent BPD shows a risk ratio of "death or BPD" of 0.92, with 95% confidence intervals (CIs) just including the possibility of no effect (0.85 to 1.01).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Brain injury</HEADING>
<P>Three studies of early routine use of iNO in intubated preterm infants showed no effect on serious brain injury diagnosed by ultrasonography - severe intraventricular haemorrhage or the combined outcome of severe haemorrhage or periventricular leukomalacia. Early rescue studies showed a possible effect on this outcome; the 20% increase in severe haemorrhage is important, given that researchers demonstrated no benefit.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Neurological and developmental outcomes</HEADING>
<P>Data regarding long-term neurodevelopmental outcomes are accumulating. Early rescue studies that reported neurodevelopmental outcomes reported no improvement.</P>
<P>As for early routine use, <LINK REF="STD-Schreiber-2003" TYPE="STUDY">Schreiber 2003</LINK> demonstrated a reduction in abnormal neurodevelopmental outcome at two years of age, largely due to improved Bayley scores of mental development. The other study that showed improvement in appearances of the brain on ultrasonography (<LINK REF="STD-Kinsella-2006" TYPE="STUDY">Kinsella 2006</LINK>) has not yet reported longer-term outcomes.</P>
<P>Early routine use of iNO in intubated preterm infants previously appeared to decrease the incidence of severe brain injury as demonstrated on ultrasonography. Although the criteria for study entry for <LINK REF="STD-Kinsella-2006" TYPE="STUDY">Kinsella 2006</LINK> required only that infants must be less than or equal to 34 weeks' gestation, in fact, the mean gestational age was 25.6 weeks in each group, and mean birth weight less than 800 grams, demonstrating that a higher-risk group was enrolled. Similarly, for <LINK REF="STD-Schreiber-2003" TYPE="STUDY">Schreiber 2003</LINK>, the actual birth weight was approximately 1 kilogram for the two groups and gestational age was less than 28 weeks. In addition, this hospital served a somewhat deprived inner city neighbourhood, with a low rate of antenatal steroid use (&lt; 60%). However, the addition of <LINK REF="STD-EUNO-2009" TYPE="STUDY">EUNO 2009</LINK> abolished this apparent benefit, and no significant change in the overall frequency of severe intraventricular haemorrhage or periventricular leukomalacia is apparent. Of note, only <LINK REF="STD-Kinsella-2006" TYPE="STUDY">Kinsella 2006</LINK> carefully reported head abnormalities on ultrasonography before enrolment and described a lower frequency of new lesions in the group treated with iNO than in the control group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Overall</HEADING>
<P>Further analysis of patient characteristics associated with a possible beneficial response would be helpful. An editorial accompanying published results of <LINK REF="STD-Schreiber-2003" TYPE="STUDY">Schreiber 2003</LINK> suggested that maternal ethnicity may have influenced findings; however, the somewhat similar study of <LINK REF="STD-Kinsella-2006" TYPE="STUDY">Kinsella 2006</LINK> showed no effect of ethnicity.</P>
<P>One particular finding of this review is our inability to replicate the analysis performed by authors of the Ballard trial. The authors of this study randomised multiples (twins or triplets from the same pregnancy) as clusters. The analysis technique that they utilised (multiple outputation) cannot be replicated without access to the original data; therefore, results of the RevMan analysis differ from those reported in the original publication. We did not find a significant effect, whereas multiple outputation revealed a statistically significant result. Ballard and associates used this technique in part because significant evidence of a genetic effect may influence outcomes such as BPD, and thus infants from multiple gestations may be more likely to show coherent effects of an intervention than non-related infants.</P>
<P>Various approaches are being utilised by investigators, including generalised estimating equations (GEEs) with sensitivity analysis and the multiple outputation techniques mentioned above. We recently performed an individual participant meta-analysis using data from all but one of the relevant trials and confirmed the original authors' conclusions based on these techniques (<LINK REF="REF-Askie-2010" TYPE="REFERENCE">Askie 2010</LINK>). We advise caution when attempts are made to combine trial results because some trials used specific techniques to account for multiples.</P>
<P>Overall results of meta-analysis when individual participant data were combined confirm overall results of RevMan analyses and should allow further in-depth analysis of subgroups of infants who may benefit and who should be entered into future trials. In future studies, investigators need to be specific regarding techniques used to account for outcomes of multiple pregnancies.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-12-12 09:24:11 -0500" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-12-12 09:24:11 -0500" MODIFIED_BY="[Empty name]">
<P>In very sick preterm infants who meet the criteria for poor oxygenation, rescue therapy with iNO does not improve survival, survival without BPD or brain injury, even though oxygenation may be improved in the short term. In fact, some evidence suggests a potential increase in severe intracranial haemorrhage and in the combined outcome of severe intraventricular haemorrhage or periventricular leukomalacia. In view of these findings, iNO should not be routinely used for preterm infants as rescue therapy in cases of hypoxic respiratory failure.</P>
<P>Early routine use of iNO in ventilated preterm infants who are not severely ill but nevertheless are at risk for serious brain injury or BPD does not appear to be effective. Although some trials have shown potential benefit, meta-analysis of the three trials in this grouping did not confirm an overall benefit. Only a single study in this group has reported longer-term neurodevelopmental outcomes, and this study has suggested beneficial effects. Current data do not support widespread routine treatment with iNO to prevent BPD or to prevent brain injury.</P>
<P>Use of iNO in small preterm infants who remain on respiratory support at five to 21 days does not seem to reduce BPD. The effect appears to be most marked in infants who are less sick, as determined by subgroup analyses, and in infants treated earlier, that is, between seven and 14 days of age. The risk difference is 0.07, and, if this effect is confirmed, the number needed to treat for an additional beneficial outcome (NNTB) is approximately 14. Owing to inability to replicate the original analysis, the 95% CI of the risk difference includes 1; therefore, we calculated the 95% CI of the NNTB to include 7 and infinity.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-12-12 09:05:47 -0500" MODIFIED_BY="[Empty name]">
<P>Additional studies on the use of inhaled nitric oxide in preterm infants are warranted. Further analysis of the results of <LINK REF="STD-Kinsella-2006" TYPE="STUDY">Kinsella 2006,</LINK> <LINK REF="STD-Schreiber-2003" TYPE="STUDY">Schreiber 2003</LINK> and <LINK REF="STD-EUNO-2009" TYPE="STUDY">EUNO 2009</LINK> may delineate groups that are more likely to benefit from early routine iNO with reduction in both brain injury and BPD for inclusion in future studies. Long-term follow-up should be provided in future studies.</P>
<P>Later use at between seven and 14 days of age for infants who continue to require respiratory support also warrants further investigation. Lack of apparent effect as determined by subgroup analysis of sicker infants is disappointing, and other approaches should be considered for these infants, including investigation of other doses.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-12-11 11:08:23 -0500" MODIFIED_BY="[Empty name]">
<P>The Cochrane Neonatal Review Group has been funded in part with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, USA, under Contract No. HHSN267200603418C.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-12-11 11:11:10 -0500" MODIFIED_BY="[Empty name]">
<P>Dr Barrington was Chair of the Canadian Medical Advisory Committee for iNO therapeutics for one meeting in 2004.<BR/>Dr Barrington and Dr Finer were participants in a research project funded by Ikaria, an individual patient data meta-analysis of iNO in the preterm, from which neither received any income.</P>
<P>Dr Barrington received an honorarium for speaking at a symposium funded by Mallinckrodt on the topic of probiotics.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-12-11 11:09:55 -0500" MODIFIED_BY="[Empty name]">
<P>KJB and NF were involved in development and writing of the review protocol, the literature search and appraisal, data extraction and completion of the final review. TP assisted in revision of the article, analysis of publications and completion of the latest update.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-12-11 11:12:15 -0500" MODIFIED_BY="[Empty name]">
<P>The initial protocol did not foresee dividing included trials into three groups according to indications for enrolment. We added methods, the plan for Summary of findings tables and GRADE recommendations, which were not included in the original protocol.</P>
<P>We added the following outcomes post hoc (as reported in trials but not prespecified): oxygenation within two hours of therapy, pulmonary artery pressure, duration of assisted ventilation.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-12-23 16:45:02 +0000" MODIFIED_BY="Colleen Ovelman">
<STUDIES MODIFIED="2016-12-11 16:48:19 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-12-11 16:46:02 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ballard-2006" MODIFIED="2016-12-11 16:35:11 -0500" MODIFIED_BY="[Empty name]" NAME="Ballard 2006" YEAR="">
<REFERENCE MODIFIED="2010-11-09 21:11:46 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, et al</AU>
<TI>Inhaled nitric oxide in preterm infants undergoing mechanical ventilation</TI>
<SO>New England Jounal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<PG>343-53</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261742"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-08 15:32:52 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Di Fiore JM, Hibbs AM, Zadell AE, Merrill JD, Eichenwald EC, Puri AR, et al</AU>
<TI>The effect of inhaled nitric oxide on pulmonary function in preterm infants</TI>
<SO>Journal of Perinatology</SO>
<YR>2007</YR>
<VL>27</VL>
<PG>766-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261743"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-11 16:34:54 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hibbs AM, Walsh MC, Martin RJ, Truog WE, Lorch SA, Alessandrini E, et al</AU>
<TI>One-year respiratory outcomes of preterm infants enrolled in the Nitric Oxide (to prevent) Chronic Lung Disease trial</TI>
<SO>Journal of Pediatrics</SO>
<YR>2008</YR>
<VL>153</VL>
<PG>525-9</PG>
<IDENTIFIERS MODIFIED="2010-11-09 15:53:15 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261744"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-11 16:35:11 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walsh MC, Hibbs AM, Martin CR, Cnaan A, Keller RL, Vittinghoff E, et al</AU>
<TI>Two-year neurodevelopmental outcomes of ventilated preterm infants treated with inhaled nitric oxide</TI>
<SO>Journal of Pediatrics</SO>
<YR>2010</YR>
<VL>156</VL>
<PG>556-61.e1</PG>
<IDENTIFIERS MODIFIED="2010-11-09 15:53:26 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261745"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261741"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dani-2006" NAME="Dani 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dani C, Bertini G, Pezzati M, Filippi L, Cecchi A, Rubaltelli FF</AU>
<TI>Inhaled nitric oxide in very preterm infants with severe respiratory distress syndrome</TI>
<SO>Acta Paediatrica</SO>
<YR>2006</YR>
<VL>95</VL>
<PG>1116-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261747"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261746"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EUNO-2009" MODIFIED="2016-07-18 16:06:07 -0400" MODIFIED_BY="[Empty name]" NAME="EUNO 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-07-18 16:06:07 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Durrmeyer X, Hummler H, Sanchez-Luna M, Carnielli VP, Field D, Greenough A, et al</AU>
<TI>Two-year outcomes of a randomized controlled trial of inhaled nitric oxide in premature infants</TI>
<SO>Pediatrics</SO>
<YR>2013</YR>
<VL>132</VL>
<NO>3</NO>
<PG>e695-703</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261749"/><IDENTIFIER TYPE="PUBMED" VALUE="23940237"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-10 09:22:43 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mercier JC, Hummler H, Durrmeyer X, Sanchez-Luna M, Carnielli V, Field D, et al</AU>
<TI>Inhaled nitric oxide for the prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomized controlled trial</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>376</VL>
<PG>346-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261750"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-11-06 00:25:03 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261748"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hascoet-2005" MODIFIED="2016-12-11 16:36:05 -0500" MODIFIED_BY="[Empty name]" NAME="Hascoet 2005" YEAR="">
<REFERENCE MODIFIED="2016-12-11 16:36:05 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hascoet JM, Fresson J, Claris O, Hamon I, Lombet J, Liska A, et al</AU>
<TI>The safety and efficacy of nitric oxide therapy in premature infants</TI>
<SO>Journal of Pediatrics</SO>
<YR>2005</YR>
<VL>146</VL>
<PG>318-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261752"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261751"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-INNOVO-2005" MODIFIED="2010-11-10 09:23:41 -0500" MODIFIED_BY="[Empty name]" NAME="INNOVO 2005" YEAR="">
<REFERENCE MODIFIED="2010-11-08 15:33:28 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahluwalia J, Tooley J, Cheema I, Sweet DG, Curley AE, Halliday HL, et al</AU>
<TI>A dose response study of inhaled nitric oxide in hypoxic respiratory failure in preterm infants</TI>
<SO>Early Human Development</SO>
<YR>2006</YR>
<VL>82</VL>
<PG>477-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261754"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 21:20:34 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Field D, Elbourne D, Truesdale A, Grieve R, Hardy P, Fenton AC, et al</AU>
<TI>Neonatal ventilation with inhaled nitric oxide versus ventilatory support without inhaled nitric oxide for preterm infants with severe respiratory failure: the INNOVO multicentre randomized controlled trial (ISRCTN 17821339)</TI>
<SO>Pediatrics</SO>
<YR>2005</YR>
<VL>115</VL>
<PG>926-36</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261755"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-10 09:23:41 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huddy CL, Bennett CC, Hardy P, Field D, Elbourne D, Grieve R, et al</AU>
<TI>The INNOVO multicentre randomised controlled trial: neonatal ventilation with inhaled nitric oxide versus ventilatory support without nitric oxide for severe respiratory failure in preterm infants: follow up at 4-5 years</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>2008</YR>
<VL>93</VL>
<PG>F430-5</PG>
<IDENTIFIERS MODIFIED="2010-11-09 15:53:41 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261756"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261753"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinsella-1999" MODIFIED="2010-11-08 11:13:11 -0500" MODIFIED_BY="[Empty name]" NAME="Kinsella 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-08 11:13:11 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinsella JP, Walsh WF, Bose CL, Gerstmann DR, Labella JJ, Sardesai S</AU>
<TI>Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomized controlled trial</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<PG>1061-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261758"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261757"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kinsella-2006" MODIFIED="2010-11-10 09:24:12 -0500" MODIFIED_BY="[Empty name]" NAME="Kinsella 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-11-09 21:21:56 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kinsella JP, Cutter GR, Walsh WF, Gerstmann DR, Bose CL, Hart C, et al</AU>
<TI>Early inhaled nitric oxide therapy in premature newborns with respiratory failure</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<PG>354-64</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261760"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-10 09:24:12 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watson RS, Clermont G, Kinsella JP, Kong L, Arendt RE, Cutter G, et al</AU>
<TI>Clinical and economic effects of iNO in premature newborns with respiratory failure at 1 year</TI>
<SO>Pediatrics</SO>
<YR>2009</YR>
<VL>124</VL>
<PG>1333-43</PG>
<IDENTIFIERS MODIFIED="2010-11-09 15:53:55 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261761"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261759"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinsella-2014" MODIFIED="2016-07-18 16:07:53 -0400" MODIFIED_BY="[Empty name]" NAME="Kinsella 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-07-18 16:07:53 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinsella JP, Cutter GR, Steinhorn RH, Nelin LD, Walsh WF, Finer NN, et al</AU>
<TI>Noninvasive inhaled nitric oxide does not prevent bronchopulmonary dysplasia in premature newborns</TI>
<SO>Journal of Pediatrics</SO>
<YR>2014</YR>
<VL>165</VL>
<NO>6</NO>
<PG>1101-8</PG>
<IDENTIFIERS MODIFIED="2014-10-17 15:39:33 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261763"/><IDENTIFIER TYPE="PUBMED" VALUE="25063725"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261762"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mercier-1999" MODIFIED="2010-11-10 09:12:47 -0500" MODIFIED_BY="[Empty name]" NAME="Mercier 1999" YEAR="1998">
<REFERENCE MODIFIED="2010-11-08 11:13:11 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Franco-Belgium Collaborative NO Trial Group</AU>
<TI>Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomized controlled trial</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<PG>1066-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261765"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Mercier JC, Dehan M, Breart G, Clement S, O'Nody P. Inhaled nitric oxide in neonatal respiratory failure. A randomized clinical trial. Pediatr Res 1998;43:290A (Abstract).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mercier JC, Dehan M, Breart G, Clement S, O'Nody P</AU>
<TI>Inhaled nitric oxide in neonatal respiratory failure. A randomized clinical trial</TI>
<SO>Pediatric Research</SO>
<YR>1998</YR>
<VL>43</VL>
<PG>290A (Abstract)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261766"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-10 09:12:47 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;ProCite field[35]: ENG&lt;/p&gt;" NOTES_MODIFIED="2010-11-10 09:12:47 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Truffert P, Llado-Paris J, Mercier JC, Dehan M, Bréart G; Franco-Belgian iNO Study Group</AU>
<TI>Early inhaled nitric oxide in moderately hypoxemic preterm and term newborns with RDS: the RDS subgroup analysis of the Franco-Belgian iNO Randomized Trial</TI>
<SO>European Journal of Pediatrics</SO>
<YR>2003</YR>
<VL>162</VL>
<PG>646-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261767"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261764"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schreiber-2003" MODIFIED="2010-11-09 21:25:47 -0500" MODIFIED_BY="[Empty name]" NAME="Schreiber 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-09 21:25:14 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mestan K, Marks J, Hecox K, Huo D, Schreiber MD</AU>
<TI>Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<PG>23-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261771"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 21:25:47 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P</AU>
<TI>Inhaled nitric oxide in premature infants with the respiratory distress syndrome</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<PG>2099-107</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261772"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261770"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Srisuparp-2002" NAME="Srisuparp 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Srisuparp P, Heitschmidt M, Schreiber MD</AU>
<TI>Inhaled nitric oxide therapy in premature infants with mild to moderate respiratory distress syndrome</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2002</YR>
<VL>85</VL>
<PG>S469-78</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261774"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261773"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-2007" MODIFIED="2010-11-08 15:34:15 -0500" MODIFIED_BY="[Empty name]" NAME="Su 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-08 15:34:15 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Su PH, Chen JY</AU>
<TI>Inhaled nitric oxide in the management of preterm infants with severe respiratory failure</TI>
<SO>Journal of Perinatology</SO>
<YR>2008</YR>
<VL>28</VL>
<PG>112-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261776"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261775"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Subhedar-1997" MODIFIED="2016-12-11 16:43:45 -0500" MODIFIED_BY="[Empty name]" NAME="Subhedar 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-09 15:54:38 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bennett AJ, Shaw NJ, Gregg JE, Subhedar NV</AU>
<TI>Neurodevelopmental outcome in high-risk preterm infants treated with inhaled nitric oxide</TI>
<SO>Acta Paediatrica</SO>
<YR>2001</YR>
<VL>90</VL>
<PG>573-6</PG>
<IDENTIFIERS MODIFIED="2010-11-09 15:54:38 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261778"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-11 16:43:27 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Subhedar NV, Ryan SW, Shaw NJ. Open randomized controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Arch Dis Child 1997;77:F185-F190.&lt;/p&gt;" NOTES_MODIFIED="2016-12-11 16:43:27 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Subhedar NV, Ryan SW, Shaw NJ</AU>
<TI>Open randomized controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants</TI>
<SO>Archives of Disease in Childhood. Fetal Neonatal Edition</SO>
<YR>1997</YR>
<VL>77</VL>
<PG>F185-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261779"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-11 16:43:45 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Subhedar NV, Shaw NJ. Changes in oxygenation and pulmonary haemodynamics in preterm infants treated with inhaled nitric oxide. Arch Dis Child 1997;77:F191-F197.&lt;/p&gt;" NOTES_MODIFIED="2016-12-11 16:43:45 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Subhedar NV, Shaw NJ</AU>
<TI>Changes in oxygenation and pulmonary haemodynamics in preterm infants treated with inhaled nitric oxide</TI>
<SO>Archives of Disease in Childhood. Fetal Neonatal Edition</SO>
<YR>1997</YR>
<VL>77</VL>
<PG>F191-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261780"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261777"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Meurs-2005" MODIFIED="2016-12-11 16:44:59 -0500" MODIFIED_BY="[Empty name]" NAME="Van Meurs 2005" YEAR="">
<REFERENCE MODIFIED="2010-11-10 09:25:14 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Report of a small subgroup of patients from the main Van Meurs 2005 trial&lt;/p&gt;" NOTES_MODIFIED="2010-11-10 09:25:14 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chock VY, Van Meurs KP, Hintz SR, Ehrenkranz RA, Lemons JA, Kendrick DE, et al</AU>
<TI>Inhaled nitric oxide for preterm premature rupture of membranes, oligohydramnios, and pulmonary hypoplasia</TI>
<SO>American Journal of Perinatology</SO>
<YR>2009</YR>
<VL>26</VL>
<PG>317-22</PG>
<IDENTIFIERS MODIFIED="2010-11-09 15:54:57 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261782"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-12-11 16:44:59 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hintz SR, Van Meurs KP, Perritt R, Poole WK, Das A, Stevenson DK, et al</AU>
<TI>Neurodevelopmental outcomes of premature infants with severe respiratory failure enrolled in a randomized controlled trial of inhaled nitric oxide</TI>
<SO>Journal of Pediatrics</SO>
<YR>2007</YR>
<VL>151</VL>
<PG>16-22, 22.e1-3</PG>
<IDENTIFIERS MODIFIED="2010-11-09 15:55:12 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261783"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-09 21:29:23 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van Meurs KP, Wright L, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK, et al</AU>
<TI>Inhaled nitric oxide for premature infants with severe respiratory failure</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<PG>13-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261784"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261781"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Meurs-2007" MODIFIED="2010-11-08 15:34:51 -0500" MODIFIED_BY="[Empty name]" NAME="Van Meurs 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-11-08 15:34:51 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Meurs KP, Hintz SR, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK, et al</AU>
<TI>Inhaled nitric oxide in infants &gt;1500 g and &lt;34 weeks gestation with severe respiratory failure</TI>
<SO>Journal of Perinatology</SO>
<YR>2007</YR>
<VL>27</VL>
<PG>347-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261786"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-11-06 00:25:37 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261785"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wei-2014" MODIFIED="2016-08-23 11:17:52 -0400" MODIFIED_BY="[Empty name]" NAME="Wei 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-07-18 16:14:16 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wei QF, Pan XN, Li Y, Feng L, Yao LP, Liu GL, et al</AU>
<TI>Efficacy of inhaled nitric oxide in premature infants with hypoxic respiratory failure</TI>
<SO>Zhongguo Dang Dai Er Ke za Zhi [Chinese Journal of Contemporary Pediatrics]</SO>
<YR>2014</YR>
<VL>16</VL>
<NO>8</NO>
<PG>805-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261788"/><IDENTIFIER TYPE="PUBMED" VALUE="25140772"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-08-23 11:17:52 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261787"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoder-2013" MODIFIED="2016-12-11 16:46:02 -0500" MODIFIED_BY="[Empty name]" NAME="Yoder 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-12-11 16:46:02 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Yoder BA</AU>
<TI>Inhaled NO for prevention of BPD: update on the NEWNO Trial</TI>
<SO>Hot Topics in Neonatology; 2013 December 8; Washington, DC</SO>
<YR>2013</YR>
<IDENTIFIERS MODIFIED="2016-08-23 11:16:56 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-08-23 11:16:46 -0400" MODIFIED_BY="[Empty name]" OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261769"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-08-23 11:17:59 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261768"/><IDENTIFIER MODIFIED="2016-08-23 11:17:59 -0400" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT 00931632"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-12-11 16:48:19 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Day-1996" MODIFIED="2016-12-11 16:48:19 -0500" MODIFIED_BY="[Empty name]" NAME="Day 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-12-11 16:48:19 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;ProCite field[35]: eng&lt;/p&gt;" NOTES_MODIFIED="2016-12-11 16:48:19 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Day RW, Lynch JM, White KS, Ward RM</AU>
<TI>Acute response to inhaled nitric oxide in newborns with respiratory failure and pulmonary hypertension</TI>
<SO>Pediatrics</SO>
<YR>1996</YR>
<VL>98</VL>
<PG>698-705</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261790"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261789"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindwall-2005" MODIFIED="2010-11-09 21:30:16 -0500" MODIFIED_BY="[Empty name]" NAME="Lindwall 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-09 21:30:16 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindwall R, Blennow M, Svensson M, Jonsson B, Berggren-Bostrom E, Flanby M, et al</AU>
<TI>A pilot study of inhaled nitric oxide in preterm infants treated with nasal continuous positive airway pressure for respiratory distress syndrome</TI>
<SO>Intensive Care Medicine</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>959-64</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261792"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261791"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skimming-1997" NAME="Skimming 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Skimming JW, Bender KA, Hutchison AA, Drummond WH. Nitric oxide inhalation in infants with respiratory distress syndrome. J Pediatr 1997;130:225-30.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skimming JW, Bender KA, Hutchison AA, Drummond WH</AU>
<TI>Nitric oxide inhalation in infants with respiratory distress syndrome</TI>
<SO>Journal of Pediatrics</SO>
<YR>1997</YR>
<VL>130</VL>
<PG>225-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3261794"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3261793"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-05-20 15:35:03 -0400" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2016-02-05 14:46:26 -0500" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-12-11 16:54:59 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-12-11 16:54:59 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abman-1990" NAME="Abman 1990" NOTES="&lt;p&gt;Abman SH, Chatfield BA, Hall SL, McMurtry IF. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol 1990;259:H1921-H1927.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Abman SH, Chatfield BA, Hall SL, McMurtry IF</AU>
<TI>Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth</TI>
<SO>American Journal of Physiology</SO>
<YR>1990</YR>
<VL>259</VL>
<PG>H1921-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Abman-1993" NAME="Abman 1993" NOTES="&lt;p&gt;Abman SH, Kinsella,JP, Schaffer MS, Wilkening RB. Inhaled nitric oxide in the management of a premature newborn with severe respiratory distress and pulmonary hypertension. Pediatrics 1993;92:606&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Abman SH, Kinsella JP, Schaffer MS, Wilkening RB</AU>
<TI>Inhaled nitric oxide in the management of a premature newborn with severe respiratory distress and pulmonary hypertension</TI>
<SO>Pediatrics</SO>
<YR>1993</YR>
<VL>92</VL>
<PG>606-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Askie-2010" MODIFIED="2010-11-10 09:26:09 -0500" MODIFIED_BY="[Empty name]" NAME="Askie 2010" TYPE="JOURNAL_ARTICLE">
<AU>Askie LM, Ballard RA, Cutter G, Dani C, Elbourne D, Field D, et al</AU>
<TI>Inhaled nitric oxide in preterm infants: a systematic review and individual patient data meta-analysis</TI>
<SO>BMC Pediatrics</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-2005" MODIFIED="2010-11-08 15:35:28 -0500" MODIFIED_BY="[Empty name]" NAME="Bland 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bland RD, Albertine KH, Carlton DP, MacRitchie AJ</AU>
<TI>Inhaled nitric oxide effects on lung structure and function in chronically ventilated preterm lambs</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>2005</YR>
<VL>172</VL>
<PG>899-906</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cornfield-1992" NAME="Cornfield 1992" NOTES="&lt;p&gt;Cornfield DN, Chatfield BA, McQueston JA, McMurtry IF, Abman SH. Effects of birth-related stimuli on L-arginine-dependent pulmonary vasodilation in ovine fetus. Am J Physiol 1992;262:H1474-H1481.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Cornfield DN, Chatfield BA, McQueston JA, McMurtry IF, Abman SH</AU>
<TI>Effects of birth-related stimuli on L-arginine-dependent pulmonary vasodilation in ovine fetus</TI>
<SO>American Journal of Physiology</SO>
<YR>1992</YR>
<VL>262</VL>
<PG>H1474-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Finer-1998" NAME="Finer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Finer NN, Barrington KJ</AU>
<TI>Nitric oxide therapy for the newborn infant</TI>
<SO>Seminars in Neonatology</SO>
<YR>1998</YR>
<VL>3</VL>
<PG>127-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Finer-2000" MODIFIED="2016-03-01 07:46:24 -0500" MODIFIED_BY="[Empty name]" NAME="Finer 2000" TYPE="COCHRANE_REVIEW">
<AU>Finer NN, Barrington KJ</AU>
<TI>Nitric oxide for respiratory failure in infants born at or near term</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2016-03-01 07:46:24 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-03-01 07:46:24 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000399"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Frostell-1991" NAME="Frostell 1991" NOTES="&lt;p&gt;Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide - A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991;83:2038-2047.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM</AU>
<TI>Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction</TI>
<SO>Circulation</SO>
<YR>1991</YR>
<VL>83</VL>
<PG>2038-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADEpro" MODIFIED="2016-12-11 16:50:33 -0500" MODIFIED_BY="[Empty name]" NAME="GRADEpro" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro [www.gradepro.org]</TI>
<PB>McMaster University, 2014</PB>
<CY>Ontario</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-12-11 16:50:50 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoehn-2006" MODIFIED="2010-11-09 21:34:50 -0500" MODIFIED_BY="[Empty name]" NAME="Hoehn 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hoehn T, Krause MF, Buhrer C</AU>
<TI>Meta-analysis of inhaled nitric oxide in premature infants: an update</TI>
<SO>Klinische Padiatrie</SO>
<YR>2006</YR>
<VL>218</VL>
<PG>57-61</PG>
<IDENTIFIERS MODIFIED="2010-11-09 21:34:50 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Hogman-1993" NAME="Hogman 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hogman M, Frostell C, Arnberg H, Hedenstierna G</AU>
<TI>Bleeding time prolongation and NO inhalation</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<PG>1664-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kinsella-1992" NAME="Kinsella 1992" NOTES="&lt;p&gt;Kinsella JP, McQueston JA, Rosenberg AA, Abman SH. Hemodynamic effects of exogenous nitric oxide in ovine transitional pulmonary circulation. Am J Physiol 1992;263:H875-H880.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kinsella JP, McQueston JA, Rosenberg AA, Abman SH</AU>
<TI>Hemodynamic effects of exogenous nitric oxide in ovine transitional pulmonary circulation</TI>
<SO>American Journal of Physiology</SO>
<YR>1992</YR>
<VL>263</VL>
<PG>H875-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kinsella-1994" NAME="Kinsella 1994" NOTES="&lt;p&gt;Kinsella JP, Ivy DD, Abman SH. Inhaled nitric oxide improves gas exchange and lowers pulmonary vascular resistance in severe experimental hyaline membrane disease. Pediatr Res 1994;36:402-8.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kinsella JP, Ivy DD, Abman SH</AU>
<TI>Inhaled nitric oxide improves gas exchange and lowers pulmonary vascular resistance in severe experimental hyaline membrane disease</TI>
<SO>Pediatric Research</SO>
<YR>1994</YR>
<VL>36</VL>
<PG>402-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McAndrew-1997" MODIFIED="2010-11-09 21:35:36 -0500" MODIFIED_BY="[Empty name]" NAME="McAndrew 1997" NOTES="&lt;p&gt;McAndrew J, Patel RP, Jo H, Cornwell T, Lincoln T, Moellering D, White CR, Matalon S, Darley-Usmar V. The interplay of nitric oxide and peroxynitrite with signal transduction pathways: implications for disease. Semin Perinatol 1997;21:351-66&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 21:35:36 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>McAndrew J, Patel RP, Jo H, Cornwell T, Lincoln T, Moellering D, et al</AU>
<TI>The interplay of nitric oxide and peroxynitrite with signal transduction pathways: implications for disease</TI>
<SO>Seminars in Perinatology</SO>
<YR>1997</YR>
<VL>21</VL>
<PG>351-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCurnin-2005" MODIFIED="2016-12-11 16:51:51 -0500" MODIFIED_BY="[Empty name]" NAME="McCurnin 2005" TYPE="JOURNAL_ARTICLE">
<AU>McCurnin DC, Pierce RA, Chang LY, Gibson LL, Osborne-Lawrence S, Yoder BA, et al</AU>
<TI>Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease</TI>
<SO>American Journal of Physiology. Lung Cellular and Molecular Physiology</SO>
<YR>2005</YR>
<VL>288</VL>
<PG>L450-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peliowski-1995" NAME="Peliowski 1995" NOTES="&lt;p&gt;Peliowski A, Finer N, Etches P, Tierney AJ, Ryan CA. Inhaled nitric oxide for premature infants after prolonged rupture of the membranes. J Pediatr 1995;126:450-453&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Peliowski A, Finer N, Etches P, Tierney AJ, Ryan CA</AU>
<TI>Inhaled nitric oxide for premature infants after prolonged rupture of the membranes</TI>
<SO>Journal of Pediatrics</SO>
<YR>1995</YR>
<VL>126</VL>
<PG>450-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roberts-1993" MODIFIED="2010-11-09 21:36:34 -0500" MODIFIED_BY="[Empty name]" NAME="Roberts 1993" NOTES="&lt;p&gt;Roberts JD Jr, Chen T-Y. Inhaled nitric oxide reverses pulmonary vasoconstriction in the hypoxic and acidotic newborn lamb. Circ Res 1993;72:246.&lt;/p&gt;" NOTES_MODIFIED="2010-11-09 21:36:34 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Roberts JD Jr, Chen TY, Kawai N, Wain J, Dupuy P, Shimouchi A, et al</AU>
<TI>Inhaled nitric oxide reverses pulmonary vasoconstriction in the hypoxic and acidotic newborn lamb</TI>
<SO>Circulation Research</SO>
<YR>1993</YR>
<VL>72</VL>
<PG>246-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rossaint-1993" NAME="Rossaint 1993" NOTES="&lt;p&gt;Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993;328:399-405.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM</AU>
<TI>Inhaled nitric oxide for the adult respiratory distress syndrome</TI>
<SO>New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>328</VL>
<PG>399-405</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ryan-1996" NAME="Ryan 1996" NOTES="&lt;p&gt;Ryan SW, Nycyk J, Shaw BNJ. Prediction of chronic neonatal lung disease on day 4 of life. Eur J Pediatr 1996;155:668-71.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Ryan SW, Nycyk J, Shaw BNJ</AU>
<TI>Prediction of chronic neonatal lung disease on day 4 of life</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>155</VL>
<PG>668-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Samama-1995" NAME="Samama 1995" NOTES="&lt;p&gt;Samama CM, Diaby M, Fellahi JL, et al. Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiol 1995;83:56-65.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Samama CM, Diaby M, Fellahi JL Mdhafar A, Eyraud D, Arock M</AU>
<TI>Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome</TI>
<SO>Anesthesiology</SO>
<YR>1995</YR>
<VL>83</VL>
<PG>56-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2013" MODIFIED="2016-12-11 16:53:05 -0500" MODIFIED_BY="[Empty name]" NAME="Schünemann 2013" TYPE="OTHER">
<AU>Schünemann H, Bro&#380;ek J, Guyatt G, Oxman A, editors; GRADE Working Group</AU>
<SO>GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. www.guidelinedevelopment.org/handbook.</SO>
<YR>Updated October 2013</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skimming-1995" NAME="Skimming 1995" NOTES="&lt;p&gt;Skimming JW, DeMarco VG, Cassin S. The effects of nitric oxide inhalation on the pulmonary circulation of preterm lambs. Pediatr Res 1995;37:35-40.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Skimming JW, DeMarco VG, Cassin S</AU>
<TI>The effects of nitric oxide inhalation on the pulmonary circulation of preterm lambs</TI>
<SO>Pediatric Research</SO>
<YR>1995</YR>
<VL>37</VL>
<PG>35-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soll-2001" MODIFIED="2008-10-28 10:49:06 -0400" MODIFIED_BY="[Empty name]" NAME="Soll 2001" TYPE="COCHRANE_REVIEW">
<AU>Soll R</AU>
<TI>Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1997</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-10-28 10:49:06 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-10-28 10:49:06 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000511"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Van-Meurs-1997" NAME="Van Meurs 1997" NOTES="&lt;p&gt;Van Meurs KP, Rhine WD, Asselin JM, Durand DJ, Premie INO Collaborative Group. Response of premature infants with severe respiratory failure to inhaled nitric oxide. Pediatr Res 1997;41:271A (Abstract).&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Van Meurs KP, Rhine WD, Asselin JM, Durand DJ, Premie INO Collaborative Group</AU>
<TI>Response of premature infants with severe respiratory failure to inhaled nitric oxide</TI>
<SO>Pediatric Research</SO>
<YR>1997</YR>
<VL>41</VL>
<PG>271A (Abstract)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vohr-2005" MODIFIED="2016-12-11 16:54:31 -0500" MODIFIED_BY="[Empty name]" NAME="Vohr 2005" TYPE="JOURNAL_ARTICLE">
<AU>Vohr BR, Wright LL, Poole K, McDonald SA</AU>
<TI>Neurodevelopmental outcomes of extremely low birth weight infants &lt;32 weeks' gestation between 1993 and 1998</TI>
<SO>Pediatrics</SO>
<YR>2005</YR>
<VL>116</VL>
<PG>635-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walther-1992" NAME="Walther 1992" NOTES="&lt;p&gt;Walther FJ, Benders MJ. Persistent pulmonary hypertension in premature neonates with severe respiratory distress syndrome. Pediatrics 1992;90:899.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Walther FJ, Benders MJ, Leighton JO</AU>
<TI>Persistent pulmonary hypertension in premature neonates with severe respiratory distress syndrome</TI>
<SO>Pediatrics</SO>
<YR>1992</YR>
<VL>90</VL>
<PG>899-904</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wirbelauer-2010" MODIFIED="2010-11-09 15:55:41 -0500" MODIFIED_BY="[Empty name]" NAME="Wirbelauer 2010" TYPE="JOURNAL_ARTICLE">
<AU>Wirbelauer J, Speer CP</AU>
<TI>Significance of nitric oxide inhalation (NO) in preterm infants &lt; 34 weeks of gestation</TI>
<TO>Stellenwert der Inhalation von Stickstoffmonoxid (NO) bei Fruhgeborenen&lt;34 Gestationswochen.</TO>
<SO>Klinische Padiatrie</SO>
<YR>2010</YR>
<VL>222</VL>
<PG>56-61</PG>
<IDENTIFIERS MODIFIED="2010-11-09 15:55:41 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2005" MODIFIED="2016-12-11 16:54:59 -0500" MODIFIED_BY="[Empty name]" NAME="Wood 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wood NS, Costeloe K, Gibson AT, Hennessy EM, Marlow N, Wilkinson AR</AU>
<TI>The EPICure study: associations and antecedents of neurological and developmental disability at 30 months of age following extremely preterm birth</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>2005</YR>
<VL>90</VL>
<PG>F134-40</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-03-01 07:47:12 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Barrington-1999" MODIFIED="2016-03-01 07:46:49 -0500" MODIFIED_BY="[Empty name]" NAME="Barrington 1999" TYPE="COCHRANE_REVIEW">
<AU>Barrington KJ, Finer NN</AU>
<TI>Inhaled nitric oxide for respiratory failure in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2016-03-01 07:46:49 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-03-01 07:46:49 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000509"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Barrington-2001" MODIFIED="2016-03-01 07:47:01 -0500" MODIFIED_BY="[Empty name]" NAME="Barrington 2001" TYPE="COCHRANE_REVIEW">
<AU>Barrington KJ, Finer NN</AU>
<TI>Inhaled nitric oxide for respiratory failure in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2016-03-01 07:47:01 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-03-01 07:47:01 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000509"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Barrington-2006" MODIFIED="2016-03-01 07:47:12 -0500" MODIFIED_BY="[Empty name]" NAME="Barrington 2006" TYPE="COCHRANE_REVIEW">
<AU>Barrington KJ, Finer NN</AU>
<TI>Inhaled nitric oxide for respiratory failure in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2016-03-01 07:47:12 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-03-01 07:47:12 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000509"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2016-07-18 16:19:05 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Kinsella-2014" MODIFIED="2016-07-18 16:19:05 -0400" MODIFIED_BY="[Empty name]" NAME="Kinsella 2014" TYPE="JOURNAL_ARTICLE">
<AU>Kinsella JP, Cutter GR, Steinhorn RH, Nelin LD, Walsh WF, Finer NN, et al</AU>
<TI>Noninvasive inhaled nitric oxide does not prevent bronchopulmonary dysplasia in premature newborns</TI>
<SO>Journal of Pediatrics</SO>
<YR>2014</YR>
<VL>165</VL>
<NO>6</NO>
<PG>1104-8.e1</PG>
<IDENTIFIERS MODIFIED="2014-10-17 15:37:52 -0400" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="25063725"/></IDENTIFIERS>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-12-23 11:44:13 -0500" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-12-23 11:44:13 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-12-11 12:54:51 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ballard-2006">
<CHAR_METHODS MODIFIED="2016-12-11 12:53:42 -0500" MODIFIED_BY="[Empty name]">
<P>Multi-centre trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-11 12:53:51 -0500" MODIFIED_BY="[Empty name]">
<P>582 infants &lt; 1250 grams on assisted ventilation at 7-21 days (or, if &lt; 800 grams, on CPAP)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-11 12:54:15 -0500" MODIFIED_BY="[Empty name]">
<P>Inhaled NO at 20 ppm initial dose for 48-96 hours; the dose was subsequently decreased to 10, 5 and 2 ppm at weekly intervals, with a minimum treatment duration of 24 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-11 12:54:51 -0500" MODIFIED_BY="[Empty name]">
<P>Survival without BPD at 36 weeks' postmenstrual age</P>
<P>Secondary outcomes included duration of oxygen therapy and duration of hospitalisation. In addition, investigators prospectively evaluated the need for hospitalisation and respiratory support, including mechanical ventilation, continuous positive airway pressure and oxygen supplementation at 40, 44, 52 and 60 weeks' postmenstrual age.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-11 14:32:26 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dani-2006">
<CHAR_METHODS MODIFIED="2016-12-11 12:58:19 -0500" MODIFIED_BY="[Empty name]">
<P>Single-centre trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-11 12:58:28 -0500" MODIFIED_BY="[Empty name]">
<P>40 preterm infants ventilated with severe RDS with FiO<SUB>2</SUB> &gt; 0.5 and arterial-alveolar oxygen ratio &lt; 0.15, despite surfactant treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-11 13:08:29 -0500" MODIFIED_BY="[Empty name]">
<P>iNO at 10 ppm for 4 hours followed by 6 ppm compared with no treatment. Weaning started at 72 hours or when the infant was extubated, or when FiO<SUB>2</SUB> was &lt; 0.3 with mean airway pressure &lt; 8 cmH<SUB>2</SUB>O</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-11 14:30:56 -0500" MODIFIED_BY="[Empty name]">
<P>The primary endpoint was death or BPD. Bronchopulmonary dysplasia was defined as oxygen requirement at 36 weeks' postmenstrual age.</P>
<P>Secondary endpoints were evaluation of ventilation changes during iNO therapy, duration of oxygen treatment, NCPAP and mechanical ventilation, incidence of patent ductus arteriosus (PDA), pulmonary hypertension, intraventricular haemorrhage (IVH), periventricular leukomalacia (PVL), retinopathy of prematurity (ROP), necrotising enterocolitis (NEC), sepsis and length of stay in the intensive care unit and in hospital.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-11 14:32:26 -0500" MODIFIED_BY="[Empty name]">
<P>Study terminated after 40 infants enrolled. Initially planned to include 26 per group. Unplanned interim analysis was performed because of an impression that the results were significant. No evidence indicated that the analysis was adjusted to account for potential multiple looks at the data.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-11 14:36:09 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EUNO-2009">
<CHAR_METHODS MODIFIED="2016-12-11 14:33:06 -0500" MODIFIED_BY="[Empty name]">
<P>Multi-centre trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-11 14:35:20 -0500" MODIFIED_BY="[Empty name]">
<P>800 infants between 24 weeks' and 28 weeks' gestation and 6 days enrolled at less than 24 hours of age. If intubated, they had to have received surfactant and could be enrolled if on CPAP requiring &gt; 30% oxygen. Patients were ineligible if they required more than 50% O<SUB>2</SUB> to maintain saturation over 85% on a mean airway pressure &#8805; 8 cmH<SUB>2</SUB>O.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-11 14:35:31 -0500" MODIFIED_BY="[Empty name]">
<P>Inhaled NO at 5 ppm for at least 7 and a maximum of 21 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-11 14:36:09 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome was survival without BPD at 36 weeks' postmenstrual age. Secondary outcome was survival without severe brain injury on head ultrasonography.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-23 11:44:13 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hascoet-2005">
<CHAR_METHODS MODIFIED="2016-12-11 14:39:33 -0500" MODIFIED_BY="[Empty name]">
<P>Multi-centre trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-11 15:32:53 -0500" MODIFIED_BY="[Empty name]">
<P>860 infants &lt; 32 weeks enrolled but not eligible for study gas unless they developed hypoxic respiratory failure (i.e. need for mechanical ventilation, FiO<SUB>2</SUB> &gt; .40, and arterial alveolar O<SUB>2</SUB> ratio &lt; 0.22 at 6 to 48 hours of age; n = 145<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-11 15:34:17 -0500" MODIFIED_BY="[Empty name]">
<P>Inhaled NO was started at 5 ppm, with adjustments allowed depending on response up to a maximum of 10 ppm. Eventually, 61 were treated with iNO and 84 were given the control intervention. Participants were allowed to receive iNO in either group if they developed refractory hypoxaemia.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-23 11:44:13 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome was survival to 28 days without death, need for oxygen, IVH &gt; grade 1 or refractory hypoxaemia defined as need for 100% oxygen with PaO<SUB>2</SUB> &lt; 50.</P>
<P>Secondary outcomes included incidence and severity of IVH and periventricular leukomalacia (PVL), BPD or steroid treatment and pulmonary haemorrhage, patent ductus arteriosus (PDA), necrotising enterocolitis and nosocomial infection.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-11 15:36:39 -0500" MODIFIED_BY="[Empty name]">
<P>Open-label iNO provided to all infants when they met refractory hypoxaemia criteria - 20 infants received treatment before 6 hours and were not included; 28 control infants received open-label iNO after the randomised intervention.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-12 09:17:43 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-INNOVO-2005">
<CHAR_METHODS MODIFIED="2016-12-11 15:37:25 -0500" MODIFIED_BY="[Empty name]">
<P>Multi-centre trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-11 15:37:29 -0500" MODIFIED_BY="[Empty name]">
<P>108 preterm infants (&lt; 34 weeks) less than 28 days of age, with "severe respiratory failure"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-11 15:37:36 -0500" MODIFIED_BY="[Empty name]">
<P>Inhaled NO usually at 5 ppm up to 40 ppm (n = 55) or no supplemental gas (n = 53)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-11 15:38:31 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcomes were (1) death or severe disability at 1 year corrected postnatal age; and (2) death or continued oxygen need at expected date of birth.</P>
<P>Secondary outcomes included length of stay in hospital; length of time on supplemental oxygen; length of time on ventilatory support; pneumothorax; other pulmonary air leak; pulmonary haemorrhage; major cerebral abnormality; necrotising enterocolitis; patent ductus arteriosus needing medical treatment; treatment of retinopathy of prematurity; infection; and age at which full oral feeding was established.<BR/>Secondary outcomes at 1 year corrected age included disability and/or impairment of neuromotor development, vision and hearing; respiratory problems; seizures; growth; and hospital admissions.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-12 09:17:43 -0500" MODIFIED_BY="[Empty name]">
<P>Initially planned 200 participants</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-11 15:42:44 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinsella-1999">
<CHAR_METHODS MODIFIED="2016-12-11 15:40:07 -0500" MODIFIED_BY="[Empty name]">
<P>Multi-centre trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-11 15:42:44 -0500" MODIFIED_BY="[Empty name]">
<P>80 preterm infants (&#8804; 34 weeks) &lt; 7 days of age, with a/AO<SUB>2</SUB> &lt; 0.1 on 2 blood gases after surfactant treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-11 15:40:47 -0500" MODIFIED_BY="[Empty name]">
<P>Inhaled NO at 5 ppm (n = 48) or no supplemental gas (n = 32) for 7 days, after which "trials off" were allowed. Maximum treatment duration was 14 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-11 15:40:57 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome was survival.</P>
<P>Bronchopulmonary dysplasia, intraventricular haemorrhage and duration of ventilation were secondary outcomes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-11 15:41:05 -0500" MODIFIED_BY="[Empty name]">
<P>Initially planned 210 participants</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-11 15:45:24 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinsella-2006">
<CHAR_METHODS MODIFIED="2016-12-11 15:43:53 -0500" MODIFIED_BY="[Empty name]">
<P>Multi-centre trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-11 15:44:00 -0500" MODIFIED_BY="[Empty name]">
<P>793 preterm infants &lt; 34 weeks, respiratory failure needing assisted ventilation in first 48 hours</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-11 15:44:46 -0500" MODIFIED_BY="[Empty name]">
<P>iNO at 5 ppm (n = 398) or no iNO (n = 395) for 21 days or until extubation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-11 15:45:12 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome was death or bronchopulmonary dysplasia.</P>
<P>Secondary outcomes included severe intraventricular haemorrhage, periventricular leukomalacia and ventriculomegaly.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-11 15:45:24 -0500" MODIFIED_BY="[Empty name]">
<P>Baseline and follow-up cranial ultrasonography was required.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-11 15:47:15 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinsella-2014">
<CHAR_METHODS MODIFIED="2016-12-11 15:46:01 -0500" MODIFIED_BY="[Empty name]">
<P>Multi-centre parallel-group randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-11 15:46:26 -0500" MODIFIED_BY="[Empty name]">
<P>124 preterm infants with birth weight of 500 to 1250 grams, receiving oxygen by non-invasive means at &lt; 72 hours of age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-11 15:47:00 -0500" MODIFIED_BY="[Empty name]">
<P>iNO at 10 ppm (to give effective concentration &#8805; 5 ppm) or placebo, for at least 2 weeks and until 30 weeks' postmenstrual age</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-11 15:47:15 -0500" MODIFIED_BY="[Empty name]">
<P>Death or BPD, IVH, retinopathy of prematurity, necrotising enterocolitis, treatment of infants with PDA</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-11 15:49:17 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mercier-1999">
<CHAR_METHODS MODIFIED="2016-12-11 15:47:45 -0500" MODIFIED_BY="[Empty name]">
<P>Multi-centre parallel-group randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-11 15:48:42 -0500" MODIFIED_BY="[Empty name]">
<P>85 preterm infants (&lt; 33 weeks) with OI of 12.5 to 30 at &lt; 7 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-11 15:49:05 -0500" MODIFIED_BY="[Empty name]">
<P>10 ppm inhaled NO (n = 40) or control (n = 45). Open-label treatment with NO allowed in controls if OI &gt; 30</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-11 15:49:10 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome was decrease in OI after 2 hours of therapy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-11 15:49:17 -0500" MODIFIED_BY="[Empty name]">
<P>Initially planned 360 infants across both gestational age strata</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-11 15:52:23 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schreiber-2003">
<CHAR_METHODS MODIFIED="2016-12-11 15:49:49 -0500" MODIFIED_BY="[Empty name]">
<P>Single-centre trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-11 15:50:11 -0500" MODIFIED_BY="[Empty name]">
<P>207 infants &lt; 34 weeks, &lt; 72 hours of age, intubated and ventilated for RDS, birth weight &lt; 2000 grams</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-11 15:50:50 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised to iNO (N = 105) (starting at 10 ppm for 1 day, then 5 ppm for 6 days; thereafter weaned by 1 ppm, stopped if extubated) vs control (N = 102); HFOV (N= 102) vs CMV (N = 105)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-11 15:51:49 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome was a decrease in death or BPD at 36 weeks.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-11 15:52:23 -0500" MODIFIED_BY="[Empty name]">
<P>Factorial 2 × 2 design comparing high-frequency ventilation vs conventional treatment and iNO vs placebo gas</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-11 15:54:56 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Srisuparp-2002">
<CHAR_METHODS MODIFIED="2016-12-11 15:52:50 -0500" MODIFIED_BY="[Empty name]">
<P>Single-centre trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-11 15:54:36 -0500" MODIFIED_BY="[Empty name]">
<P>34 infants weighing &lt; 2000 grams, ventilated after surfactant with an arterial catheter at &lt; 72 hours of age. Also required to satisfy a severity of illness criterion. OI &gt; 4 for birth weight &lt; 1000 grams, &gt; 6 for birth weight 1001-1250 grams, &gt; 8 for 1251-1500 grams, &gt; 10 for 1501-1750 grams and &gt; 12 for 1751-2000 grams</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-11 15:54:48 -0500" MODIFIED_BY="[Empty name]">
<P>iNO at 20 ppm or standard care, trial of weaning after 72 hours, maximum duration 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-09-22 13:35:59 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome was severe intraventricular haemorrhage (grade 3 or 4).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-11 15:54:56 -0500" MODIFIED_BY="[Empty name]">
<P>Performed as a preliminary pilot study, before <LINK REF="STD-Schreiber-2003" TYPE="STUDY">Schreiber 2003</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-11 15:57:54 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Su-2007">
<CHAR_METHODS MODIFIED="2016-12-11 15:56:03 -0500" MODIFIED_BY="[Empty name]">
<P>Single-centre randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-11 15:57:03 -0500" MODIFIED_BY="[Empty name]">
<P>65 preterm infants with birth weight &lt; 1500 grams or gestational age &lt; 32 weeks, intubated with OI &#8805; 25 </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-11 15:57:34 -0500" MODIFIED_BY="[Empty name]">
<P>iNO initially at a dose of 5ppm, could be increased to 20 ppm in cases of poor response, or decreased if good response obtained; duration of therapy not clear according to protocol, but mean duration of receipt of iNO was 4.9 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-09-22 13:35:53 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome variable was OI 24 hours after randomisation. Secondary outcomes included mortality, BPD, intracranial haemorrhage, patent ductus arteriosus and retinopathy of prematurity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-11 15:57:54 -0500" MODIFIED_BY="[Empty name]">
<P>Not all of the infants received surfactant: 23 of 32 iNO treated and 24 of 33 controls</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-11 16:00:04 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Subhedar-1997">
<CHAR_METHODS MODIFIED="2016-12-11 15:58:58 -0500" MODIFIED_BY="[Empty name]">
<P>Single-centre randomised comparison of iNO, dexamethasone, combined therapy and control, using a 2 × 2 factorial design<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-11 15:59:08 -0500" MODIFIED_BY="[Empty name]">
<P>42 preterm infants less than 32 weeks' gestation with "high risk" of developing BPD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-11 15:59:51 -0500" MODIFIED_BY="[Empty name]">
<P>iNO initially administered at 20 ppm and weaned if effective (n = 20) or control (n = 22). Dexamethasone at 1 mg/kg/d for 3 days, followed by 0.5 mg/kg/d for 3 days (n = 21) (3 infants received a lower dose), or no steroids (n = 21)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-09-22 13:35:35 -0400" MODIFIED_BY="[Empty name]">
<P>Primary outcome was survival without bronchopulmonary dysplasia. Secondary outcomes included duration of ventilation, intraventricular haemorrhage and other neonatal complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-11 16:00:04 -0500" MODIFIED_BY="[Empty name]">
<P>Initially planned 88 participants</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-11 16:02:54 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Meurs-2005">
<CHAR_METHODS MODIFIED="2016-12-11 16:00:40 -0500" MODIFIED_BY="[Empty name]">
<P>Multi-centre trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-11 16:01:37 -0500" MODIFIED_BY="[Empty name]">
<P>420 preterm infants, &lt; 34 weeks, OI &#8805; 10 on 2 blood gases 30 minutes to 12 hours apart. &#8805; 4 hours after surfactant</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-11 16:02:18 -0500" MODIFIED_BY="[Empty name]">
<P>iNO initially at 5 ppm to 10 ppm (210) or placebo (210) (if no response at 10 ppm, study gas was stopped). Weaning &#8805; 10 hours after initiation. Maximum duration was 336 hours.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-11 16:02:41 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome was reduced death or BPD at 36 weeks. Secondary outcomes were grade 3 or 4 intraventricular haemorrhage or periventricular leukomalacia, number of days of assisted ventilation and oxygen use, length of hospitalisation and threshold retinopathy of prematurity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-12-11 16:02:54 -0500" MODIFIED_BY="[Empty name]">
<P>Initially planned 220 infants per arm; stopped by the data monitoring committee because of apparent increase in severe IVH with no evidence of benefit</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-11 16:05:40 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Meurs-2007">
<CHAR_METHODS MODIFIED="2016-12-11 16:03:41 -0500" MODIFIED_BY="[Empty name]">
<P>Multi-centre trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-11 16:04:41 -0500" MODIFIED_BY="[Empty name]">
<P>29 infants at less than 34 weeks' gestation with birth weight &gt; 1500 grams; ventilated with OI &gt; 15 on 2 consecutive blood gases between 30 minutes and 12 hours apart</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-11 16:05:16 -0500" MODIFIED_BY="[Empty name]">
<P>iNO initially at 5 ppm to 10 ppm (210) or placebo (210) (if no response at 10 ppm, study gas was stopped). Weaning &#8805; 10 hours after initiation. Maximum duration was 14 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-11 16:05:40 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome was reduced death or BPD at 36 weeks. Secondary outcomes were grade 3 or 4 intraventricular haemorrhage or periventricular leukomalacia, number of days of assisted ventilation and oxygen use, length of hospitalisation and threshold retinopathy of prematurity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-11 16:08:04 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wei-2014">
<CHAR_METHODS MODIFIED="2016-12-11 16:06:37 -0500" MODIFIED_BY="[Empty name]">
<P>Single-centre randomised trial of iNO vs no treatment gas<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-11 16:07:23 -0500" MODIFIED_BY="[Empty name]">
<P>60 preterm infants at less than 34 weeks, receiving mechanical ventilation or CPAP, with OI &#8805; 11 2 hours after surfactant therapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-11 16:07:42 -0500" MODIFIED_BY="[Empty name]">
<P>iNO initially at 5 ppm or placebo. Duration of therapy 7 days or until ventilation withdrawal</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-11 16:08:04 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome was change in OI status over different times during first 3 days of therapy. Secondary outcomes included mortality, BPD, intraventricular haemorrhage and other neonatal complications.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-05-20 15:35:03 -0400" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-12-11 16:09:54 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yoder-2013">
<CHAR_METHODS MODIFIED="2016-12-11 16:09:17 -0500" MODIFIED_BY="[Empty name]">
<P>Multi-centre parallel-group randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-12-11 16:09:36 -0500" MODIFIED_BY="[Empty name]">
<P>451 preterm infants, &lt; 1250 grams and &lt; 30 weeks, at 5 to 14 days of age, on invasive ventilation, or on non-invasive support if they weighed &lt; 800 grams</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-12-11 16:09:45 -0500" MODIFIED_BY="[Empty name]">
<P>iNO at 20 ppm for 3 to 4 days, then 10 ppm for 10 days, then 5 ppm until 24 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-12-11 16:09:54 -0500" MODIFIED_BY="[Empty name]">
<P>Survival without BPD, duration of respiratory support and hospitalisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>a/AO2: arterial-alveolar oxygen ratio.<BR/>BPD: bronchopulmonary dysplasia.<BR/>CMV: cytomegalovirus.<BR/>CPAP: continuous positive airway pressure.<BR/>FiO2: fraction of inspired oxygen.<BR/>HVOF: high-velocity oxygen fuel.<BR/>iNO: inhaled nitric oxide.<BR/>IVH: intraventricular haemorrhage.<BR/>MRC: Medical Research Council.<BR/>NEC: necrotising enterocolitis.<BR/>NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development.<BR/>NO: nitric oxide.<BR/>PDA: patent ductus arteriosus.<BR/>PVL: periventricular leukomalacia.<BR/>RDS: respiratory distress syndrome.<BR/>ROP: retinopathy of prematurity.<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-12-11 16:11:41 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-12-11 16:10:50 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Day-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-12-11 16:10:50 -0500" MODIFIED_BY="[Empty name]">
<P>This was a randomised controlled trial of 50 infants with pulmonary hypertension, 16 of whom were at less than 36 weeks' gestation. The definition of prematurity is not the same as that used in this review, and in any case, it is not possible to extract data that refer solely to preterm infants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-12-11 16:11:41 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lindwall-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-12-11 16:11:41 -0500" MODIFIED_BY="[Empty name]">
<P>No untreated control group was included. Short-term randomised cross-over trial of response to inhaled nitric oxide among infants on continuous positive airway pressure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-12-11 16:11:15 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Skimming-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-12-11 16:11:15 -0500" MODIFIED_BY="[Empty name]">
<P>No untreated control group was included. This was a randomised comparison of 5 ppm and 20 ppm for 15 minutes in preterm infants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-05-20 15:35:03 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-02-05 14:46:26 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-12-16 16:16:33 -0500" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-12-11 16:09:59 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-22 13:22:08 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ballard-2006">
<DESCRIPTION>
<P>Randomised in permuted blocks at study centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 11:51:44 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dani-2006">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:31:55 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EUNO-2009">
<DESCRIPTION>
<P>Computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-22 13:22:19 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hascoet-2005">
<DESCRIPTION>
<P>Stratified, blocked central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:38:46 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-INNOVO-2005">
<DESCRIPTION>
<P>Central randomisation with minimisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:43:01 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-1999">
<DESCRIPTION>
<P>Central stratified randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:45:31 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-2006">
<DESCRIPTION>
<P>Central stratified, blocked randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:47:18 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-2014">
<DESCRIPTION>
<P>Central computer-generated randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-22 13:22:49 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mercier-1999">
<DESCRIPTION>
<P>Centralised phone randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-22 13:23:08 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schreiber-2003">
<DESCRIPTION>
<P>Stratified blocked randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 13:01:56 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Srisuparp-2002">
<DESCRIPTION>
<P>No details available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 14:38:41 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Su-2007">
<DESCRIPTION>
<P>No details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 16:00:07 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Subhedar-1997">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-22 13:23:32 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Meurs-2005">
<DESCRIPTION>
<P>Stratified blocked central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-09-22 13:24:09 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Meurs-2007">
<DESCRIPTION>
<P>Central telephone randomisation, stratified and blocked</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 13:02:25 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2014">
<DESCRIPTION>
<P>No details available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 16:09:59 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yoder-2013">
<DESCRIPTION>
<P>Centralised computer-generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-12-11 16:10:01 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 12:56:42 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ballard-2006">
<DESCRIPTION>
<P>Sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 14:32:38 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dani-2006">
<DESCRIPTION>
<P>Masking of allocation: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 14:36:20 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EUNO-2009">
<DESCRIPTION>
<P>Centralised interactive Web-based enrolment and randomisation system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:36:56 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hascoet-2005">
<DESCRIPTION>
<P>Masking of allocation: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:38:55 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-INNOVO-2005">
<DESCRIPTION>
<P>Masking of allocation: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:43:06 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-1999">
<DESCRIPTION>
<P>Sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:45:39 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-2006">
<DESCRIPTION>
<P>Masking of allocation: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:47:21 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-2014">
<DESCRIPTION>
<P>Placebo-controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:49:23 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mercier-1999">
<DESCRIPTION>
<P>Masking of allocation: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 12:49:25 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schreiber-2003">
<DESCRIPTION>
<P>Masked allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:55:10 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Srisuparp-2002">
<DESCRIPTION>
<P>Masking of allocation: unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:58:07 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Su-2007">
<DESCRIPTION>
<P>No details of randomisation procedures provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 16:00:12 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Subhedar-1997">
<DESCRIPTION>
<P>Masking of allocation: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 16:02:59 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Meurs-2005">
<DESCRIPTION>
<P>Masking of allocation: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 16:05:45 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Meurs-2007">
<DESCRIPTION>
<P>Masked allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 16:08:40 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wei-2014">
<DESCRIPTION>
<P>No details of randomisation procedures provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 16:10:01 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yoder-2013">
<DESCRIPTION>
<P>Placebo-controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-12-11 16:08:45 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-12-11 12:56:54 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ballard-2006">
<DESCRIPTION>
<P>Masking of intervention: yes<BR/>Masking of outcome assessment: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-02-05 13:57:20 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dani-2006">
<DESCRIPTION>
<P>Unmasked trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-12-11 14:36:29 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EUNO-2009">
<DESCRIPTION>
<P>Masking of intervention: yes</P>
<P>Masking of outcome assessment: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-12-11 15:37:05 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hascoet-2005">
<DESCRIPTION>
<P>Masking of intervention: no</P>
<P>Masking of outcome assessment: no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-12-11 15:39:09 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-INNOVO-2005">
<DESCRIPTION>
<P>Masking of intervention: no</P>
<P>Masking of outcome assessment: no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-12-11 15:43:10 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-1999">
<DESCRIPTION>
<P>Masked intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-20 10:23:59 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-2006">
<DESCRIPTION>
<P>Blinded trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-20 10:17:37 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-2014">
<DESCRIPTION>
<P>Masked trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-20 10:25:01 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mercier-1999">
<DESCRIPTION>
<P>Unmasked trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-12-11 15:52:27 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schreiber-2003">
<DESCRIPTION>
<P>Placebo-controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-12-11 15:55:51 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Srisuparp-2002">
<DESCRIPTION>
<P>Unmasked trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-12-11 15:58:17 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Su-2007">
<DESCRIPTION>
<P>Masking of intervention: no</P>
<P>Masking of outcome assessment: no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-12-11 16:00:18 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Subhedar-1997">
<DESCRIPTION>
<P>Masking of intervention: no</P>
<P>Masking of outcome measurement: no</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-12-11 16:03:06 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Meurs-2005">
<DESCRIPTION>
<P>Masking of intervention: yes<BR/>Masking of outcome assessment: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-12-11 16:05:52 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Meurs-2007">
<DESCRIPTION>
<P>Placebo-controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2016-12-11 16:08:45 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wei-2014">
<DESCRIPTION>
<P>Unmasked trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-10-20 10:34:12 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yoder-2013">
<DESCRIPTION>
<P>Masked trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-12-16 16:16:33 -0500" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-11 12:57:00 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ballard-2006">
<DESCRIPTION>
<P>Completeness of follow-up: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-09-22 15:05:50 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dani-2006">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-11 14:36:33 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EUNO-2009">
<DESCRIPTION>
<P>Completeness of follow-up: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-11 15:37:08 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hascoet-2005">
<DESCRIPTION>
<P>Completeness of follow-up: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-11 15:39:13 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-INNOVO-2005">
<DESCRIPTION>
<P>Completeness of follow-up: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-09-22 15:06:13 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-1999">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-09-22 15:06:18 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-2006">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-09-22 15:06:23 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-2014">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-11 15:49:27 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mercier-1999">
<DESCRIPTION>
<P>Completeness of follow-up: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-11 15:52:30 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schreiber-2003">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-11 15:55:56 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Srisuparp-2002">
<DESCRIPTION>
<P>Completeness of follow-up: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-11 15:58:19 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Su-2007">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-11 16:00:22 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Subhedar-1997">
<DESCRIPTION>
<P>Completeness of follow-up: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-11 16:03:09 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Meurs-2005">
<DESCRIPTION>
<P>Completeness of follow-up: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-11 16:05:54 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Meurs-2007">
<DESCRIPTION>
<P>Complete follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-12-16 16:16:33 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wei-2014">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-04-15 12:25:41 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yoder-2013">
<DESCRIPTION>
<P>No significant attrition</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-12-11 16:10:06 -0500" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-07 22:30:52 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ballard-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 11:52:12 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dani-2006">
<DESCRIPTION>
<P>No evidence of selective reporting, but protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 14:36:40 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EUNO-2009">
<DESCRIPTION>
<P>Registered trial, primary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 12:45:04 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hascoet-2005">
<DESCRIPTION>
<P>Registration documents or protocol not found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:39:16 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-INNOVO-2005">
<DESCRIPTION>
<P>Registered trial, primary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:43:15 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kinsella-1999">
<DESCRIPTION>
<P>No protocol or registration document found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 12:01:42 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-2006">
<DESCRIPTION>
<P>Registered trial, primary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 12:22:59 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-2014">
<DESCRIPTION>
<P>Registered trial, primary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:49:30 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mercier-1999">
<DESCRIPTION>
<P>No protocol or registration found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:52:37 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schreiber-2003">
<DESCRIPTION>
<P>No protocol or registration documents found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 13:03:13 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Srisuparp-2002">
<DESCRIPTION>
<P>No registration or protocol found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 12:32:54 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Su-2007">
<DESCRIPTION>
<P>No registration documents or protocol found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 13:03:20 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Subhedar-1997">
<DESCRIPTION>
<P>No registration or protocol found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 16:03:12 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Meurs-2005">
<DESCRIPTION>
<P>Registered trial, primary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 16:05:57 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Meurs-2007">
<DESCRIPTION>
<P>No evidence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 12:43:56 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2014">
<DESCRIPTION>
<P>No registration or protocol found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 16:10:06 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yoder-2013">
<DESCRIPTION>
<P>Registered trial, primary outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-12-11 16:03:17 -0500" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-07 22:30:53 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ballard-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 14:32:57 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dani-2006">
<DESCRIPTION>
<P>Early termination of trial due to impression of an effect</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-07 22:17:01 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EUNO-2009">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hascoet-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:39:27 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-INNOVO-2005">
<DESCRIPTION>
<P>Recruited half of planned sample size in the 2-year time frame</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:43:33 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kinsella-1999">
<DESCRIPTION>
<P>Study terminated early after planned first interim analysis, as little difference in outcomes was apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-10-20 10:23:52 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 12:48:11 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-2014">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-02-05 14:34:44 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mercier-1999">
<DESCRIPTION>
<P>Stopped early because of slowing enrolment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Schreiber-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Srisuparp-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Su-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-07 22:28:21 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Subhedar-1997">
<DESCRIPTION>
<P>Terminated early because frequency of adverse primary outcome was close to 100% in all groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 16:03:17 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Van-Meurs-2005">
<DESCRIPTION>
<P>Study terminated a little early because of an increase in severe IVH in the intervention group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-01 22:59:16 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Van-Meurs-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-06-01 22:59:21 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2014">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 12:49:00 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yoder-2013">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2016-12-11 16:03:24 -0500" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Funding Source</NAME>
<DESCRIPTION>
<P>Funding by local agencies, foundations, government bodies or industry.</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 12:57:08 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ballard-2006">
<DESCRIPTION>
<P>Funded by a government agency (NICHD); study gas provided by industry (Ikaria)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 14:32:59 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dani-2006">
<DESCRIPTION>
<P>Funding source unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 14:36:43 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-EUNO-2009">
<DESCRIPTION>
<P>Funded by industry (Ikaria), initiated by investigators</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 11:55:01 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hascoet-2005">
<DESCRIPTION>
<P>Supported by local sources (University of Nantes) and industry (Air Liquide)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 11:57:21 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-INNOVO-2005">
<DESCRIPTION>
<P>Funded by government agency (MRC, UK)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:43:46 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-1999">
<DESCRIPTION>
<P>Funded by government agency (NIH) and in part by industry (iNOtherapeutics)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:45:51 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-2006">
<DESCRIPTION>
<P>Funded by government agency (NHLBI) and in part by industry (iNOtherapeutics)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:47:30 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinsella-2014">
<DESCRIPTION>
<P>Funded by government agency (NHLBI), funded in part by industry (Ikaria supplied gases)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:49:42 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mercier-1999">
<DESCRIPTION>
<P>Funded by local agency, supported in part by industry (Air Liquide)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:52:44 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schreiber-2003">
<DESCRIPTION>
<P>Funded by industry (Ikaria), investigator initiated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 12:30:51 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Srisuparp-2002">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 15:58:23 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Su-2007">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 12:36:03 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Subhedar-1997">
<DESCRIPTION>
<P>Government agency and local funds, some support from industry</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-12-11 16:03:24 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Meurs-2005">
<DESCRIPTION>
<P>Support from government agency (NICHHD), partial support from industry (Ikaria)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 13:03:41 -0400" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Van-Meurs-2007">
<DESCRIPTION>
<P>Government agency (NICHHD), partial support from industry (Ikaria)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 12:43:44 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wei-2014">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-04-15 12:26:12 -0400" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yoder-2013">
<DESCRIPTION>
<P>Industry initiated and funded (Ikaria)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-12-11 16:27:14 -0500" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-12-11 16:27:14 -0500" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-12-11 16:11:59 -0500" MODIFIED_BY="[Empty name]">Inhaled NO compared with control for respiratory failure in preterm infants</TITLE>
<TABLE COLS="7" ROWS="26">
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Inhaled NO compared with control for respiratory failure in preterm infants</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Patient or population: </B>respiratory failure in preterm infants<BR/>
<B>Setting:</B> neonatal intensive care units<BR/>
<B>Intervention: </B>inhaled NO<BR/>
<B>Comparison: </B>placebo or no treatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Anticipated absolute effects* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with placebo or no treatment</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>Risk with Inhaled NO</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Death before discharge - Studies with entry before 3 days based on oxygenation</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.02<BR/>(0.89 to 1.18)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>1066<BR/>(10 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>High</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>394 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>402 per 1000<BR/>(351 to 465)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Death before discharge - Studies with entry after 3 days based on BPD risk</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.18<BR/>(0.81 to 1.71)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>1075<BR/>(3 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>High</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>83 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>98 per 1000<BR/>(67 to 141)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Death before discharge - Studies of routine use in preterm infants on respiratory support</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.90<BR/>(0.74 to 1.10)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>1924<BR/>(4 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>170 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>153 per 1000<BR/>(126 to 187)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Death or bronchopulmonary dysplasia at 36 weeks - Studies with entry before 3 days based on oxygenation</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.94<BR/>(0.87 to 1.01)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>958<BR/>(8 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>High</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>743 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>698 per 1000<BR/>(646 to 750)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Death or bronchopulmonary dysplasia at 36 weeks - Studies with entry after 3 days based on BPD risk</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.92<BR/>(0.85 to 1.01)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>1075<BR/>(3 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>High</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>667 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>614 per 1000<BR/>(567 to 674)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Death or bronchopulmonary dysplasia at 36 weeks - Studies of routine use in preterm infants on respiratory support</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.94<BR/>(0.87 to 1.02)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>1924<BR/>(4 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>High</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>548 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>515 per 1000<BR/>(477 to 559)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Intraventricular haemorrhage (grade 3 or 4) - Studies with entry before 3 days based on oxygenation</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.20<BR/>(0.98 to 1.47)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>773<BR/>(6 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>High</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>231 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>278 per 1000<BR/>(227 to 340)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Intraventricular haemorrhage (grade 3 or 4) - Studies of routine use in preterm infants on respiratory support</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.89<BR/>(0.73 to 1.09)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>1913<BR/>(4 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate<SUP>b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>127 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>113 per 1000<BR/>(93 to 139)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Neurodevelopmental disability - Studies with entry before 3 days based on oxygenation</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 1.05<BR/>(0.78 to 1.40)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>208<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate<SUP>c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>455 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>477 per 1000<BR/>(355 to 636)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Neurodevelopmental disability - Studies with entry after 3 days based on BPD risk</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.90<BR/>(0.74 to 1.09)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>498<BR/>(2 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate<SUP>c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>480 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>432 per 1000<BR/>(355 to 523)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>Neurodevelopmental disability - Studies of routine use in preterm infants on respiratory support</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP">
<P>Study population</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>RR 0.91<BR/>(0.74 to 1.13)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>1223<BR/>(3 RCTs)</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>High</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>195 per 1000</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP">
<P>178 per 1000<BR/>(144 to 220)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on assumed risk in the comparison group and <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: confidence interval; OR: odds ratio; RR: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>GRADE Working Group grades of evidence.</B>
<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of effect.<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of effect but may be substantially different.<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of effect.<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Highly variable risk ratio in individual trials (I<SUP>2</SUP> = 50%).</P>
<P>
<SUP>b</SUP>Highly variable risk ratio in individual trials (I<SUP>2</SUP> = 33%).</P>
<P>
<SUP>c</SUP>Based on 2 studies, wide confidence intervals.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-12-11 16:32:50 -0500" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-12-11 16:32:50 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Inhaled NO compared with control</NAME>
<DICH_OUTCOME CHI2="19.149007180134102" CI_END="1.1102603954288048" CI_START="0.8866840036880281" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9921946041755448" ESTIMABLE="YES" EVENTS_1="417" EVENTS_2="420" I2="16.44475429201886" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.045424848187736795" LOG_CI_START="-0.05223112639788133" LOG_EFFECT_SIZE="-0.003403139105072238" METHOD="MH" MODIFIED="2016-12-11 16:28:02 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.26101202407534463" P_Q="0.40644040072896903" P_Z="0.8913449202724293" Q="1.8006361627420504" RANDOM="NO" SCALE="1.2" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2032" TOTAL_2="2033" WEIGHT="300.0" Z="0.13660260129755047">
<NAME>Death before discharge</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.233180959419961" CI_END="1.1777535489856283" CI_START="0.88829827378697" DF="9" EFFECT_SIZE="1.0228374477454427" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="212" I2="2.525467230034771" ID="CMP-001.01.01" LOG_CI_END="0.07105442159424709" LOG_CI_START="-0.051441181846370976" LOG_EFFECT_SIZE="0.009806619873938048" MODIFIED="2016-12-11 16:27:51 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.41603429038790196" P_Z="0.7536597798890444" STUDIES="10" TAU2="0.0" TOTAL_1="528" TOTAL_2="538" WEIGHT="100.0" Z="0.31381733259203604">
<NAME>Studies with entry before 3 days based on oxygenation</NAME>
<DICH_DATA CI_END="2.0086608078120443" CI_START="0.2212640594748102" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3029066058709399" LOG_CI_START="-0.6550891239823023" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2015-05-20 15:44:27 -0400" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Dani-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="2.8464323408588594"/>
<DICH_DATA CI_END="2.0538143802504747" CI_START="0.8536326802688506" EFFECT_SIZE="1.3240857503152585" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.3125611903441742" LOG_CI_START="-0.06872896683950563" LOG_EFFECT_SIZE="0.12191611175233429" MODIFIED="2015-05-20 15:44:27 -0400" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.22397172574641144" STUDY_ID="STD-Hascoet-2005" TOTAL_1="61" TOTAL_2="84" VAR="0.05016333393382574" WEIGHT="10.378026879545175"/>
<DICH_DATA CI_END="1.1641291778662288" CI_START="0.621026111785606" EFFECT_SIZE="0.8502673796791443" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="34" LOG_CI_END="0.06600117457652327" LOG_CI_START="-0.2068901390086183" LOG_EFFECT_SIZE="-0.0704444822160475" MODIFIED="2015-05-20 15:44:26 -0400" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.1602977084337004" STUDY_ID="STD-INNOVO-2005" TOTAL_1="55" TOTAL_2="53" VAR="0.02569535532909562" WEIGHT="16.428482954956998"/>
<DICH_DATA CI_END="1.3993857673771717" CI_START="0.5813502433747149" EFFECT_SIZE="0.9019607843137255" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" LOG_CI_END="0.14593745255383345" LOG_CI_START="-0.235562141386558" LOG_EFFECT_SIZE="-0.04481234441636228" MODIFIED="2015-05-20 15:44:25 -0400" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.22409474993403258" STUDY_ID="STD-Kinsella-1999" TOTAL_1="48" TOTAL_2="32" VAR="0.05021845694799659" WEIGHT="9.677869958920121"/>
<DICH_DATA CI_END="1.464874909973306" CI_START="0.4083663132827846" EFFECT_SIZE="0.7734375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.16580054057559326" LOG_CI_START="-0.38895009067623015" LOG_EFFECT_SIZE="-0.11157477505031844" MODIFIED="2015-05-20 15:44:24 -0400" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.32586326685723366" STUDY_ID="STD-Mercier-1999" TOTAL_1="40" TOTAL_2="45" VAR="0.10618686868686869" WEIGHT="7.143987051567334"/>
<DICH_DATA CI_END="5.600502509609148" CI_START="0.14108081470090528" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.748226996177506" LOG_CI_START="-0.8505320410722688" LOG_EFFECT_SIZE="-0.05115252244738131" MODIFIED="2015-05-20 15:44:24 -0400" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.9391189724653871" STUDY_ID="STD-Srisuparp-2002" TOTAL_1="18" TOTAL_2="16" VAR="0.8819444444444444" WEIGHT="1.0046231791266562"/>
<DICH_DATA CI_END="1.5032108608986758" CI_START="0.2546891939505526" EFFECT_SIZE="0.61875" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.17701990493927836" LOG_CI_START="-0.5939894810560281" LOG_EFFECT_SIZE="-0.20848478805837484" MODIFIED="2015-05-20 15:44:23 -0400" MODIFIED_BY="[Empty name]" ORDER="173" O_E="0.0" SE="0.45289472989165636" STUDY_ID="STD-Su-2007" TOTAL_1="32" TOTAL_2="33" VAR="0.20511363636363636" WEIGHT="4.671068456794027"/>
<DICH_DATA CI_END="1.4314056573881864" CI_START="0.9596754155357464" EFFECT_SIZE="1.1720430107526882" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="93" LOG_CI_END="0.15576272935662674" LOG_CI_START="-0.01787563058324968" LOG_EFFECT_SIZE="0.06894354938668855" ORDER="7" O_E="0.0" SE="0.10199603215242734" STUDY_ID="STD-Van-Meurs-2005" TOTAL_1="210" TOTAL_2="210" VAR="0.010403190574838992" WEIGHT="44.119701283312324"/>
<DICH_DATA CI_END="4.001805450607376" CI_START="0.4482192466946533" EFFECT_SIZE="1.3392857142857142" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.602255971411277" LOG_CI_START="-0.3485094986402777" LOG_EFFECT_SIZE="0.1268732363854996" MODIFIED="2015-05-20 15:44:22 -0400" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.5584843434732633" STUDY_ID="STD-Van-Meurs-2007" TOTAL_1="14" TOTAL_2="15" VAR="0.3119047619047619" WEIGHT="1.8321863343459326"/>
<DICH_DATA CI_END="2.1080777784770572" CI_START="0.029647862445166522" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3238866303262053" LOG_CI_START="-1.52800661298213" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2015-06-01 23:09:11 -0400" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="1.0878112581387145" STUDY_ID="STD-Wei-2014" TOTAL_1="30" TOTAL_2="30" VAR="1.1833333333333331" WEIGHT="1.897621560572573"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.559163220281717" CI_END="1.707051925045039" CI_START="0.80986329896139" DF="2" EFFECT_SIZE="1.1757885454091508" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="44" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.23224673166983348" LOG_CI_START="-0.0915882817596421" LOG_EFFECT_SIZE="0.07032922495509566" MODIFIED="2016-12-11 16:28:02 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4585979895388027" P_Z="0.3945945893281876" STUDIES="3" TAU2="0.0" TOTAL_1="543" TOTAL_2="532" WEIGHT="99.99999999999999" Z="0.851314664914221">
<NAME>Studies with entry after 3 days based on BPD risk</NAME>
<DICH_DATA CI_END="1.6738515722533358" CI_START="0.45296883746239675" EFFECT_SIZE="0.8707482993197279" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="18" LOG_CI_END="0.22371694457164487" LOG_CI_START="-0.3439316747722603" LOG_EFFECT_SIZE="-0.06010736510030775" ORDER="8" O_E="0.0" SE="0.33343960890859325" STUDY_ID="STD-Ballard-2006" TOTAL_1="294" TOTAL_2="288" VAR="0.11118197278911564" WEIGHT="41.1930864006611"/>
<DICH_DATA CI_END="3.3350077262797804" CI_START="0.7404443880724249" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.523096844392534" LOG_CI_START="-0.13050755410459758" LOG_EFFECT_SIZE="0.1962946451439682" ORDER="9" O_E="0.0" SE="0.3839304590711674" STUDY_ID="STD-Subhedar-1997" TOTAL_1="20" TOTAL_2="22" VAR="0.14740259740259737" WEIGHT="15.101018068269568"/>
<DICH_DATA CI_END="2.327092777156353" CI_START="0.7562419766847615" EFFECT_SIZE="1.3265915881406574" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="19" LOG_CI_END="0.3668136982002847" LOG_CI_START="-0.12133921994280539" LOG_EFFECT_SIZE="0.12273723912873966" MODIFIED="2013-12-09 14:47:45 -0500" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.286743440513167" STUDY_ID="STD-Yoder-2013" TOTAL_1="229" TOTAL_2="222" VAR="0.08222180067732815" WEIGHT="43.70589553106932"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.991512406256431" CI_END="1.10439916796687" CI_START="0.7394079390584821" DF="3" EFFECT_SIZE="0.9036600647833708" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="164" I2="49.92916985588893" ID="CMP-001.01.03" LOG_CI_END="0.043126070778224126" LOG_CI_START="-0.13111589069720989" LOG_EFFECT_SIZE="-0.04399490995949286" MODIFIED="2014-10-20 10:53:59 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.11202394714729147" P_Z="0.3222938263863262" STUDIES="4" TAU2="0.0" TOTAL_1="961" TOTAL_2="963" WEIGHT="100.0" Z="0.9897551461603086">
<NAME>Studies of routine use in preterm infants on respiratory support</NAME>
<DICH_DATA CI_END="1.9387049628646098" CI_START="0.903755676299622" EFFECT_SIZE="1.3236750412616909" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="41" LOG_CI_END="0.28751172204973807" LOG_CI_START="-0.04394896197640389" LOG_EFFECT_SIZE="0.12178138003666711" MODIFIED="2009-10-14 09:25:23 -0400" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.19470164655380354" STUDY_ID="STD-EUNO-2009" TOTAL_1="399" TOTAL_2="401" VAR="0.03790873117076223" WEIGHT="24.860976224955603"/>
<DICH_DATA CI_END="1.0273560535005124" CI_START="0.6073571057024377" EFFECT_SIZE="0.7899189826684443" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="98" LOG_CI_END="0.011720984270906506" LOG_CI_START="-0.21655588316939062" LOG_EFFECT_SIZE="-0.10241744944924205" ORDER="10" O_E="0.0" SE="0.13409096192314857" STUDY_ID="STD-Kinsella-2006" TOTAL_1="398" TOTAL_2="395" VAR="0.017980386069475277" WEIGHT="59.79809836948465"/>
<DICH_DATA CI_END="5.918870342821846" CI_START="0.051265343553647987" EFFECT_SIZE="0.5508474576271186" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7722388265382066" LOG_CI_START="-1.2901761278647466" LOG_EFFECT_SIZE="-0.25896865066326985" MODIFIED="2014-10-20 10:53:59 -0400" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="1.2114727533349694" STUDY_ID="STD-Kinsella-2014" TOTAL_1="59" TOTAL_2="65" VAR="1.4676662320730118" WEIGHT="1.1569423931760012"/>
<DICH_DATA CI_END="1.2032798345396196" CI_START="0.37952413589129114" EFFECT_SIZE="0.675776397515528" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="23" LOG_CI_END="0.08036663853164892" LOG_CI_START="-0.4207605998710261" LOG_EFFECT_SIZE="-0.17019698066968858" ORDER="11" O_E="0.0" SE="0.29436462045756834" STUDY_ID="STD-Schreiber-2003" TOTAL_1="105" TOTAL_2="102" VAR="0.08665052977712825" WEIGHT="14.183983012383742"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.290165739808941" CI_END="1.2735420855557873" CI_START="0.8895746294373306" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0643827924347211" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="164" I2="34.90730581372644" I2_Q="52.13124984567542" ID="CMP-001.02" LOG_CI_END="0.10501330126087678" LOG_CI_START="-0.05081761161238742" LOG_EFFECT_SIZE="0.027097844824244675" METHOD="MH" MODIFIED="2016-12-11 16:28:36 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.13871952118971154" P_Q="0.12380529371642146" P_Z="0.4954624947998765" Q="4.178091121143081" RANDOM="NO" SCALE="1.2" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="931" TOTAL_2="944" WEIGHT="300.0" Z="0.6816465223093339">
<NAME>Death before 36 weeks' postmenstrual age</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.5377343822716805" CI_END="1.11384308800803" CI_START="0.7188025882858535" DF="4" EFFECT_SIZE="0.8947811434113259" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="98" I2="38.81672508986039" ID="CMP-001.02.01" LOG_CI_END="0.046824014166214185" LOG_CI_START="-0.14339036773969155" LOG_EFFECT_SIZE="-0.048283176786738664" MODIFIED="2016-12-11 16:28:25 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1624283580592557" P_Z="0.31972792900485414" STUDIES="5" TAU2="0.0" TOTAL_1="224" TOTAL_2="234" WEIGHT="99.99999999999999" Z="0.995017165505402">
<NAME>Studies with entry before 3 days based on oxygenation</NAME>
<DICH_DATA CI_END="2.0086608078120443" CI_START="0.2212640594748102" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3029066058709399" LOG_CI_START="-0.6550891239823023" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="12" O_E="0.0" SE="0.5627314338711378" STUDY_ID="STD-Dani-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.31666666666666665" WEIGHT="6.18902541796612"/>
<DICH_DATA CI_END="2.1215257778973866" CI_START="0.8938210719838697" EFFECT_SIZE="1.3770491803278688" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="26" LOG_CI_END="0.3266483130908861" LOG_CI_START="-0.0487494109886569" LOG_EFFECT_SIZE="0.13894945105111461" ORDER="13" O_E="0.0" SE="0.22051048137302726" STUDY_ID="STD-Hascoet-2005" TOTAL_1="61" TOTAL_2="84" VAR="0.0486248723953642" WEIGHT="22.565044397458085"/>
<DICH_DATA CI_END="0.9778312373044461" CI_START="0.4613072133185783" EFFECT_SIZE="0.6716253443526171" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="33" LOG_CI_END="-0.009736093097690636" LOG_CI_START="-0.3360097544098081" LOG_EFFECT_SIZE="-0.17287292375374938" ORDER="14" O_E="0.0" SE="0.19165476373540902" STUDY_ID="STD-INNOVO-2005" TOTAL_1="55" TOTAL_2="53" VAR="0.03673154846247545" WEIGHT="34.670003498791694"/>
<DICH_DATA CI_END="1.3993857673771717" CI_START="0.5813502433747149" EFFECT_SIZE="0.9019607843137255" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" LOG_CI_END="0.14593745255383345" LOG_CI_START="-0.235562141386558" LOG_EFFECT_SIZE="-0.04481234441636228" ORDER="15" O_E="0.0" SE="0.22409474993403258" STUDY_ID="STD-Kinsella-1999" TOTAL_1="48" TOTAL_2="32" VAR="0.05021845694799659" WEIGHT="21.04268642108481"/>
<DICH_DATA CI_END="1.464874909973306" CI_START="0.4083663132827846" EFFECT_SIZE="0.7734375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.16580054057559326" LOG_CI_START="-0.38895009067623015" LOG_EFFECT_SIZE="-0.11157477505031844" ORDER="16" O_E="0.0" SE="0.32586326685723366" STUDY_ID="STD-Mercier-1999" TOTAL_1="40" TOTAL_2="45" VAR="0.10618686868686869" WEIGHT="15.533240264699282"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.24499671121886357" CI_END="2.1991760004102106" CI_START="0.8073861283669302" DF="1" EFFECT_SIZE="1.3325104864760617" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="22" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.34225998740912716" LOG_CI_START="-0.09291871643852213" LOG_EFFECT_SIZE="0.12467063548530254" MODIFIED="2016-12-11 16:28:36 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6206203217820548" P_Z="0.2614431473419656" STUDIES="2" TAU2="0.0" TOTAL_1="249" TOTAL_2="244" WEIGHT="100.0" Z="1.1229867331304804">
<NAME>Studies with entry after 3 days based on BPD risk</NAME>
<DICH_DATA CI_END="3.3350077262797804" CI_START="0.7404443880724249" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.523096844392534" LOG_CI_START="-0.13050755410459758" LOG_EFFECT_SIZE="0.1962946451439682" ORDER="17" O_E="0.0" SE="0.3839304590711674" STUDY_ID="STD-Subhedar-1997" TOTAL_1="20" TOTAL_2="22" VAR="0.14740259740259737" WEIGHT="30.442119473506587"/>
<DICH_DATA CI_END="2.355259517101682" CI_START="0.6402077109156582" EFFECT_SIZE="1.227947598253275" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="15" LOG_CI_END="0.3720387673611453" LOG_CI_START="-0.19367909934534866" LOG_EFFECT_SIZE="0.08917983400789833" MODIFIED="2013-12-09 14:46:47 -0500" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.33230547525199816" STUDY_ID="STD-Yoder-2013" TOTAL_1="229" TOTAL_2="222" VAR="0.11042692888245635" WEIGHT="69.55788052649342"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5258452867350787" CI_END="1.8899686105949138" CI_START="0.902086260938642" DF="1" EFFECT_SIZE="1.3057238288485686" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="44" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.2764545912850835" LOG_CI_START="-0.044751931572872036" LOG_EFFECT_SIZE="0.11585132985610574" MODIFIED="2014-10-20 10:55:08 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4683589160406968" P_Z="0.15741415443234233" STUDIES="2" TAU2="0.0" TOTAL_1="458" TOTAL_2="466" WEIGHT="100.0" Z="1.4138220610136858">
<NAME>Studies of routine use in preterm infants on respiratory support</NAME>
<DICH_DATA CI_END="1.9503063303819803" CI_START="0.920698841469013" EFFECT_SIZE="1.340016708437761" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="42" LOG_CI_END="0.29010283041176066" LOG_CI_START="-0.03588240332829264" LOG_EFFECT_SIZE="0.12711021354173402" MODIFIED="2010-06-27 09:31:22 -0400" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.191485339951839" STUDY_ID="STD-EUNO-2009" TOTAL_1="399" TOTAL_2="401" VAR="0.03666663541647135" WEIGHT="95.65455958224851"/>
<DICH_DATA CI_END="5.918870342821846" CI_START="0.051265343553647987" EFFECT_SIZE="0.5508474576271186" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7722388265382066" LOG_CI_START="-1.2901761278647466" LOG_EFFECT_SIZE="-0.25896865066326985" MODIFIED="2014-10-20 10:55:08 -0400" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="1.2114727533349694" STUDY_ID="STD-Kinsella-2014" TOTAL_1="59" TOTAL_2="65" VAR="1.4676662320730118" WEIGHT="4.345440417751492"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.042775267929066" CI_END="0.9863893577848003" CI_START="0.8626420113678626" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9224428977401985" ESTIMABLE="YES" EVENTS_1="780" EVENTS_2="852" I2="12.733303520200495" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.005951622016814944" LOG_CI_START="-0.06416939518038466" LOG_EFFECT_SIZE="-0.03506050859859981" METHOD="MH" MODIFIED="2016-12-11 16:29:05 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.31076912920877053" P_Q="0.7794574195070133" P_Z="0.018240504119098333" Q="0.4983144591485894" RANDOM="NO" SCALE="1.2" SORT_BY="USER" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1712" TOTAL_2="1741" WEIGHT="300.0" Z="2.360699504594347">
<NAME>Bronchopulmonary dysplasia among survivors at 36 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.840232049064566" CI_END="1.0370205774646053" CI_START="0.7592803325261059" DF="7" EFFECT_SIZE="0.8873496091697679" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="164" I2="28.863466175419763" ID="CMP-001.03.01" LOG_CI_END="0.015787374123529267" LOG_CI_START="-0.11959784941222978" LOG_EFFECT_SIZE="-0.051905237644350274" MODIFIED="2016-12-11 16:28:56 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.19780975257868672" P_Z="0.1328756150704156" STUDIES="8" TAU2="0.0" TOTAL_1="329" TOTAL_2="352" WEIGHT="100.0" Z="1.5028581958214788">
<NAME>Studies with entry before 3 days based on oxygenation</NAME>
<DICH_DATA CI_END="1.3866159418545692" CI_START="0.2647104589938193" EFFECT_SIZE="0.6058479532163743" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.14195618895352982" LOG_CI_START="-0.577228898919409" LOG_EFFECT_SIZE="-0.2176363549829396" ORDER="1" O_E="0.0" SE="0.4224528806401646" STUDY_ID="STD-Hascoet-2005" TOTAL_1="57" TOTAL_2="74" VAR="0.17846643636117318" WEIGHT="8.229792439047836"/>
<DICH_DATA CI_END="2.0971074401145615" CI_START="0.3650862065313044" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3216206810393053" LOG_CI_START="-0.43760457499467886" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="2" O_E="0.0" SE="0.44597267361999154" STUDY_ID="STD-Mercier-1999" TOTAL_1="29" TOTAL_2="29" VAR="0.1988916256157635" WEIGHT="5.043755833989551"/>
<DICH_DATA CI_END="2.785412350224835" CI_START="1.0016155104698548" EFFECT_SIZE="1.6703030303030304" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="15" LOG_CI_END="0.44488949687817403" LOG_CI_START="7.010411651898324E-4" LOG_EFFECT_SIZE="0.22279526902168195" ORDER="3" O_E="0.0" SE="0.26091849765412395" STUDY_ID="STD-INNOVO-2005" TOTAL_1="55" TOTAL_2="53" VAR="0.06807846241808507" WEIGHT="9.632172599632824"/>
<DICH_DATA CI_END="1.0681664778949462" CI_START="0.23404591435286307" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.02863894444973777" LOG_CI_START="-0.6306989357777002" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="4" O_E="0.0" SE="0.3872983346207417" STUDY_ID="STD-Dani-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.15000000000000002" WEIGHT="7.565633750984327"/>
<DICH_DATA CI_END="1.0496719576161657" CI_START="0.7303065431635088" EFFECT_SIZE="0.8755468570112825" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="86" LOG_CI_END="0.021053595016005244" LOG_CI_START="-0.13649480829039143" LOG_EFFECT_SIZE="-0.05772060663719307" ORDER="5" O_E="0.0" SE="0.09254471197935148" STUDY_ID="STD-Van-Meurs-2005" TOTAL_1="101" TOTAL_2="117" VAR="0.00856452371534112" WEIGHT="50.240898135359224"/>
<DICH_DATA CI_END="1.127854286647638" CI_START="0.49873463856039335" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.05225299451204678" LOG_CI_START="-0.30213046772864666" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="6" O_E="0.0" SE="0.20816659994661324" STUDY_ID="STD-Kinsella-1999" TOTAL_1="25" TOTAL_2="15" VAR="0.04333333333333332" WEIGHT="9.457042188730409"/>
<DICH_DATA CI_END="2.0779819490167823" CI_START="0.209626460040285" EFFECT_SIZE="0.66" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.31764177061458787" LOG_CI_START="-0.6785538995308504" LOG_EFFECT_SIZE="-0.1804560644581313" MODIFIED="2010-06-28 14:09:51 -0400" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.5851702678915278" STUDY_ID="STD-Van-Meurs-2007" TOTAL_1="10" TOTAL_2="11" VAR="0.3424242424242424" WEIGHT="3.0022356154699708"/>
<DICH_DATA CI_END="1.8972095628035128" CI_START="0.46326260800690744" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.2781153050280789" LOG_CI_START="-0.33417275222856596" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2009-10-13 12:06:33 -0400" MODIFIED_BY="[Empty name]" ORDER="174" O_E="0.0" SE="0.3596610357073179" STUDY_ID="STD-Su-2007" TOTAL_1="32" TOTAL_2="33" VAR="0.1293560606060606" WEIGHT="6.828469436785855"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.2410146182969055" CI_END="1.006719170754255" CI_START="0.8259895331305489" DF="2" EFFECT_SIZE="0.9118878756979284" ESTIMABLE="YES" EVENTS_1="289" EVENTS_2="315" I2="10.754709778737114" ID="CMP-001.03.02" LOG_CI_END="0.0029083388741405307" LOG_CI_START="-0.08302545598766461" LOG_EFFECT_SIZE="-0.04005855855676204" MODIFIED="2016-12-11 16:29:05 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.326114623739438" P_Z="0.0676549537490565" STUDIES="3" TAU2="0.0" TOTAL_1="498" TOTAL_2="492" WEIGHT="100.00000000000001" Z="1.8272981466745193">
<NAME>Studies with entry after 3 days based on BPD risk</NAME>
<DICH_DATA CI_END="1.0205514548808678" CI_START="0.7629355836316742" EFFECT_SIZE="0.8823916476574838" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="164" LOG_CI_END="0.008834906168675168" LOG_CI_START="-0.11751212895770068" LOG_EFFECT_SIZE="-0.0543386113945128" ORDER="24" O_E="0.0" SE="0.07421687386114381" STUDY_ID="STD-Ballard-2006" TOTAL_1="278" TOTAL_2="270" VAR="0.005508144365720932" WEIGHT="52.62397506872601"/>
<DICH_DATA CI_END="1.2911765046159576" CI_START="0.8592342378820477" EFFECT_SIZE="1.0532915360501567" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.11098561464528224" LOG_CI_START="-0.06588842597995645" LOG_EFFECT_SIZE="0.0225485943326629" ORDER="25" O_E="0.0" SE="0.10389668700388685" STUDY_ID="STD-Subhedar-1997" TOTAL_1="10" TOTAL_2="15" VAR="0.01079452157038363" WEIGHT="3.7365645409339727"/>
<DICH_DATA CI_END="1.0802316783015709" CI_START="0.8098988134984637" EFFECT_SIZE="0.935349322210636" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="137" LOG_CI_END="0.03351690902167965" LOG_CI_START="-0.09156923727482265" LOG_EFFECT_SIZE="-0.029026164126571528" MODIFIED="2014-10-20 11:40:54 -0400" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.07347622152097572" STUDY_ID="STD-Yoder-2013" TOTAL_1="210" TOTAL_2="207" VAR="0.005398755128999496" WEIGHT="43.63946039034003"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.3284003844777965" CI_END="1.0546029250977642" CI_START="0.8492043483760245" DF="3" EFFECT_SIZE="0.946347393826969" ESTIMABLE="YES" EVENTS_1="352" EVENTS_2="373" I2="9.86661298350139" ID="CMP-001.03.03" LOG_CI_END="0.023088971577330662" LOG_CI_START="-0.07098779068258415" LOG_EFFECT_SIZE="-0.023949409552626737" MODIFIED="2014-10-20 10:55:54 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.34370943381608166" P_Z="0.31832395126293667" STUDIES="4" TAU2="0.0" TOTAL_1="885" TOTAL_2="897" WEIGHT="100.0" Z="0.997908070953003">
<NAME>Studies of routine use in preterm infants on respiratory support</NAME>
<DICH_DATA CI_END="1.1416026619511006" CI_START="0.8793184925678419" EFFECT_SIZE="1.001914333572625" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="210" LOG_CI_END="0.057514972781193066" LOG_CI_START="-0.05585379328598394" LOG_EFFECT_SIZE="8.305897476045637E-4" ORDER="26" O_E="0.0" SE="0.06659337437230245" STUDY_ID="STD-Kinsella-2006" TOTAL_1="398" TOTAL_2="395" VAR="0.004434677510289628" WEIGHT="56.593999900358114"/>
<DICH_DATA CI_END="1.029726381585177" CI_START="0.5313611983410931" EFFECT_SIZE="0.7397003745318352" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="42" LOG_CI_END="0.012721839506957357" LOG_CI_START="-0.2746101623111497" LOG_EFFECT_SIZE="-0.13094416140209617" ORDER="27" O_E="0.0" SE="0.16878024018430396" STUDY_ID="STD-Schreiber-2003" TOTAL_1="89" TOTAL_2="79" VAR="0.028486769476671336" WEIGHT="11.947340066306458"/>
<DICH_DATA CI_END="1.1506489959612092" CI_START="0.690003614459685" EFFECT_SIZE="0.8910398230088495" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="96" LOG_CI_END="0.06094286284309336" LOG_CI_START="-0.1611486342833463" LOG_EFFECT_SIZE="-0.050102885720126465" MODIFIED="2010-06-27 09:29:22 -0400" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.1304576447827119" STUDY_ID="STD-EUNO-2009" TOTAL_1="339" TOTAL_2="358" VAR="0.017019197082252236" WEIGHT="25.071444883715273"/>
<DICH_DATA CI_END="1.6345305501934597" CI_START="0.684340296948846" EFFECT_SIZE="1.0576271186440678" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" LOG_CI_END="0.213393042173316" LOG_CI_START="-0.16472788609275646" LOG_EFFECT_SIZE="0.02433257804027979" MODIFIED="2014-10-20 10:55:54 -0400" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="0.2221101049922727" STUDY_ID="STD-Kinsella-2014" TOTAL_1="59" TOTAL_2="65" VAR="0.0493328987396784" WEIGHT="6.387215149620161"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.459866634401898" CI_END="0.9790179286171143" CI_START="0.8908702458124834" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9339046753935634" ESTIMABLE="YES" EVENTS_1="1168" EVENTS_2="1240" I2="14.944632839616457" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.009209354950502851" LOG_CI_START="-0.050185545829802454" LOG_EFFECT_SIZE="-0.029697450390152664" METHOD="MH" MODIFIED="2016-12-11 16:29:26 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.28610462871521614" P_Q="0.9596801880805257" P_Z="0.004497744705242296" Q="0.08231037685927553" RANDOM="NO" SCALE="1.2" SORT_BY="USER" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1982" TOTAL_2="1975" WEIGHT="300.0" Z="2.8409635912140763">
<NAME>Death or bronchopulmonary dysplasia at 36 weeks</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.426817091812664" CI_END="1.008865137643368" CI_START="0.8687453833397423" DF="7" EFFECT_SIZE="0.936187444233306" ESTIMABLE="YES" EVENTS_1="337" EVENTS_2="358" I2="25.743759194398628" ID="CMP-001.04.01" LOG_CI_END="0.0038331148079063185" LOG_CI_START="-0.0611074903102063" LOG_EFFECT_SIZE="-0.028637187751150005" MODIFIED="2016-12-11 16:29:16 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.22344686527937563" P_Z="0.08388241067846106" STUDIES="8" TAU2="0.0" TOTAL_1="476" TOTAL_2="482" WEIGHT="100.00000000000001" Z="1.7285905023115025">
<NAME>Studies with entry before 3 days based on oxygenation</NAME>
<DICH_DATA CI_END="1.3078207907167827" CI_START="0.5443513878608844" EFFECT_SIZE="0.84375" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" LOG_CI_END="0.1165482371571956" LOG_CI_START="-0.26412066547903296" LOG_EFFECT_SIZE="-0.07378621416091867" ORDER="1" O_E="0.0" SE="0.22360679774997894" STUDY_ID="STD-Mercier-1999" TOTAL_1="40" TOTAL_2="45" VAR="0.04999999999999999" WEIGHT="6.321515685926409"/>
<DICH_DATA CI_END="1.4123763372760936" CI_START="0.7730782619277057" EFFECT_SIZE="1.0449293966623876" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="41" LOG_CI_END="0.14995043285275234" LOG_CI_START="-0.11177653841947882" LOG_EFFECT_SIZE="0.019086947216636743" ORDER="2" O_E="0.0" SE="0.15373971849471108" STUDY_ID="STD-Hascoet-2005" TOTAL_1="57" TOTAL_2="74" VAR="0.02363590104283301" WEIGHT="9.985189912777127"/>
<DICH_DATA CI_END="1.094589563661625" CI_START="0.9027408096499131" EFFECT_SIZE="0.9940476190476191" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="168" LOG_CI_END="0.03925130305573282" LOG_CI_START="-0.044436924212291944" LOG_EFFECT_SIZE="-0.0025928105782795645" ORDER="3" O_E="0.0" SE="0.04915887896064389" STUDY_ID="STD-Van-Meurs-2005" TOTAL_1="210" TOTAL_2="210" VAR="0.002416595380667236" WEIGHT="47.01627291407766"/>
<DICH_DATA CI_END="0.8817746773656374" CI_START="0.35002363214912363" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="-0.054642377315413125" LOG_CI_START="-0.4559026328911989" LOG_EFFECT_SIZE="-0.25527250510330607" ORDER="4" O_E="0.0" SE="0.23570226039551584" STUDY_ID="STD-Dani-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.05555555555555555" WEIGHT="5.037457812222606"/>
<DICH_DATA CI_END="1.1168066915350723" CI_START="0.8664789929665834" EFFECT_SIZE="0.9837121212121213" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="48" LOG_CI_END="0.04797800743529213" LOG_CI_START="-0.06224196191634881" LOG_EFFECT_SIZE="-0.007131977240528335" ORDER="5" O_E="0.0" SE="0.06474375559480146" STUDY_ID="STD-INNOVO-2005" TOTAL_1="55" TOTAL_2="53" VAR="0.004191753888519386" WEIGHT="13.681984181345351"/>
<DICH_DATA CI_END="1.0288582769714807" CI_START="0.7031846445542372" EFFECT_SIZE="0.8505747126436781" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="29" LOG_CI_END="0.012355555745709927" LOG_CI_START="-0.15293062152099463" LOG_EFFECT_SIZE="-0.07028753288764235" ORDER="6" O_E="0.0" SE="0.09708991870623518" STUDY_ID="STD-Kinsella-1999" TOTAL_1="48" TOTAL_2="32" VAR="0.009426452314383355" WEIGHT="9.739085103630371"/>
<DICH_DATA CI_END="1.6239357002652204" CI_START="0.427630505524959" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.2105688293553776" LOG_CI_START="-0.36893132145062724" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2010-06-28 14:10:13 -0400" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.34040125715545744" STUDY_ID="STD-Van-Meurs-2007" TOTAL_1="14" TOTAL_2="15" VAR="0.11587301587301586" WEIGHT="2.4318761852109136"/>
<DICH_DATA CI_END="1.210179753033761" CI_START="0.5101282988976661" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="21" LOG_CI_END="0.08284988267402474" LOG_CI_START="-0.29232058371405073" LOG_EFFECT_SIZE="-0.104735350520013" MODIFIED="2009-10-13 12:08:13 -0400" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="0.2203769890801154" STUDY_ID="STD-Su-2007" TOTAL_1="32" TOTAL_2="33" VAR="0.04856601731601731" WEIGHT="5.7866182048095585"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.096758034349522" CI_END="1.0092850160676246" CI_START="0.8455417036413558" DF="2" EFFECT_SIZE="0.9237924939863457" ESTIMABLE="YES" EVENTS_1="334" EVENTS_2="355" I2="51.180909801582715" ID="CMP-001.04.02" LOG_CI_END="0.004013825727775792" LOG_CI_START="-0.07286496735108998" LOG_EFFECT_SIZE="-0.03442557081165709" MODIFIED="2016-12-11 16:29:26 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.12894402048700637" P_Z="0.07920708945922496" STUDIES="3" TAU2="0.0" TOTAL_1="543" TOTAL_2="532" WEIGHT="100.0" Z="1.7553053640908338">
<NAME>Studies with entry after 3 days based on BPD risk</NAME>
<DICH_DATA CI_END="1.0155431209490828" CI_START="0.7766351784576747" EFFECT_SIZE="0.8880915003363983" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="182" LOG_CI_END="0.006698368698627742" LOG_CI_START="-0.10978294154681768" LOG_EFFECT_SIZE="-0.05154228642409497" ORDER="34" O_E="0.0" SE="0.06842169822995953" STUDY_ID="STD-Ballard-2006" TOTAL_1="294" TOTAL_2="288" VAR="0.004681528788671646" WEIGHT="51.2535405698487"/>
<DICH_DATA CI_END="1.1856431455691854" CI_START="0.9198010265660715" EFFECT_SIZE="1.044296788482835" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" LOG_CI_END="0.07395399490454761" LOG_CI_START="-0.0363061100569025" LOG_EFFECT_SIZE="0.018823942423822546" MODIFIED="2016-02-05 16:12:16 -0500" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.06476733145067783" STUDY_ID="STD-Subhedar-1997" TOTAL_1="20" TOTAL_2="22" VAR="0.004194807223241961" WEIGHT="5.720489806180577"/>
<DICH_DATA CI_END="1.082541433477283" CI_START="0.8342108181109984" EFFECT_SIZE="0.9502987818892209" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="152" LOG_CI_END="0.03444452764543609" LOG_CI_START="-0.07872418248893176" LOG_EFFECT_SIZE="-0.02213982742174786" MODIFIED="2013-12-09 15:01:51 -0500" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="0.06647586052707755" STUDY_ID="STD-Yoder-2013" TOTAL_1="229" TOTAL_2="222" VAR="0.004419040032815467" WEIGHT="43.025969623970724"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.354885378193405" CI_END="1.0160178691009243" CI_START="0.8682440047561575" DF="3" EFFECT_SIZE="0.9392291645663501" ESTIMABLE="YES" EVENTS_1="497" EVENTS_2="527" I2="10.578167006841515" ID="CMP-001.04.03" LOG_CI_END="0.006901346120818313" LOG_CI_START="-0.06135820681974284" LOG_EFFECT_SIZE="-0.027228430349462256" MODIFIED="2014-10-20 10:56:43 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3400764654297177" P_Z="0.11790172828502878" STUDIES="4" TAU2="0.0" TOTAL_1="963" TOTAL_2="961" WEIGHT="100.0" Z="1.5636417333988084">
<NAME>Studies of routine use in preterm infants on respiratory support</NAME>
<DICH_DATA CI_END="1.033149597963261" CI_START="0.8712023149581496" EFFECT_SIZE="0.9487266842688017" ESTIMABLE="YES" EVENTS_1="282" EVENTS_2="295" LOG_CI_END="0.014163211031711857" LOG_CI_START="-0.059880979243770824" LOG_EFFECT_SIZE="-0.022858884106029487" ORDER="36" O_E="0.0" SE="0.043493923892471614" STUDY_ID="STD-Kinsella-2006" TOTAL_1="398" TOTAL_2="395" VAR="0.001891721415564113" WEIGHT="56.06638737276635"/>
<DICH_DATA CI_END="0.9740989234531542" CI_START="0.5963927027202987" EFFECT_SIZE="0.7621978021978022" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="65" LOG_CI_END="-0.011396936624167738" LOG_CI_START="-0.22446767908171175" LOG_EFFECT_SIZE="-0.11793230785293972" ORDER="37" O_E="0.0" SE="0.12515880883674674" STUDY_ID="STD-Schreiber-2003" TOTAL_1="105" TOTAL_2="102" VAR="0.01566472742943331" WEIGHT="12.485415014093244"/>
<DICH_DATA CI_END="1.613777911205509" CI_START="0.6953640669577477" EFFECT_SIZE="1.0593220338983051" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.20784376670915344" LOG_CI_START="-0.1577877553052914" LOG_EFFECT_SIZE="0.025028005701931054" MODIFIED="2014-10-20 10:56:43 -0400" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.21477376593650865" STUDY_ID="STD-Kinsella-2014" TOTAL_1="59" TOTAL_2="65" VAR="0.04612777053455021" WEIGHT="4.684619771647336"/>
<DICH_DATA CI_END="1.184816585548562" CI_START="0.8120771607280177" EFFECT_SIZE="0.9808988167878177" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="141" LOG_CI_END="0.07365112498800369" LOG_CI_START="-0.09040270365744149" LOG_EFFECT_SIZE="-0.008375789334718916" MODIFIED="2009-10-14 11:20:07 -0400" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="0.09636603102588337" STUDY_ID="STD-EUNO-2009" TOTAL_1="401" TOTAL_2="399" VAR="0.009286411935681516" WEIGHT="26.763577841493063"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.0112504183615165" CI_END="1.1825116900755324" CI_START="0.8860308982710382" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0235926411290908" ESTIMABLE="YES" EVENTS_1="272" EVENTS_2="267" I2="14.423253457231944" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.07280544277999874" LOG_CI_START="-0.05255113283684069" LOG_EFFECT_SIZE="0.010127154971579054" METHOD="MH" MODIFIED="2016-12-11 16:29:46 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.3198082106396025" P_Q="0.8388804583771925" P_Z="0.7514876514114918" Q="0.3513742112647515" RANDOM="NO" SCALE="1.2" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1167" TOTAL_2="1178" WEIGHT="300.0" Z="0.316678385836257">
<NAME>Intraventricular haemorrhage (all grades)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.5017493879630526" CI_END="1.2798984340950939" CI_START="0.6923398079474439" DF="3" EFFECT_SIZE="0.9413419336530331" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="54" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.10717550772431242" LOG_CI_START="-0.1596806967362737" LOG_EFFECT_SIZE="-0.026252594505980654" MODIFIED="2016-12-11 16:29:38 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6818666608727639" P_Z="0.6997692656068604" STUDIES="4" TAU2="0.0" TOTAL_1="154" TOTAL_2="160" WEIGHT="100.0" Z="0.38563195363183556">
<NAME>Studies with entry before 3 days based on oxygenation</NAME>
<DICH_DATA CI_END="3.9855442667258254" CI_START="0.39204181297015506" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6004876371237167" LOG_CI_START="-0.4066676111076039" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="38" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Dani-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.35000000000000003" WEIGHT="7.673561111420031"/>
<DICH_DATA CI_END="1.457131542611237" CI_START="0.6150997458990893" EFFECT_SIZE="0.9467213114754098" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="32" LOG_CI_END="0.16349875949235876" LOG_CI_START="-0.211054452385529" LOG_EFFECT_SIZE="-0.023777846446585118" ORDER="39" O_E="0.0" SE="0.2200144107253721" STUDY_ID="STD-Hascoet-2005" TOTAL_1="61" TOTAL_2="84" VAR="0.04840634092683273" WEIGHT="51.65100444652379"/>
<DICH_DATA CI_END="1.6581707546358828" CI_START="0.6314503243180996" EFFECT_SIZE="1.0232558139534884" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="13" LOG_CI_END="0.2196292511706432" LOG_CI_START="-0.19966080935744135" LOG_EFFECT_SIZE="0.009984220906600923" ORDER="40" O_E="0.0" SE="0.24629305707347" STUDY_ID="STD-Kinsella-1999" TOTAL_1="43" TOTAL_2="26" VAR="0.06066026996259555" WEIGHT="31.083483052781137"/>
<DICH_DATA CI_END="1.9031160339754112" CI_START="0.08407264567351506" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.27946526825494583" LOG_CI_START="-1.075345285599021" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2015-06-01 23:16:11 -0400" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="0.7958224257542215" STUDY_ID="STD-Wei-2014" TOTAL_1="30" TOTAL_2="30" VAR="0.6333333333333333" WEIGHT="9.591951389275039"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.53923374773345" CI_START="0.4765217070228609" DF="0" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.4047026814480358" LOG_CI_START="-0.32191731113158567" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2016-12-11 16:29:46 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8232997783316482" STUDIES="1" TAU2="0.0" TOTAL_1="229" TOTAL_2="229" WEIGHT="100.0" Z="0.22330288998932804">
<NAME>Studies with entry after 3 days based on BPD risk</NAME>
<DICH_DATA CI_END="2.5392337477334497" CI_START="0.4765217070228609" EFFECT_SIZE="1.1" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.40470268144803573" LOG_CI_START="-0.32191731113158567" LOG_EFFECT_SIZE="0.04139268515822508" MODIFIED="2016-01-07 18:07:34 -0500" MODIFIED_BY="[Empty name]" ORDER="113" O_E="0.0" SE="0.4268201804682417" STUDY_ID="STD-Yoder-2013" TOTAL_1="229" TOTAL_2="229" VAR="0.18217546645494243" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.315478279026897" CI_END="1.2288293477650232" CI_START="0.8818787564499453" DF="1" EFFECT_SIZE="1.040998797836105" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="203" I2="81.18701747036262" ID="CMP-001.05.03" LOG_CI_END="0.08949157493695273" LOG_CI_START="-0.054591118977258636" LOG_EFFECT_SIZE="0.01745022797984703" MODIFIED="2016-01-07 18:06:28 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.02113685201615112" P_Z="0.6349633075411693" STUDIES="2" TAU2="0.0" TOTAL_1="784" TOTAL_2="789" WEIGHT="100.0" Z="0.4747526220307557">
<NAME>Studies of routine use in preterm infants on respiratory support</NAME>
<DICH_DATA CI_END="1.6089372424599417" CI_START="1.000453004939612" EFFECT_SIZE="1.2687261717873963" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="91" LOG_CI_END="0.20653910451861204" LOG_CI_START="1.9669299746163712E-4" LOG_EFFECT_SIZE="0.10336789875803683" MODIFIED="2010-06-28 11:13:05 -0400" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.12120655393893393" STUDY_ID="STD-EUNO-2009" TOTAL_1="392" TOTAL_2="397" VAR="0.0146910287177517" WEIGHT="44.67040673211781"/>
<DICH_DATA CI_END="1.0830281510132176" CI_START="0.6783700653244182" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="112" LOG_CI_END="0.03463974533335987" LOG_CI_START="-0.1685333245945863" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2010-11-07 17:29:53 -0500" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="0.1193448669985918" STUDY_ID="STD-Kinsella-2006" TOTAL_1="392" TOTAL_2="392" VAR="0.014243197278911567" WEIGHT="55.32959326788219"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.161490782492875" CI_END="1.1802082199042976" CI_START="0.8871018630669254" CI_STUDY="95" CI_TOTAL="90" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0232130328939335" ESTIMABLE="YES" EVENTS_1="219" EVENTS_2="212" I2="19.36561006602484" I2_Q="65.62383479021737" ID="CMP-001.06" LOG_CI_END="0.07195863508407384" LOG_CI_START="-0.05202650865994028" LOG_EFFECT_SIZE="0.00996606321206675" METHOD="MH" MODIFIED="2016-12-11 16:29:58 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.26480189770814877" P_Q="0.08808704082034713" P_Z="0.7914483559594839" Q="2.9089923029443208" RANDOM="NO" SCALE="1.2" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1338" TOTAL_2="1348" WEIGHT="199.99999999999997" Z="0.2644303135969395">
<NAME>Intraventricular haemorrhage (grade 3 or 4)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.5740458632938363" CI_END="1.46647474696345" CI_START="0.9819542416634536" DF="5" EFFECT_SIZE="1.2000046241882152" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="90" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.1662745887288766" LOG_CI_START="-0.00790874954103405" LOG_EFFECT_SIZE="0.07918291959392128" MODIFIED="2016-12-11 16:29:58 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6122145165425796" P_Z="0.1347878288949844" STUDIES="6" TAU2="0.0" TOTAL_1="384" TOTAL_2="389" WEIGHT="99.99999999999997" Z="1.495485317715573">
<NAME>Studies with entry before 3 days based on oxygenation</NAME>
<DICH_DATA CI_END="6.41978801003991" CI_START="0.15576838338526122" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8075206873227565" LOG_CI_START="-0.8075206873227565" LOG_EFFECT_SIZE="0.0" ORDER="41" O_E="0.0" SE="0.9486832980505138" STUDY_ID="STD-Dani-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.8999999999999999" WEIGHT="2.221283007592107"/>
<DICH_DATA CI_END="2.278269172452612" CI_START="0.6372501911932074" EFFECT_SIZE="1.2049180327868851" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" LOG_CI_END="0.357605033704817" LOG_CI_START="-0.19569002555796128" LOG_EFFECT_SIZE="0.08095750407342783" ORDER="42" O_E="0.0" SE="0.325008256665671" STUDY_ID="STD-Hascoet-2005" TOTAL_1="61" TOTAL_2="84" VAR="0.1056303669008587" WEIGHT="14.951532520068252"/>
<DICH_DATA CI_END="1.8023939656729941" CI_START="0.5192781218787171" EFFECT_SIZE="0.9674418604651163" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.2558497247214848" LOG_CI_START="-0.28459997462717246" LOG_EFFECT_SIZE="-0.014375124952843788" ORDER="43" O_E="0.0" SE="0.3174628286665592" STUDY_ID="STD-Kinsella-1999" TOTAL_1="43" TOTAL_2="26" VAR="0.10078264758497316" WEIGHT="13.84277816325516"/>
<DICH_DATA CI_END="3.43695642172622" CI_START="0.3592038273835614" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5361740256129843" LOG_CI_START="-0.44465904449163407" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="44" O_E="0.0" SE="0.5761462005814535" STUDY_ID="STD-Srisuparp-2002" TOTAL_1="18" TOTAL_2="16" VAR="0.3319444444444445" WEIGHT="4.703893427842109"/>
<DICH_DATA CI_END="1.544864923947421" CI_START="0.17209863238117562" EFFECT_SIZE="0.515625" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.18889051266130472" LOG_CI_START="-0.764222580873304" LOG_EFFECT_SIZE="-0.28766603410599967" MODIFIED="2009-10-13 12:08:56 -0400" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="0.559863349128133" STUDY_ID="STD-Su-2007" TOTAL_1="32" TOTAL_2="33" VAR="0.3134469696969697" WEIGHT="8.748437691439683"/>
<DICH_DATA CI_END="1.8809716389825168" CI_START="1.0124554568138815" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="50" LOG_CI_END="0.2743822473705539" LOG_CI_START="0.00537592543191904" LOG_EFFECT_SIZE="0.13987908640123647" ORDER="45" O_E="0.0" SE="0.1580156451095235" STUDY_ID="STD-Van-Meurs-2005" TOTAL_1="210" TOTAL_2="210" VAR="0.02496894409937888" WEIGHT="55.532075189802676"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.506709975819185" CI_END="1.093484991327606" CI_START="0.7290054019709248" DF="3" EFFECT_SIZE="0.8928361919478592" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="122" I2="33.43259237677726" ID="CMP-001.06.02" LOG_CI_END="0.03881282648811948" LOG_CI_START="-0.1372692535236278" LOG_EFFECT_SIZE="-0.04922821351775415" MODIFIED="2014-10-20 10:58:20 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2116928647328239" P_Z="0.3577185139281579" STUDIES="4" TAU2="0.0" TOTAL_1="954" TOTAL_2="959" WEIGHT="100.0" Z="0.9197211385464931">
<NAME>Studies of routine use in preterm infants on respiratory support</NAME>
<DICH_DATA CI_END="1.9179675209490759" CI_START="0.8355792700367963" EFFECT_SIZE="1.2659438775510203" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="36" LOG_CI_END="0.28284124851137843" LOG_CI_START="-0.07801234300995005" LOG_EFFECT_SIZE="0.1024144527507142" MODIFIED="2010-06-28 11:19:50 -0400" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.21196718591371472" STUDY_ID="STD-EUNO-2009" TOTAL_1="392" TOTAL_2="397" VAR="0.0449300879041793" WEIGHT="29.2991018739755"/>
<DICH_DATA CI_END="1.0914674233163881" CI_START="0.5459191516527016" EFFECT_SIZE="0.7719151312116136" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="63" LOG_CI_END="0.038010777988297884" LOG_CI_START="-0.26287166973288917" LOG_EFFECT_SIZE="-0.11243044587229567" ORDER="46" O_E="0.0" SE="0.1767398391835621" STUDY_ID="STD-Kinsella-2006" TOTAL_1="398" TOTAL_2="395" VAR="0.031236970754631388" WEIGHT="51.795636871000355"/>
<DICH_DATA CI_END="2.8981996448239205" CI_START="0.10469703911398248" EFFECT_SIZE="0.5508474576271186" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.46212829889186413" LOG_CI_START="-0.9800656002184039" LOG_EFFECT_SIZE="-0.25896865066326985" MODIFIED="2014-10-20 10:58:20 -0400" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.847151835312308" STUDY_ID="STD-Kinsella-2014" TOTAL_1="59" TOTAL_2="65" VAR="0.7176662320730118" WEIGHT="3.1176909409869284"/>
<DICH_DATA CI_END="1.2740993252991248" CI_START="0.34673522362489845" EFFECT_SIZE="0.6646616541353384" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.10520328572922219" LOG_CI_START="-0.46000203763724745" LOG_EFFECT_SIZE="-0.17739937595401267" MODIFIED="2009-10-15 14:25:36 -0400" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.3320044047569375" STUDY_ID="STD-Schreiber-2003" TOTAL_1="105" TOTAL_2="102" VAR="0.11022692477800838" WEIGHT="15.78757031403722"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.63491868503312" CI_END="1.1422817093252684" CI_START="0.8448392257259838" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9823667313520512" ESTIMABLE="YES" EVENTS_1="262" EVENTS_2="264" I2="53.77842576816373" I2_Q="28.799870500996555" ID="CMP-001.07" LOG_CI_END="0.057773222752120504" LOG_CI_START="-0.0732259301312154" LOG_EFFECT_SIZE="-0.007726353689547419" METHOD="MH" MODIFIED="2016-12-11 16:30:12 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.017076426884072737" P_Q="0.23597315992883539" P_Z="0.8171609377465153" Q="1.4044918275239886" RANDOM="NO" SCALE="1.2" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1321" TOTAL_2="1327" WEIGHT="200.0" Z="0.2311980593770307">
<NAME>Intraventricular haemorrhage (grade 3 or 4) or periventricular leukomalacia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.082431712419238" CI_END="1.3340676681063215" CI_START="0.8769412913455482" DF="7" EFFECT_SIZE="1.0816187052799622" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="118" I2="30.57230438389571" ID="CMP-001.07.01" LOG_CI_END="0.12517785892074057" LOG_CI_START="-0.057029480406044906" LOG_EFFECT_SIZE="0.034074189257347814" MODIFIED="2016-12-11 16:30:12 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1839502612115892" P_Z="0.46352366407799606" STUDIES="8" TAU2="0.0" TOTAL_1="447" TOTAL_2="454" WEIGHT="100.0" Z="0.7330570106951306">
<NAME>Studies with entry before 3 days based on oxygenation</NAME>
<DICH_DATA CI_END="6.41978801003991" CI_START="0.15576838338526122" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8075206873227565" LOG_CI_START="-0.8075206873227565" LOG_EFFECT_SIZE="0.0" ORDER="47" O_E="0.0" SE="0.9486832980505138" STUDY_ID="STD-Dani-2006" TOTAL_1="20" TOTAL_2="20" VAR="0.8999999999999999" WEIGHT="1.68236585392935"/>
<DICH_DATA CI_END="2.0923587991174175" CI_START="0.6293616131287658" EFFECT_SIZE="1.1475409836065573" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.32063615969600073" LOG_CI_START="-0.20109974968902117" LOG_EFFECT_SIZE="0.059768205003489776" ORDER="48" O_E="0.0" SE="0.3064702558071655" STUDY_ID="STD-Hascoet-2005" TOTAL_1="61" TOTAL_2="84" VAR="0.09392401769450949" WEIGHT="12.73957039734087"/>
<DICH_DATA CI_END="1.0768428447316667" CI_START="0.2022372891673388" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.03215232665364818" LOG_CI_START="-0.6941387647364969" LOG_EFFECT_SIZE="-0.3309932190414244" ORDER="49" O_E="0.0" SE="0.4266269822814563" STUDY_ID="STD-INNOVO-2005" TOTAL_1="27" TOTAL_2="21" VAR="0.182010582010582" WEIGHT="9.463307928352593"/>
<DICH_DATA CI_END="1.5633562099824605" CI_START="0.5261800280970835" EFFECT_SIZE="0.9069767441860465" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" LOG_CI_END="0.19405794308910243" LOG_CI_START="-0.27886564019527715" LOG_EFFECT_SIZE="-0.04240384855308735" ORDER="50" O_E="0.0" SE="0.2777976538307371" STUDY_ID="STD-Kinsella-1999" TOTAL_1="43" TOTAL_2="26" VAR="0.07717153647386206" WEIGHT="12.581170733732531"/>
<DICH_DATA CI_END="2.3555554508804812" CI_START="0.6305738045541622" EFFECT_SIZE="1.21875" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.3720933321904514" LOG_CI_START="-0.2002640747772649" LOG_EFFECT_SIZE="0.08591462870659324" ORDER="51" O_E="0.0" SE="0.3362055740676945" STUDY_ID="STD-Mercier-1999" TOTAL_1="40" TOTAL_2="45" VAR="0.11303418803418802" WEIGHT="9.50041893983633"/>
<DICH_DATA CI_END="1.3324790192169569" CI_START="0.2715820933667762" EFFECT_SIZE="0.6015625" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.1246603794922029" LOG_CI_START="-0.566098868442976" LOG_EFFECT_SIZE="-0.2207192444753865" MODIFIED="2009-10-13 12:10:29 -0400" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.4057554015505473" STUDY_ID="STD-Su-2007" TOTAL_1="32" TOTAL_2="33" VAR="0.16463744588744586" WEIGHT="9.938899813982623"/>
<DICH_DATA CI_END="1.8809716389825168" CI_START="1.0124554568138815" EFFECT_SIZE="1.38" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="50" LOG_CI_END="0.2743822473705539" LOG_CI_START="0.00537592543191904" LOG_EFFECT_SIZE="0.13987908640123647" ORDER="52" O_E="0.0" SE="0.1580156451095235" STUDY_ID="STD-Van-Meurs-2005" TOTAL_1="210" TOTAL_2="210" VAR="0.02496894409937888" WEIGHT="42.05914634823375"/>
<DICH_DATA CI_END="4.090331773254378" CI_START="0.01112650846777186" EFFECT_SIZE="0.21333333333333335" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6117585357457006" LOG_CI_START="-1.953641097217251" LOG_EFFECT_SIZE="-0.6709412807357752" MODIFIED="2010-06-28 14:12:51 -0400" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="1.5069284433354269" STUDY_ID="STD-Van-Meurs-2007" TOTAL_1="14" TOTAL_2="15" VAR="2.270833333333333" WEIGHT="2.035119984591956"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.035321459489136" CI_END="1.1188254401345896" CI_START="0.7266499808879179" DF="2" EFFECT_SIZE="0.901662067900561" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="146" I2="80.07039427612104" ID="CMP-001.07.02" LOG_CI_END="0.04876233290905192" LOG_CI_START="-0.13867473353455664" LOG_EFFECT_SIZE="-0.04495620031275235" MODIFIED="2014-10-20 10:45:30 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.00662001391597089" P_Z="0.3471239207540101" STUDIES="3" TAU2="0.0" TOTAL_1="874" TOTAL_2="873" WEIGHT="100.0" Z="0.9401825921264301">
<NAME>Studies of routine use in preterm infants on respiratory support</NAME>
<DICH_DATA CI_END="2.045201199981639" CI_START="0.9745684719042851" EFFECT_SIZE="1.4118033178183553" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="42" LOG_CI_END="0.31073603886833234" LOG_CI_START="-0.011187642512976829" LOG_EFFECT_SIZE="0.1497741981776778" MODIFIED="2009-10-14 12:07:15 -0400" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.18909956399130426" STUDY_ID="STD-EUNO-2009" TOTAL_1="399" TOTAL_2="401" VAR="0.035758645101701375" WEIGHT="28.655772605137937"/>
<DICH_DATA CI_END="1.0129542267106726" CI_START="0.5556050265273766" EFFECT_SIZE="0.7502016129032258" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="80" LOG_CI_END="0.005589820941609219" LOG_CI_START="-0.25523383387893595" LOG_EFFECT_SIZE="-0.12482200646866337" ORDER="53" O_E="0.0" SE="0.15320910593950215" STUDY_ID="STD-Kinsella-2006" TOTAL_1="372" TOTAL_2="366" VAR="0.023473030142781598" WEIGHT="55.16409378905419"/>
<DICH_DATA CI_END="0.9736058742227176" CI_START="0.27195315669911707" EFFECT_SIZE="0.5145631067961165" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="24" LOG_CI_END="-0.011616814466964732" LOG_CI_START="-0.5655058957418017" LOG_EFFECT_SIZE="-0.2885613551043832" ORDER="54" O_E="0.0" SE="0.3253571881360106" STUDY_ID="STD-Schreiber-2003" TOTAL_1="103" TOTAL_2="106" VAR="0.1058572998717714" WEIGHT="16.18013360580786"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.870599080622952" CI_END="1.0565691695586497" CI_START="0.8159842150453286" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9285169704767972" ESTIMABLE="YES" EVENTS_1="270" EVENTS_2="288" I2="32.36082540235106" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.02389793392436149" LOG_CI_START="-0.08831824245326807" LOG_EFFECT_SIZE="-0.0322101542644533" METHOD="MH" MODIFIED="2016-12-11 16:30:57 -0500" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.18098739547627118" P_Q="0.6713770721750318" P_Z="0.26052000638114414" Q="0.7968493539888507" RANDOM="NO" SCALE="291.059502072487" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="961" TOTAL_2="968" WEIGHT="300.0" Z="1.125162954801816">
<NAME>Neurodevelopmental disability</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours inhaled NO</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6123392682131321" CI_END="1.3961964119093893" CI_START="0.7835842801289845" DF="1" EFFECT_SIZE="1.04596250427283" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="50" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.14494651757672286" LOG_CI_START="-0.10591428518587481" LOG_EFFECT_SIZE="0.019516116195424017" MODIFIED="2016-12-11 16:30:47 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4339085783457092" P_Z="0.7603988666360683" STUDIES="2" TAU2="0.0" TOTAL_1="98" TOTAL_2="110" WEIGHT="100.0" Z="0.30495704741349094">
<NAME>Studies with entry before 3 days based on oxygenation</NAME>
<DICH_DATA CI_END="1.4370769201923501" CI_START="0.8033094361390614" EFFECT_SIZE="1.074438202247191" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="48" LOG_CI_END="0.15748001456500688" LOG_CI_START="-0.09511713153148442" LOG_EFFECT_SIZE="0.031181441516761232" MODIFIED="2009-10-20 17:54:25 -0400" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.14837681399311797" STUDY_ID="STD-Van-Meurs-2005" TOTAL_1="89" TOTAL_2="102" VAR="0.02201567893074833" WEIGHT="95.48000315532066"/>
<DICH_DATA CI_END="4.0249658627023575" CI_START="0.049076407337504444" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.604762201299449" LOG_CI_START="-1.309127237522174" LOG_EFFECT_SIZE="-0.35218251811136253" MODIFIED="2010-06-28 14:14:26 -0400" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="1.1242281302693367" STUDY_ID="STD-Van-Meurs-2007" TOTAL_1="9" TOTAL_2="8" VAR="1.2638888888888888" WEIGHT="4.519996844679341"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4577646799267532" CI_END="1.0864644302625268" CI_START="0.7402476775503168" DF="1" EFFECT_SIZE="0.896801411262752" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="119" I2="31.401822683051563" ID="CMP-001.08.02" LOG_CI_END="0.03601551253084042" LOG_CI_START="-0.13062294649005007" LOG_EFFECT_SIZE="-0.047303716979604817" MODIFIED="2016-12-11 16:30:57 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.22728641639646263" P_Z="0.2658152708631979" STUDIES="2" TAU2="0.0" TOTAL_1="250" TOTAL_2="248" WEIGHT="100.0" Z="1.1127513079472042">
<NAME>Studies with entry after 3 days based on BPD risk</NAME>
<DICH_DATA CI_END="1.1151848013996812" CI_START="0.76017856402027" EFFECT_SIZE="0.9207277452891488" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="114" LOG_CI_END="0.047346841893433494" LOG_CI_START="-0.11908438106147014" LOG_EFFECT_SIZE="-0.03586876958401831" MODIFIED="2010-06-28 11:54:55 -0400" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.09776252421155089" STUDY_ID="STD-Ballard-2006" TOTAL_1="243" TOTAL_2="234" VAR="0.009557511140214074" WEIGHT="96.81098378141837"/>
<DICH_DATA CI_END="2.706586066731163" CI_START="0.010734833975261725" EFFECT_SIZE="0.17045454545454544" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.4324218417770217" LOG_CI_START="-1.9692046679659967" LOG_EFFECT_SIZE="-0.7683914130944874" ORDER="55" O_E="0.0" SE="1.4107273000660032" STUDY_ID="STD-Subhedar-1997" TOTAL_1="7" TOTAL_2="14" VAR="1.990151515151515" WEIGHT="3.1890162185816266"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.020589626020325" CI_END="1.1333847225357174" CI_START="0.7380695271088843" DF="2" EFFECT_SIZE="0.9146128832431626" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="119" I2="66.78066229001524" ID="CMP-001.08.03" LOG_CI_END="0.05437735427057965" LOG_CI_START="-0.13190272514515483" LOG_EFFECT_SIZE="-0.0387626854372876" MODIFIED="2014-10-20 10:46:00 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.04927727889566669" P_Z="0.41467704728330435" STUDIES="3" TAU2="0.0" TOTAL_1="613" TOTAL_2="610" WEIGHT="100.0" Z="0.8156907345050413">
<NAME>Studies of routine use in preterm infants on respiratory support</NAME>
<DICH_DATA CI_END="2.0128597134586887" CI_START="0.48518482933005264" EFFECT_SIZE="0.9882352941176471" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.3038135077282774" LOG_CI_START="-0.3140927870330995" LOG_EFFECT_SIZE="-0.005139639652411056" MODIFIED="2013-10-25 16:21:27 -0400" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.3629612162283217" STUDY_ID="STD-EUNO-2009" TOTAL_1="306" TOTAL_2="324" VAR="0.13174084448594253" WEIGHT="11.937037197464328"/>
<DICH_DATA CI_END="1.3645280988437687" CI_START="0.8210066291884475" EFFECT_SIZE="1.0584359285590428" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="73" LOG_CI_END="0.13498248324310824" LOG_CI_START="-0.08565333617125481" LOG_EFFECT_SIZE="0.024664573535926704" MODIFIED="2010-11-07 15:22:51 -0500" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.12960257248891718" STUDY_ID="STD-Kinsella-2006" TOTAL_1="237" TOTAL_2="218" VAR="0.01679682679574503" WEIGHT="62.299451147309306"/>
<DICH_DATA CI_END="0.868159151613275" CI_START="0.3268864003875848" EFFECT_SIZE="0.5327188940092166" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="31" LOG_CI_END="-0.06140065232166466" LOG_CI_START="-0.4856031472063739" LOG_EFFECT_SIZE="-0.2735018997640193" ORDER="56" O_E="0.0" SE="0.2491786453314936" STUDY_ID="STD-Schreiber-2003" TOTAL_1="70" TOTAL_2="68" VAR="0.062089997289238266" WEIGHT="25.76351165522636"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.04028461223084247" CI_END="0.9030671437499546" CI_START="0.3639528039385935" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5733008103191665" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.04427995835091025" LOG_CI_START="-0.4389549304112903" LOG_EFFECT_SIZE="-0.24161744438110025" METHOD="MH" MODIFIED="2016-12-11 16:31:12 -0500" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.8409252274857086" P_Q="1.0" P_Z="0.016406077864900295" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="376" TOTAL_2="392" WEIGHT="99.99999999999999" Z="2.3997543424218835">
<NAME>Bayley MDI or PDI &lt; -2 SD</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.04028461223084247" CI_END="0.9030671437499546" CI_START="0.3639528039385935" DF="1" EFFECT_SIZE="0.5733008103191665" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="40" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="-0.04427995835091025" LOG_CI_START="-0.4389549304112903" LOG_EFFECT_SIZE="-0.24161744438110025" MODIFIED="2014-10-20 10:47:07 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8409252274857086" P_Z="0.016406077864900295" STUDIES="2" TAU2="0.0" TOTAL_1="376" TOTAL_2="392" WEIGHT="99.99999999999999" Z="2.3997543424218835">
<NAME>Studies of routine use in preterm infants on respiratory support</NAME>
<DICH_DATA CI_END="1.5482479985411297" CI_START="0.24639973029696902" EFFECT_SIZE="0.6176470588235294" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.18984052725864428" LOG_CI_START="-0.608359771875316" LOG_EFFECT_SIZE="-0.20925962230833584" MODIFIED="2013-10-25 16:15:41 -0400" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.4688668068664923" STUDY_ID="STD-EUNO-2009" TOTAL_1="306" TOTAL_2="324" VAR="0.2198360825811806" WEIGHT="29.097072928724984"/>
<DICH_DATA CI_END="0.9296633187747189" CI_START="0.3314514722647892" EFFECT_SIZE="0.5551020408163265" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="28" LOG_CI_END="-0.031674304426667736" LOG_CI_START="-0.4795800475619622" LOG_EFFECT_SIZE="-0.25562717599431495" ORDER="59" O_E="0.0" SE="0.2631020506868585" STUDY_ID="STD-Schreiber-2003" TOTAL_1="70" TOTAL_2="68" VAR="0.06922268907563024" WEIGHT="70.902927071275"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.0442719611626012" CI_END="1.5435994644513036" CI_START="0.8484932861351706" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1444360104736202" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="74" I2="0.0" I2_Q="13.237418070826102" ID="CMP-001.10" LOG_CI_END="0.1885346192217975" LOG_CI_START="-0.07135158977056409" LOG_EFFECT_SIZE="0.05859151472561672" METHOD="MH" MODIFIED="2016-12-11 16:31:44 -0500" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.6931603666148007" P_Q="0.3158242739597178" P_Z="0.3768310258372509" Q="2.305141174374734" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="962" TOTAL_2="968" WEIGHT="300.0" Z="0.8837503083146073">
<NAME>Cerebral palsy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7140142249111703" CI_START="0.9260435299106768" DF="0" EFFECT_SIZE="1.8545454545454545" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="0.5698435627824897" LOG_CI_START="-0.03336859824714227" LOG_EFFECT_SIZE="0.2682374822676737" MODIFIED="2016-12-11 16:31:35 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.08131253213879716" STUDIES="2" TAU2="0.0" TOTAL_1="99" TOTAL_2="110" WEIGHT="100.0" Z="1.7431207078151594">
<NAME>Studies with entry before 3 days based on oxygenation</NAME>
<DICH_DATA CI_END="3.7140142249111703" CI_START="0.9260435299106768" EFFECT_SIZE="1.8545454545454545" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.5698435627824897" LOG_CI_START="-0.03336859824714227" LOG_EFFECT_SIZE="0.2682374822676737" MODIFIED="2010-06-28 12:10:30 -0400" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.3543298093371597" STUDY_ID="STD-Van-Meurs-2005" TOTAL_1="90" TOTAL_2="102" VAR="0.12554961378490792" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-28 14:14:57 -0400" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.0" STUDY_ID="STD-Van-Meurs-2007" TOTAL_1="9" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5815938347454881" CI_END="2.2333223188560822" CI_START="0.5422914628805936" DF="1" EFFECT_SIZE="1.1005051691729324" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.34895140609825936" LOG_CI_START="-0.2657672324685342" LOG_EFFECT_SIZE="0.04159208681486262" MODIFIED="2016-12-11 16:31:44 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4456884013901391" P_Z="0.7908370979227377" STUDIES="2" TAU2="0.0" TOTAL_1="250" TOTAL_2="248" WEIGHT="100.0" Z="0.2652237530622276">
<NAME>Studies with entry after 3 days based on BPD risk</NAME>
<DICH_DATA CI_END="2.5167354805527014" CI_START="0.575707148210832" EFFECT_SIZE="1.2037037037037037" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.4008375717767075" LOG_CI_START="-0.23979837813693336" LOG_EFFECT_SIZE="0.08051959681988707" MODIFIED="2010-06-28 11:56:37 -0400" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.37631272817836914" STUDY_ID="STD-Ballard-2006" TOTAL_1="243" TOTAL_2="234" VAR="0.14161126938904714" WEIGHT="87.546992481203"/>
<DICH_DATA CI_END="6.901700252848146" CI_START="0.02037541400642079" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.8389560935586465" LOG_CI_START="-1.6908935581032087" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="57" O_E="0.0" SE="1.4860462083439172" STUDY_ID="STD-Subhedar-1997" TOTAL_1="7" TOTAL_2="14" VAR="2.208333333333333" WEIGHT="12.45300751879699"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.17099492933139196" CI_END="1.4710910125639844" CI_START="0.6893051529168825" DF="2" EFFECT_SIZE="1.0069908715425722" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="49" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="0.16763954222556135" LOG_CI_START="-0.1615884749150645" LOG_EFFECT_SIZE="0.003025533655248464" MODIFIED="2014-10-20 10:46:30 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9180555060834524" P_Z="0.9712637939369994" STUDIES="3" TAU2="0.0" TOTAL_1="613" TOTAL_2="610" WEIGHT="100.0" Z="0.03602328288948697">
<NAME>Studies of routine use in preterm infants on respiratory support</NAME>
<DICH_DATA CI_END="1.7290719390639144" CI_START="0.6483867102966991" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="29" LOG_CI_END="0.23781306272941474" LOG_CI_START="-0.18816589527935046" LOG_EFFECT_SIZE="0.024823583725032145" MODIFIED="2013-10-25 16:22:28 -0400" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.25022214856419833" STUDY_ID="STD-EUNO-2009" TOTAL_1="306" TOTAL_2="324" VAR="0.06261112363208374" WEIGHT="57.70972940877089"/>
<DICH_DATA CI_END="2.059991420676226" CI_START="0.47634350757102767" EFFECT_SIZE="0.9905874716001298" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.3138654116503513" LOG_CI_START="-0.3220797497185469" LOG_EFFECT_SIZE="-0.004107169034097777" MODIFIED="2010-11-07 16:14:28 -0500" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.37355733576740957" STUDY_ID="STD-Kinsella-2006" TOTAL_1="237" TOTAL_2="218" VAR="0.13954508310564517" WEIGHT="27.742811095088644"/>
<DICH_DATA CI_END="2.3512860309024783" CI_START="0.29486464481754476" EFFECT_SIZE="0.8326530612244898" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3713054637002659" LOG_CI_START="-0.5303772975775334" LOG_EFFECT_SIZE="-0.07953591693863371" MODIFIED="2010-11-07 18:11:02 -0500" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.5296529173762324" STUDY_ID="STD-Schreiber-2003" TOTAL_1="70" TOTAL_2="68" VAR="0.28053221288515406" WEIGHT="14.547459496140469"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3446911335841087" CI_END="1.268519783776219" CI_START="0.6054925559580294" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8764013271110386" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.10329724484733775" LOG_CI_START="-0.21789119178802024" LOG_EFFECT_SIZE="-0.05729697347034126" METHOD="MH" MODIFIED="2016-12-11 16:32:25 -0500" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.6726447135465407" P_Q="0.38249510336999537" P_Z="0.4843783155206268" Q="0.7626673588134049" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="289" TOTAL_2="303" WEIGHT="200.0" Z="0.6992780039121327">
<NAME>Severe retinopathy of prematurity (&#8805;stage 3)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2978482435740442" CI_END="1.4720282530109723" CI_START="0.6427930356670656" DF="2" EFFECT_SIZE="0.9727330103068417" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="34" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.16791614560542695" LOG_CI_START="-0.19192883724122003" LOG_EFFECT_SIZE="-0.012006345817896545" MODIFIED="2016-12-11 16:32:25 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5226077680975212" P_Z="0.8959416856930267" STUDIES="3" TAU2="0.0" TOTAL_1="125" TOTAL_2="136" WEIGHT="100.0" Z="0.13078968172825034">
<NAME>Studies with entry before 3 days based on oxygenation</NAME>
<DICH_DATA CI_END="4.7370237166558695" CI_START="0.22450311125965142" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6755055590971754" LOG_CI_START="-0.6487776359812123" LOG_EFFECT_SIZE="0.013363961557981502" MODIFIED="2010-06-28 12:48:25 -0400" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.7778905040965832" STUDY_ID="STD-Su-2007" TOTAL_1="32" TOTAL_2="33" VAR="0.6051136363636364" WEIGHT="8.979700626356246"/>
<DICH_DATA CI_END="1.606765087181675" CI_START="0.6690613662868586" EFFECT_SIZE="1.036833855799373" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" LOG_CI_END="0.20595238653419523" LOG_CI_START="-0.17453404692948035" LOG_EFFECT_SIZE="0.015709169802357453" MODIFIED="2010-06-28 12:12:26 -0400" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="0.2234996144547844" STUDY_ID="STD-Van-Meurs-2005" TOTAL_1="88" TOTAL_2="98" VAR="0.049952077661437264" WEIGHT="83.42029233310787"/>
<DICH_DATA CI_END="3.3474131138717054" CI_START="0.01194952598896136" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5247093131953876" LOG_CI_START="-1.922649321867425" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2010-06-28 14:13:28 -0400" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="1.4375905768565218" STUDY_ID="STD-Van-Meurs-2007" TOTAL_1="5" TOTAL_2="5" VAR="2.066666666666667" WEIGHT="7.6000070405358855"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.1525516977028667" CI_END="1.4553798804568392" CI_START="0.2896500570460284" DF="1" EFFECT_SIZE="0.6492694859593862" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.16297636682909808" LOG_CI_START="-0.5381263816314426" LOG_EFFECT_SIZE="-0.18757500740117222" MODIFIED="2014-10-20 10:59:41 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6961088621713756" P_Z="0.2942938603426932" STUDIES="2" TAU2="0.0" TOTAL_1="164" TOTAL_2="167" WEIGHT="100.0" Z="1.0487485884583523">
<NAME>Studies of routine use in preterm infants on respiratory support</NAME>
<DICH_DATA CI_END="3.539679480551359" CI_START="0.19287737132508417" EFFECT_SIZE="0.826271186440678" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5489639382602516" LOG_CI_START="-0.7147187214754287" LOG_EFFECT_SIZE="-0.08287739160758856" MODIFIED="2014-10-20 10:59:41 -0400" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.742293449658789" STUDY_ID="STD-Kinsella-2014" TOTAL_1="59" TOTAL_2="65" VAR="0.5509995654063451" WEIGHT="27.283694122377856"/>
<DICH_DATA CI_END="1.5448692637117505" CI_START="0.21990368826638715" EFFECT_SIZE="0.5828571428571429" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.18889173265991077" LOG_CI_START="-0.6577674865086646" LOG_EFFECT_SIZE="-0.23443787692437687" ORDER="60" O_E="0.0" SE="0.4973318163703481" STUDY_ID="STD-Schreiber-2003" TOTAL_1="105" TOTAL_2="102" VAR="0.24733893557422967" WEIGHT="72.71630587762215"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.328118086255208" CI_END="1.215123980451641" CI_START="0.8366802295139183" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0083006549894455" ESTIMABLE="YES" EVENTS_1="182" EVENTS_2="178" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.08462059174423647" LOG_CI_START="-0.07744049313267394" LOG_EFFECT_SIZE="0.0035900493057812663" METHOD="MH" MODIFIED="2016-12-11 16:32:50 -0500" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.6323660600391656" P_Q="0.6947904833856211" P_Z="0.9308018800833726" Q="0.7282902361367785" RANDOM="NO" SCALE="1.2" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1096" TOTAL_2="1076" WEIGHT="300.0" Z="0.08683598961957595">
<NAME>Retinopathy of prematurity requiring surgery</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.485368693141605" CI_END="1.2886965748251904" CI_START="0.5911578931710403" DF="3" EFFECT_SIZE="0.872824811809561" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="46" I2="13.925892376800697" ID="CMP-001.12.01" LOG_CI_END="0.1101506742259644" LOG_CI_START="-0.2282965073174161" LOG_EFFECT_SIZE="-0.05907291654572583" MODIFIED="2016-12-11 16:32:40 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3226648376235244" P_Z="0.49385631876420666" STUDIES="4" TAU2="0.0" TOTAL_1="345" TOTAL_2="328" WEIGHT="100.0" Z="0.6841882290960822">
<NAME>Studies with entry before 3 days based on oxygenation</NAME>
<DICH_DATA CI_END="6.02249340968213" CI_START="0.616751221233018" EFFECT_SIZE="1.9272727272727272" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7797763334291604" LOG_CI_START="-0.20988998188810765" LOG_EFFECT_SIZE="0.2849431757705264" ORDER="63" O_E="0.0" SE="0.581334892544633" STUDY_ID="STD-INNOVO-2005" TOTAL_1="55" TOTAL_2="53" VAR="0.33795025728987993" WEIGHT="8.73741323687555"/>
<DICH_DATA CI_END="2.043065130855267" CI_START="0.024170896611949978" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.31028221172308645" LOG_CI_START="-1.6167072392737738" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="61" O_E="0.0" SE="1.1319231422671772" STUDY_ID="STD-Kinsella-1999" TOTAL_1="48" TOTAL_2="32" VAR="1.28125" WEIGHT="7.72069606022094"/>
<DICH_DATA CI_END="4.7370237166558695" CI_START="0.22450311125965142" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6755055590971754" LOG_CI_START="-0.6487776359812123" LOG_EFFECT_SIZE="0.013363961557981502" MODIFIED="2009-10-13 12:11:04 -0400" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="0.7778905040965832" STUDY_ID="STD-Su-2007" TOTAL_1="32" TOTAL_2="33" VAR="0.6051136363636364" WEIGHT="6.334930100694105"/>
<DICH_DATA CI_END="1.2634832584854607" CI_START="0.5135958460298721" EFFECT_SIZE="0.8055555555555556" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="36" LOG_CI_END="0.10156949176796154" LOG_CI_START="-0.2893784975046239" LOG_EFFECT_SIZE="-0.09390450286833116" MODIFIED="2010-06-28 12:31:43 -0400" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.2296447841224745" STUDY_ID="STD-Van-Meurs-2005" TOTAL_1="210" TOTAL_2="210" VAR="0.05273672687465791" WEIGHT="77.20696060220939"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3845854400401776" CI_START="0.776994101291534" DF="0" EFFECT_SIZE="1.0372148859543817" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="68" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.14131976036551228" LOG_CI_START="-0.10958227822130097" LOG_EFFECT_SIZE="0.01586874107210568" MODIFIED="2016-12-11 16:32:50 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8041941819792358" STUDIES="1" TAU2="0.0" TOTAL_1="294" TOTAL_2="288" WEIGHT="100.0" Z="0.24792274432283795">
<NAME>Studies with entry after 3 days based on BPD risk</NAME>
<DICH_DATA CI_END="1.3845854400401776" CI_START="0.776994101291534" EFFECT_SIZE="1.0372148859543817" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="68" LOG_CI_END="0.14131976036551228" LOG_CI_START="-0.10958227822130097" LOG_EFFECT_SIZE="0.01586874107210568" ORDER="64" O_E="0.0" SE="0.1473810994510156" STUDY_ID="STD-Ballard-2006" TOTAL_1="294" TOTAL_2="288" VAR="0.021721188475390153" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.13442337545353383" CI_END="1.4715825496110164" CI_START="0.7866529057813572" DF="1" EFFECT_SIZE="1.0759296857827858" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="64" I2="0.0" ID="CMP-001.12.03" LOG_CI_END="0.16778462921849618" LOG_CI_START="-0.10421684877772588" LOG_EFFECT_SIZE="0.03178389022038514" MODIFIED="2014-10-20 11:00:11 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7138892033546886" P_Z="0.646915773013421" STUDIES="2" TAU2="0.0" TOTAL_1="457" TOTAL_2="460" WEIGHT="99.99999999999999" Z="0.4580510413358486">
<NAME>Studies of routine use in preterm infants on respiratory support</NAME>
<DICH_DATA CI_END="1.504481069180451" CI_START="0.7921851372201155" EFFECT_SIZE="1.0917085427135678" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="60" LOG_CI_END="0.17738672740199268" LOG_CI_START="-0.10117330997999792" LOG_EFFECT_SIZE="0.038106708710997396" ORDER="65" O_E="0.0" SE="0.16362754485260483" STUDY_ID="STD-Kinsella-2006" TOTAL_1="398" TOTAL_2="395" VAR="0.02677397343449121" WEIGHT="94.05552513318433"/>
<DICH_DATA CI_END="3.539679480551359" CI_START="0.19287737132508417" EFFECT_SIZE="0.826271186440678" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5489639382602516" LOG_CI_START="-0.7147187214754287" LOG_EFFECT_SIZE="-0.08287739160758856" MODIFIED="2014-10-20 11:00:11 -0400" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="0.742293449658789" STUDY_ID="STD-Kinsella-2014" TOTAL_1="59" TOTAL_2="65" VAR="0.5509995654063451" WEIGHT="5.944474866815659"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-12-16 16:16:34 -0500" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-12-11 16:33:04 -0500" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram: review update.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAoEAAAMxCAYAAACU7ml5AABfTklEQVR42uzdAYRVef8/8B9ZGVl5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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-12-16 16:16:34 -0500" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAAEACAMAAABWJIaGAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-12-16 16:16:34 -0500" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUQAAAMYCAIAAAA8Wwk0AAApDUlEQVR42u3dsY4kRdaG4ZKQEMYY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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-12-11 16:33:54 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2016-12-11 16:33:54 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2016-12-11 16:33:54 -0500" MODIFIED_BY="[Empty name]">Search strategy January 2016</TITLE>
<APPENDIX_BODY MODIFIED="2016-08-23 11:42:14 -0400" MODIFIED_BY="[Empty name]">
<P>(nitric oxide OR nitric) and database specific terms:</P>
<P>PubMed: ((infant, newborn[MeSH] OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW or infan* or neonat*) AND (randomized controlled trial [pt] OR controlled clinical trial [pt] OR Clinical Trial[ptyp] OR randomized [tiab] OR placebo [tiab] OR clinical trials as topic [mesh: noexp] OR randomly [tiab] OR trial [ti]) NOT (animals [mh] NOT humans [mh]))<BR/>
<BR/>Embase: (infant, newborn or newborn or neonate or neonatal or premature or very low birth weight or low birth weight or VLBW or LBW or Newborn or infan* or neonat*) AND (human not animal) AND (randomised controlled trial or controlled clinical trial or randomised or placebo or clinical trials as topic or randomly or trial or clinical trial)<BR/>
<BR/>CINAHL: (infant, newborn OR newborn OR neonate OR neonatal OR premature OR low birth weight OR VLBW OR LBW or Newborn or infan* or neonat*) AND (randomised controlled trial OR controlled clinical trial OR randomised OR placebo OR clinical trials as topic OR randomly OR trial OR PT clinical trial)<BR/>
<BR/>Cochrane Library: (infant or newborn or neonate or neonatal or premature or very low birth weight or low birth weight or VLBW or LBW)</P>
<P>Clinicaltrials.gov: (infant)</P>
<P>Controlled-trials.com: (infant)</P>
<P>WHO trials database: (infant OR neonate)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;17 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;17 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="125">
<FLOWCHARTBOX TEXT="&lt;p&gt;14 studies included in previous version of review&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;3 NEW studies included&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;463 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;463 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;415 records identified through database searching (2010-2016)&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;48 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;460 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>